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LIST OF ABBREVIATIONS 
cGy centigray, one hundredth of a gray, adopted in 1977 in the International Stan-
dard of Units as the unit of absorbed radiation dose. 1 cGy = 1 rad. 
CI confidence interval, an estimated range of values with a given high probability 
of covering the true population value. 
dB decibel, a unit to express the ratio between two acoustic powers, equal to one 
tenth the common logarithm of the ratio of the powers. One decibel is approx-
imately equal to the smallest difference in acoustic power that the human ear 
can detect. 
Hz hertz, a unit of frequency equal to one cycle per second. 
kv kilovolt, a unit of electrical pressure or electromotive force of 1000 volts. 
LET linear energy transfer, the energy dissipation of ionizing radiation over a given 
linear distance. Highly penetrating radiations, such as rontgen and gamma 
rays cause low ion concentration and thus have a relatively low LET, neutrons 
and alpha particles have a relatively high LET. 
rad radiation absorbed dose, a unit of measurement of the absorbed dose of 
ionizing radiation; it corresponds with an energy transfer of 100 ergs per gram 
of any absorbing material (including tissue). The biological effect of I rad 
varies with the kind of radiation the tissue is exposed to. I rad = I cGy. 
rem rontgen-equivalent-man, the quantity of any ionizing radiation which has the 
same biological effect as I rad of X-rays; I rem = I rad x RBE (relative 
biological effect). 
RR relative risk, the ratio between the incidence rate of disease in the exposed 
group and the incidence rate of disease in the non-exposed group . 
. ··, 
II 

Samuel James Crowe (1883-1955) 
13 

CHAPTER 1 
HISTORICAL OVERVIEW AND 
THE GOAL OF THE STUDY 
In the past nasopharyngeal irradiation was frequently used to treat children with 
diseases of the ear resulting from the malfunctioning of the eustachian tube. This 
form of treatment has all but been abandoned nowadays. What dangers threaten 
people who have been irradiated in this way? Are they more likely to contract 
tumours? Or is it so that they are more likely to run the risk of being subjected to 
unnecessary diagnostic procedures for the sake of identifying non-existent 
tumours? 
At the present time there are noticeable differences in the way in which doctors 
approach patients with a history of radium irradiation. Some subject the patients 
with such.an anamnesis and current complaints in the head and neck area to careful 
endoscopic examination based on the assumption that the problems are due to some 
form of tumour in this area. Others consider such a relationship to be impossible 
and regret that the - in their opinion - beneficial radium therapy has passed into 
disuse. 
Shortly after the discovery of the diagnostic and therapeutic advantages of using 
ionising radiation in medical practice, the adverse effects also came to light. In 1896, 
one year after the appearance of the first X-ray films, F. Batelli, an Italian, reported 
the first radiation damage to human tissue and eyesight (1). Six years later Frieben 
described the existence of a malignant skin tumour in a worker exposed to radiation 
(2). In the years which followed many researchers and doctors received burns or 
contracted tumours and more than one hundred people died, probably as a result 
of exposure to irradiation. 
The fact that radium - an element discovered by the Curies, among other people -
possessed healing powers for tumours and infections, led to the foundation of the 
Radium Institute in Paris in 1906, where patients could be treated. 
In the 1920s it started to become apparent that the same radium could induce 
tumours in people who had worked with paint containing radium (luminous paint) 
and in patients who had taken doses of radium for arthritis and other diseases (3). 
Although the damaging effects of ionising radiation were not unknown - as will be 
clear from the above - not only malignant diseases but also innumerable benign, 
often trivial, diseases were examined or treated with irradiation in the first half of 
this century. 
The exact extent of the risk of all earlier and presently applied radiation treatments 
is still unknown. Some induced solid tumours arise many decades after the irradia-
tion treatment. As the observation time increases, we gain more knowledge of the 
risks involved in many types of radiation therapy. 
As far as the indication for radiation treatment for malignant tumours is concerned, 
the risks nearly always appear to be acceptable: for a life-threatening disease there 
is often no alternative. However, knowledge of tumour induction through the 
irradiation of malignant diseases has led to subtle changes in the indication criteria. 
In the case of a malignant tumour in a young patient with a long life expectancy. 
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alternative forms of treatment, such as surgery or chemotherapy, will be considered 
first. 
Proof of harmful side effects from the irradiation of benign diseases has nearly 
always resulted in the abandonment of the treatment. Either the complaint was not 
treated any more henceforth, or there was an alternative. Differences in opinion can 
arise concerning the irradiation of benign diseases where little or nothing is known 
about the risks involved. 
Nasopharyngeal irradiation treatment of the eustachian tube to improve its function 
was introduced by Samuel James Crowe in the U.S. in 1926. The treatment 
consisted of the application of two cylinders, containing 50 mg of radium sulphate, 
near the nasopharyngeal orifice in three sessions of 8.5 minutes. Favourable results 
were described in patients with barotrauma (4) and serous otitis media (5). 
ln the Netherlands this treatment was carried out·on a large scale in the 1950s and 
60s. But owing to the danger of tumour induction and the introduction of tympanic 
tubes the therapy became obsolete. 
There are two epidemiological studies available on the long-term effects. Hazen et 
al. (1966) (6) published the results of a study on a group of 417 children who had 
been treated using 25 mg of radium (300-600 mgrnin), compared with a control 
group of 2,746 non-exposed siblings. After a follow-up period of 14.6 years, two 
malignant and five benign tumours were diagnosed in the irradiated group, which 
did not differ from the findings in the control group. 
Sandler et al. (1982) (7) described the results of a study on 904 irradiated children 
compared with 2,021 children treated in a different way after a follow-up period of 
25 years. She reported an increased incidence of benign as well as malignant head 
and neck tumours in the irradiated group. There was a strikingly high number of 
brain tumours in the irradiated group. Another interesting finding was that there 
were fewer breast tumours in the irradiated women, which supports the results of 
Hazen et al. (1966) (6). 
The present study is a non-concurrent prospective cohort study on the risks of the 
Crowe therapy in 2,542 subjects who underwent this treatment compared to 2,380 
- similar - non-irradiated control subjects. The study population consisted of 
patients from five Dutch ENT clinics. The follow-up period was 25 years. This study 
aims to answer the following questions: 
l. Does exposure to the Crowe therapy induce tumours? In this case attention is 
particularly focussed on the possibility of an increase in mortality and/ or 
incidence of tumours in the head and neck region, namely nasopharyngeal and 
brain tumours. 
2. Does the Crowe therapy have any influence on hormone dependant processes, 
such as growth, fertility and hormone dependant diseases, owing to the irradia-
tion of the pituitary gland? 
Additional aims of the study are: 
3. To gather data in order to better determine the dose-effect relationship in the 
exposure range 0-50 cGy, an area in which little is known on man. 
4. To study the follow-up procedures involved with non-concurrent prospective 
cohort studies on clinical populations in the Netherlands. 
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CHAPTER 2 
IRRADIATION OF THE NASOPHARYNX 
TO IMPROVE THE FUNCTION OF THE 
EUSTACHIAN TUBE 
2.1 THE EUSTACHIAN TUBE 
2.1.1 Anatomy 
The eustachian tube connects the nasopharynx with the tympanum. In the adult the 
opening in the pharyngeal side of the lateral wall is localized as follows: by approx-
imation I to 1.5 em (a) under the pharyngeal roof, (b) in front of the posterior wall · 
of the pharynx, (c) above the level of the palate and (d) behind the inferior nasal 
concha and the internasal septum (see Figure 2.1 ). The opening is bounded above and 
behind by the torus tubarius, an elevation produced by the cartilage ofthe tube. Folds 
of mucous membrane run from the torus tubarius to the palate - the plica salpingo-
palatina - and to the lateral wall of the pharynx - the plica salpingo-pharyngea. 
There is a deep recess behind the torus tubarius called the fossa of Rosenmiiller. It 
extends posteriorly and laterally between the m. longus capitis (medially) and the 
m. levator veli palatini (laterally) (!). The lymphatic tissue found in the fossa of 
Rosenmiiller has the collective name tube tonsil (2-4). 
The eustachian tube in the adult runs from the orifice in a posterior, lateral and 
cranial direction and is three to four centimetres long. It consists for two thirds of 
a cartilaginous portion - the antero-medial part - and for one third of an osseous 
portion - the postero-lateral part. The two parts meet at a slight angle in the 
narrowest portion - the isthmus. 
The cartilaginous portion of the eustachian tube is a cleft of the pharynx. It lies 
against the base of the skull in a groove between the ala major of the sphenoid bone 
and the pars petrosa of the temporal bone. The cartilage is of the elastic type and 
in transverse section it has the appearance of an upside down J. This part of the 
canal is completed below by connective tissue. The mucous membrane in this 
portion of the tube consists mainly of cylindrical ciliated epithelium. On the lateral 
side the tube is bounded by the m. tensor veli palatini, the n. mandibularis and the 
a. meningea media and on the medial side by the m. levator veli palatini and the 
pharyngeal recess. 
The osseous portion of the eustachian tube is an anterior extension of the tympanum 
- the protympanum. It forms a canal through the temporal bone and can be 
regarded as part of the pneumatization of the temporal bone. At the base of the 
skull it is localized between the temporal bone and the down-sloping edge of the 
tegmen tympani. This part of the tube is lined by a mucoperiosteum, which 
normally contains squamous cell of cuboidal epithelium with fields of ciliated 
epithelium. On the cranial side it is bordered by the canal of them. tensor tympani, 
anteriolaterally by the tympanic portion of the temporal bone and on the postero-
medial side by the canal of the a. carotis (2). 
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Figure 2.1 The eustachian or auditory tube in its relation to the lateral nasal wall (above) and to the 
middle ear (below). Gray's Anatomy. 
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The anatomy of the eustachian tube in newborns and young children differs 
considerably in some aspects from that of the adult. The tube is relatively short and 
wider and runs almost horizontally. The ostium pharyngeum does not have a torus 
tubarius and is situated further forward and more caudally than in the adult. The 
fossa of Rosenmiiller does not develop until the second half of the infant's first year 
(5). 
2.1.2 Lymphoid tissue in the eustachian tube 
In 1875 Gerlach described the existence of lymphoid tissue in the eustachian tube 
and since that time 'Gerlach's tonsil' is a much discussed subject in the literature. 
However, it concerns a one-off observation in a child of six months, who died of 
otitis media duplex purulenta (6). 
In her histological examination of 500 petrous bones from people of various ages, 
Wolff found only one with a circumscript amount of lymphoid tissue between the 
isthmus and the mouth of the tube, also in a child of six months old (7). 
Fowler conducted a histological examination of the petrous bones of American 
airmen who died in England in the 1940s. In one third of the 95 specimens he found 
macroscopic lymphoid tissue on and in the torus tubarius. Microscopic examination 
revealed signs of mild salpingitis in I! of the 16 cases. He attributed this to the flying 
activities or to the English climate (!). He found round cell infiltration, oedema, 
hyalinization of the submucosa, hyperplasia of the surface epithelium and 
hypersecretion of the mucous glands. He observed in some cases that the round cell 
infiltration took the form of a germinal centre and sometimes that of masses of 
lymphoid tissue with multiple germinal centres. He found abnormalities which 
resembled the pathological changes observed in the bronchi and sinuses of people 
with chronic infections (8). 
Aschan, in the description of his histological examination of the eustachian tube 
under normal and inflammatory circumstances, observed that Fowler's patient 
material was exceptional: airmen exposed to barotrauma. He suggested that Fowler 
probably described the pathological picture of aerotitis media. 
In his own examination Aschan found a striking resemblance between the 
histological findings of the mucosa of the middle ear and that of the eustachian 
tube. He established that, after birth, a moderate number of migratory cells from 
the reticulo-endothelial system appear in the mucous membrane of the eustachian 
tube in the same way as they appear at other places in the upper respiratory tract. 
If more cells are present it is his opinion that this is the result of otitis media. Under 
normal circumstances lymphoid tissue should not be found in the eustachian tube 
(9). 
Finally, Zechner recently carried out a histological examination on the mucous 
membrane of the eustachian tubes in patients suffering from an obstruction. He 
obtained his material via biopsies during the surgical treatment of otitis media 
serosa. He discovered aggregations of immuno-competent cells which he called 
'tube tonsil' (10). 
Reviewing the literature, we can conclude that under normal circumstances only 
cellular components of the reticulo-endothelial system exist in the mucous 
membrane of the eustachian tube. Under pathological conditions an accumulation 
of lymphoid tissue may arise due to cell aggregation. It is advisable to make a clear 
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distinction between lymphoid tissue which is normally present - belonging to 
Waldeyer's ring- and that which is acquired- i.e. as an expression of inflammation. 
The term 'tube tonsil' should be reserved for the lymphoid tissue found in the fossa 
of Rosenmiiller. 
2.1.3 The physiology aod dysfunction of tile eustachian tube 
The eustachian tube stands in close relation to the middle ear. In an eight to nine 
week old embryo tile first visceral arch develops on either side in a lateral direction. 
The distal portion of the entodermal sack becomes broader and forms the primitive 
middle ear cavity. The proximal portion remains narrow and forms the eustachian 
tube (11). 
Besides these fundamental anatomical relationships, there is also a physiological 
relationship which is maintained throughout life: a normally functioning middle ear 
cannot exist witllout a normally functioning eustachian tube. 
Four functions of the eustachian tube can be distinguished: 
- ventilation of tile middle ear 
- drainage of the middle ear 
- protection against invading bacteria 
- protection against piercing noises and against differences in pressure due to 
breathing. 
The first two functions require the opening and the latter two the closing of the 
eustachian tube. In order to fulfil these functions the tube remains closed and only 
opens intermittently. 
Three factors keep the tube closed: 
- the elasticity of the cartilage, 
- the surface tension of the mucous in the tube and 
- the pressure of the peri-tubal tissue. 
These processes work continuously, whereby the tube is kept constantly closed, 
except for when it is opened via special mechanisms. There is an active and a passive 
opening mechanism. 
The active opening mechanism consists of the synergetic contraction of - esentially 
- three muscles: the m. tensor veli palatini, the m. levator veli palatini and the m. 
salpingo-pharyngeus. These muscles contract unconsciously during yawning or 
swallowing. This mechanism is disturbed in patients with a cleft palate. 
Passive opening of the eustachian tube is caused by a difference in air pressure on 
either side of the tube. If this difference exceeds the pressure in the peri-tubular 
tissue by a certain degree, and subsequently overcomes the surface tension of the 
mucous and the elasticity of the cartilage, the tube opens. This occurs during flying 
and diving activities and during V alsalva and Politzer experiments. 
The drainage of the tube is of particular importance in pathological situations, 
where debris and mucous or purulent secretions need to be drained away. Three 
factors are of importance to the drainage of the middle ear: active opening of the 
tube, mucosal ciliary activity and gravity. Active opening in itself already exerts a 
sucking action on the middle ear, but of more importance is the entry of air into 
the middle ear via this mechanism. It is only possible for material to be expelled 
from the middle ear if an equal volume of air replaces it. 
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The ciliary action also plays a major part. It caters for the transport of material 
through the tube and acts as protection against invading bacteria. It is possible for 
the ciliated epithelium to work against the force of gravity. In the middle ear cavity 
the epithelium is only covered in patches of cilia and this is where the third factor 
- gravity - takes effect. Gravity helps with the deposition of material onto the 
'transport belt' in the eustachian tube. In this way drainage of the middle ear cavity 
is made easier if the affected ear is facing upwards (12). 
Ventilation and drainage of the tube can be impeded in many ways. The tube can 
become narrowed due to mucosal swelling caused by viral infections of the upper 
respiratory tract, adenoiditis, sinusitis, allergies or malignancy. Obstructive 
processes in the nasopharynx can limit the function of the tube in several ways: 
(!)by closing off the ostium or (2) by limiting pressure changes in the nasopharynx 
essential for the transtubal ventilation or (3) by interfering with the mobility of the 
cartilage during active opening. This type of obstruction occurs in relation to 
adenoidal hypertrophy, tumours, nose tamponades and scars from adenotomy or 
accidents. Deviations of the nasal septum can result in poor functioning of the tube. 
This can be put right by correcting the deviation (13). 
Disturbances in the active opening mechanism of the tube occur in patients with a 
cleft palate, owing to the absence of the connection between both m. tensores veli 
palatini (14). In children, insufficient correlation between them. levator veli palatini 
and the tube cartilage is considered to be one of the causes of frequently recurring 
otitis media serosa, a result of poor tubal function (15). 
Mann found a relationship between the cranio-facial morphology and the function 
of the tube. A more vertical out-growth of the facial bones may have a negative 
influence on tubal function, due to an unfavourable operational direction of the 
muscles (16). It is suggested that ingrowth of the muscles is the cause of otitis media 
serosa in the case of a very small non-obstructive carcinoma of the nasopharynx 
(17). Poor opening may also occur if the tube cartilage is not firm enough, whereby 
an otherwise normal musculature cannot open the tube (18). An increase in 
peri tubular tissue turgor can also interfere with the opening of the eustachian tube. 
Turgor can increase as a result of pharmaceuticals, such as bradykinine, alpha- and 
beta-adrenergic agents, cardiac and renal insufficiency, hypothyroidism and 
menstruation (14). 
From the above we can conclude that the eustachian tube has a very complicated 
operating mechanism. This explains the large number of different causes for distur-
bances in tubal function to be found in the literature. As the subject of this study 
- the irradiation of the nasopharynx - particularly affects lymphatic tissue, the 
influence of the adenoid on the function of the tubes will be discussed further. 
2.1.4 The influence of the adenoid and adenotomy on tnbal function 
An enlarged and/ or inflamed adenoid is generally considered to be the cause of 
impeded function of the eustachian tube. One of the first steps to be recommended 
in children with chronic or recurrent ear disorders is, therefore, adenotomy, 
possibly in combination with tonsillectomy. The adenoid cannot be removed 
completely because, unlike the tonsilla palatina, it is not an encapsulated anatomical 
unit. 
In the literature, opinions on the effect of adenotomy on otitis media serosa are far 
23 
from unanimous. The cure rates vary between researchers from 200Jo to 900Jo (19-
23). The variation in percentages can easily be explained by differences: in the 
compilation of the study groups, between the surgical methods and the judgement 
of the post-operative results. Selecting patients by excluding children with serious 
middle ear pathologies can give rise to biassed results (24). 
Sade observed that although the age at which otitis media serosa occurs most fre-
quently (3-7 years) corresponds with the age at which the adenoid still occupies a 
considerable area in the nasopharynx in many children, there are still a large number 
of children with otitis media serosa who have had their adenoid removed (26). 
Sade mentions the following indications for adenotomy: (l) mechanical obstruction 
of the eustachian tube and (2) the lodging of bacteria which can penetrate the midle 
ear cavity. He believes that the adenoid can contribute to poor tubal function and 
considers adenotomy to be a useful operation. In his patient material the insertion 
of tympanic tubes in combination with adenotomy produced better therapeutic 
effects, after a follow-up period of 18 months, than the insertion of tympanic tubes 
alone (25). 
Tos conducted a study on the improvement of the function of the eustachian tube 
using tympanic tubes in children with OMS. He also included the effect of 
adenotomy. On the grounds of his observations, he concluded that adenotomy does 
not immediately have any great effect on tubal function. He attributed this to the 
fact that, in OMS, the mucosa of the eustachian tube undergoes extensive 
histological changes, such as thickening and oedema, referred to as 'internal tubal 
dysfunction'. Although adenotomy eliminates the cause of 'external tubal dysfunc-
tion', it may take a long time before the mucosa of the tube becomes normalized 
(27). 
2-2 THE CROWE THERAPY 
Samuel James Crowe (1883-1955) studied medicine at the Johns Hopkins University 
in Baltimore and graduated in 1908 (28). As early as in 1912 he was asked by W.S. 
Halsted, surgeon and founder of the first American school of surgery (29), to set 
up and run an ENT clinic. A few years later he was appointed professor of the 
department. He became internationally known as an authority in the field of hearing 
impairments. In 1924 he established an otological research laboratory, with the 
assistance of the Rockefeller Foundation, in order to study ihe causes and preven-
tion of deafness. One of the studies concerned middle ear deafness in children (30). 
Using a nasopharyngoscope constructed by Edgar M. Holmes, he diagnosed an 
excess of lymphoid tissue in the nasopharynx in many cases with this disorder. 
The repeated examination of 1365 unselected school children showed that in more 
than 750Jo of those who had undergone adenotomy before puberty, the adenoid had 
recurred and almost 400Jo of the children had suffered a loss of hearing (31). In the 
knowledge that lymphoid tissue is pre-eminently sensitive to ionizing radiation (32), 
Crowe asked Curtis F. Burnam, a radiologist, to construct a needle containing 
radon (later radium), with which he could treat children who were hard of hearing 
(33). This form of therapy took root in many parts of the western world and found 
application for several decades. 
In the 1950s other radioactive elements were examined to see whether they were 
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suitable for use. Cobalt-60, although cheaper than radium, was rejected owing to 
the greater risks involved. Radioactive phosphorus (P32) had the disadvantage of a 
short half-life of 14 days, which made the dose calculation difficult (34). 
Strontium90 , introduced by Thullen in 1954, offered advantages over radium. It 
has a much shorter half-life, 28 years, and its dose fall off is steeper, so that patients 
and staff receive lower radiation doses (35). In the clinics where nasopharyngeal 
irradiation is still being applied Sr90 is used (36). 
2.3 DOSIMETRY 
In their first publications, Crowe and Burnam limited themselves to estimating the 
radiation doses received by tissues in the direct vicinity of the applicator, because 
'surrounding tissues receive only homeopathic dosage'. They considered this to be 
sufficient because the amount of radiation absorbed decreases with the square of 
the distance between the irradiated object and the source. 
Assuming that the two halves of the nasopharynx are spherical, with a diameter of 
two centimetres and that the radium applicator is placed in the centre of each half, 
they calculated a dose per treatment of 600 to 650 cGy at the wall of the 
nasopharynx. This was calculated for an applicator containing 50 mg radium 
sulphate with an exposure time of 40 minutes to both sides. They observed that the 
chance that the figures were inaccurate was fairly high due to size variations of the 
nasopharynx and the precise positioning of the applicator (37). 
In order to calculate the dose received by the thyroid gland, Hazen determined the 
distance between the middle of the adenoid shadow in the nasopharynx and the 
upper lobe of the thyroid gland. He used X-ray films for this, on which he estimated 
the position of the thyroid gland, which is not visible on an X-ray film, in relation 
to the hyoid bone. By setting out 20 points, he established that the distance was 5 
to 12.5 em in patients of 4 to 14 years old. Depending on the exposure time (25 mg 
radium sulphate for 12 to 24 minutes) and the distance, he estimated that the 
pituitary gland received a dose of 8 to 36 cGy. He considered the dose received by 
the thyroid gland to be negligible (1). 
Garsou, a radiotherapist, calculated the radiation doses received at various places 
in the patient's body. For a full treatment, he arrived at the following figures: 18 
cGy for the lens, 4.68 cGy for the skin at the level of the thyroid gland, 0.468 cGy 
for the navel and 0.108 cGy for the gonads. He also estimated the dose received by 
the operator. During a treatment of 3 x 12 minutes in 9 weeks using 50 mg of 
radium, the palm of the hand received 0.047 cGy and the navel region 0.0324 cGy 
(see Table 2.1) (38). 
Sandler estimated various tissue doses using the X-ray films of children from 2 to 
16 years of age. Distances were measured between the nasopharynx and the thyroid, 
pituitary and salivary glands. Depending on the age of the child, she estimated these 
to be 4 to 13 em for the thyroid, 2 to 4 em for the pituitary and 5 to 8 em for the 
salivary glands. According to her, the radiation dose received at the nasopharynx 
and the orifice of the eustachian tube was 700 cGy, at the pituitary and lower regions 
of the brain 78 cGy and at the thyroid gland 5 to 20 cGy. Her study group was 
exposed to two applicators containing 50 mg radium sulphate for a total of 36 
minutes (39). 
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Table 2.1 Radium irradiation* dose received by the operator (cGy) compared to the ICRP** norms (38) 
Body site Dose ICRP norms 
Palm of the hand 0.047 10 
Navel region or internal organs 0.0324 4 
* 50 mg radium. 3 x 12 mins in 9 weeks 
** International Commission on Radiological Protection (1966) maximum dose in 13 consecutive weeks 
2.4 THE EFFECTS OF NASOPHARYNGEAL IRRADIATION 
2.4.1 Tile local effect 
In his experimental research into the effects of X-rays on various types of tissue, 
Heineke established - as early as in 1904 - that lymphatic tissue was the most 
sensitive (32). In the English literature, the clinical effect of irradiation of the 
nasopharynx is accounted for by a decrease in the adenoidal tissue, which cannot 
be removed surgically (8,30). Moreover, several German authors brought forward 
a theory of 'Gewebsumstimmung', in which ionizing radiation has a favourable 
influence on an inflamed mucous membrane - however, they did not fully explain 
this mechanism (34,35,40). 
Microscopy 
One month after the irradiation of the nasopharynx using 50 mg of radium for one 
hour, Fowler extracted tissue from the nasopharynx of a young aviator, for 
microscopic examination. He observed that the germinal centres had disappeared 
and the number of lymphocytes had decreased strongly. Many of the remaining 
lymphocytes had pyknotic nuclei. The capillaries in the irradiated tissue were very 
prominent. ·The endothelium of the blood vessels appeared to be thickened and the 
walls hyalinized. Connective tissue cells were present in greater numbers than in the 
control biopsy specimen taken before irradiation (8). 
Westerbeek conducted a similar examination in !949. He sent the adenoidal tissue, 
extracted from a six-year-old boy, who he had treated one month previously (50 mg, 
36 min.), to the pathology laboratory to see whether any stuctural changes had 
resulted from the radium irradiation. In contrast to Fowler, he did not observe any 
noticeable changes (41). 
O~Jy one animal experiment is described in the literature. Microscopic examination 
was carried out on the effect of radium irradiation on the movement of the cilia on 
the mucous membrane of the eustachian tube in the horse. No adverse effects were 
observed after contact therapy varying from 2 mg of radium for l hour to 40 mg 
of radium for 24 hours (42). 
Macroscopy 
Bordley and Hardy conducted a prospective cohort study on the effect -of 
nasopharyngeal radium irradiation on the reduction of lymphoid tissue in the 
nasopharynx. They subjected a group of 385 children to nasopharyngoscopy during 
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a followed-up period of five years, between 1948 and 1953. At the beginning of the 
study the average age was 8.8 years. The entry criterium for the study was a hearing 
loss of 15 dB or more for two frequencies in one ear or of 20 dB or more for one 
frequency in one ear. Half of tbe children (n = 193) were treated using 50 mg of 
radium sulphate in the nasopharynx for 8.5 minutes in three sessions at two week 
intervals. The other half (n = 192) were treated using a placebo applicator. This 
was a double blind study. 
The children were examined using a nasopharyngoscope twice a year for five years 
- the duration of the study. In the judgement of the data obtained, attention was 
paid to I) the effect of the nasopharyngeal irradiation on the adenoid and 2) the 
changes around the ostium of the eustachian tube as a result of the irradiation. 
In the irradiated group the adenoid appeared to shrink steadily over the five year 
period. The greatest change took place in the first three years. The size of the 
adenoid in the control group also decreased but to a lesser extent than in the 
irradiated group. In the control group the greatest amount of change took place in 
the last two years, which reflected the accelerated shrinkage of the adenoid with the 
onset of puberty. Comparison of the two groups showed that irradiation of the 
nasopharynx caused the adenoid to shrink (see Figure 2.2). 
The fact that moderately to large adenoids persisted in 96 of the children in the 
irradiated group forms enough grounds to conclude that irradiation cannot replace 
the surgical removal of the adenoid. In the judgement of the ostium of the 
eustachian tube, the extent of lymphatic 'overgrowth' was examined. Figure 2.3 
shows the changes around the ostium in both groups during the five year period. 
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Figure 2.2 Effect of radium irradiation on rhe size of the adenoid (Bordley et al. 1955) (43). 
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Figure 2.3 Effect of radium irradiation on the situation at the tubal orifice (BordJey et al. 1955) (43). 
The decrease in the number of completely overgrown ostia from 130 to 36 and the 
increase in the number of clear ostia from 47 to 103 in the irradiated group clearly 
surpasses the results in the control group. It is striking that the decrease in size of 
the adenoid in the control group during the five year period did not involve a 
corresponding improvement around the ostium of the eustachian tube (43). 
It was concluded in this double blind study that radium irradiation has a clear effect 
on the size of the adenoid as well as on the amount of lymphoid overgrowth around 
the ostium of the eustachian tube. 
2.4.2 The effect on tnbal function 
In 1969 Beck published the results of intratubal irradiation using strontium90 • The 
indications were !) chronic ear infections with or without perforation of the 
tympanic membrane, whereby surgical treatment was being considered to improve 
the hearing and a tubal stenosis was present and 2) chronic otitis serosa, adhaesive 
processes and otosclerosis with tubal dysfunction. The results were judged on the 
grounds of an improvement in tubal function, as measured using the 'Tuben-
widerstandmessung' (TWM) according to Zollner. This measurement consisted of 
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creating an increase in air pressure in the nasopharynx via the nose and subsequent 
measurement of the opening pressure of the eustachian tube by ausculation of the 
sound produced by air escaping through a perforation or by the observation of 
movement in the case of an intact tympanic membrane. 
In Beck's study, 625 tubes were irradiated, 491 with a TWM of 30 to 80 mm Hg 
and 134 with a TWM of 80 mm Hg or more. In the first and second groups, the 
improvement rates were 88o/o and 36"7o, respectively. An improvement was 
considered to be a decrease in TWM value to less than 30 mm Hg (44). 
One year later Siedentop published the results of a similar study and attempted to 
compare his results with those of Beck. His indications were I) patients who had 
already undergone an unsuccessful tympanoplasty (meaning that surgery resulted in 
an atelectatic middle ear, perforation of the tympanic membrane or both) and 2) 
chronic otitis media adhaesiva. The function of the eustachian tube was measured 
using the aspiration method (ETF = Eustachian Tube Function), whereby the 
pressure in the middle ear could be varied via a manometer connected to the external 
auditory meatus. All the patients had an ETF of type Ill, IV or V. An eustachian 
tube with an ETF type Ill reduces + 500 mm H20 middle ear pressure to 0 and 
-250 mm H20 to not lower than -50 mm H20. A type IV function reduces + 500 
mm H20 to 0 but does not reduce a negative pressure. Type V does not reduce 
either a positive or a negative pressure. All the patients who underwent this test had 
a perforated tympanic membrane or a polythene drain in the tympanic membrane. 
A total of 27 eustachian tubes were irradiated, seven ETF type III and IV and 20 
ETF type V. A positive result was considered to be an improvement in function 
from types Ill, IV and V to types l or !I after eight weeks (type l reduces + 500 mm 
H20 and -250 mm H20 to 0 and type II reduces + 500 mm H20 to 0 and -250 mm 
H20 to a value between 0 and -50 mm H20. In the first group, 43"7o improved; in 
the second group IO"lo (see Table 2.2). 
Table 2.2 Results of intratubal strontium therapy in tubal disorders, per author. Studies without a 
control group 
Author Ref. Pub I. 
No. year 
Beck (44) 1969 
Siedentop (45) 1970 
* Tubenwiderstandsmessung (mm Hg) 
** Eustachian Tube Function 
N 
625 
27 
Tubal disorders 
Slight - Moderate 
TWM* 30-80 
880Jo 
ETF** type III/IV 
43% 
Serious 
TWM 80 or more 
360Jo 
ETF type V 
IOCIJo 
Siedentop subsequently measured the tubal function in 16 patients using the TWM 
as well as the ETF method in order to compare his results with Beck's. He concluded 
that ETF types lll and IV corresponded with TWM values of 30 to 80 mm Hg and 
that type V corresponded with TWM values of above 80 mm Hg. 
Reviewing the results, it is striking to see that Beck's were better. Despite 
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Siedentop's attempt to make his figures suitable for comparison, the reason for this 
is probably the differences between the groups of patients treated: the treatment 
indications were different, as were the size of the groups (45). 
2.4.3 The cliuical effect 
The nasopharyngeal application of a radioactive substance was a popular treatment 
method for recurrent ear infections and otitis media serosa in children. During the 
Second World War the method was also frequently applied to military aviators and 
divers with barotraumatic disorders. Many reports have appeared on the effects of 
the treatment for the various indications mentioned above. However, most of the 
publications lacked a control group. This is a great loss with regard to the judgement 
of the effect of a therapy which is applied for a disorder that has a strong tendency 
to disappear spontaneously, such as otitis media serosa. In the discussion of the 
existing literature, a distinction will be made between studies with a control group 
and those without. 
Studies without a control group 
In the presentation of these studies (see Table 2.3), precise data concerning the 
app1icator used, the dose and fractionation, will not be mentioned for every author. 
Table 2.3 Literature overview: Results of nasopharyngeal irradiation using radium or strontium for 
otitis serosa, recurrent ear infections, and barotrauma. per author 
Author Ref. Pub!. N Cont. Improvement Obs. time 
No. year pat. grp OJo Criterium in months 
OTITIS SEROSA 
Canfield {46) 1949 50 no 560Jo 'audiographic' 3·>24 
Krijger (47) 1951 80 no 900Jo normal hearing 12 
Falbe-Hansen {48) 1956 65 no 650Jo > 10 dB in speech region >24 
Flach (34) 1966 16 no 620Jo 1-!.5 
Riu (49) !966 98 no 650JG > 15 dB/two frequencies 
Bourdial (50) 1969 3!0 no 77f1Jo •audiographic' 
Siedentop (51) 1973 6 no 170Jo normal hearing >12 
Bordley (43) 1955 43 yes (8 dB better hearing than cont. grp) 60 
RECURRENT EAR INFECTIONS 
Falbe-Hansen (48) 1956 98 no 420Jo lower frequency >24 
Bourdial (50) 1969 470 no 720JG symptom free 
BAROTRAUMA 
Riu (49) 1966 197 no 79CIJG caisson test 
Fowler ( 8) 1946 17 yes 76CIJG able to aviate 
Owing to the vast differences in compilation of the study populations and the 
differences in study design per author, comparison is very difficult in any case. All 
the studies have in common that a radiation treatment has been given to the 
nasopharynx or intratubaliy, using an applicator containing radium226 or 
strontium90 . 
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The treatment results for otitis serosa show success rates of 17'7o to 90'7o (34,46-51). 
Although there is a large distribution between the percentages, one study in 
particular (17%) distinguishes itself from the rest .(56%-90%) and will receive 
further attention. 
Following intratubal irradiation using strontium90 in six children with otitis serosa. 
Siedentop observed that the therapy had not had any effect in five cases. On the 
grounds of sequential data analyses, he rejected the hypothesis that irradiation has 
a useful effect. He was dealing with a very small group of children with persistent 
otitis serosa, with or without atelectatic middle ear cavities. 
Nasopharyngoscopy in all the children revealed abnormalities, such as narrowed, 
scarred or polypoid ostia. It was sometimes necessary to force the applicator into 
the tubes. The patients all had type V function of the eustachian tube prior to treat-
ment, i.e. an overpressure of + 500 mm H20, or an underpressure of -250 mm 
H20 which could not be reduced transmeatally (51). The poor results of the treat-
ment are probably connected with the selection of the children. The group had 
persistent tubal disorders, possibly on account of tubal stenoses. 
Recurrent ear infections in children reacted to the therapy in a favourable manner 
in two studies, in 42% and 72% of the cases, respectively (48,50). Riu treated 
barotrauma in adults using nasopharyngeal irradiation. The therapy had a positive 
effect in 79% of the !97 patients, such that, after completion of treatment, a caisson 
test could be performed without any symptoms (49). 
Comparison of the figures in Table 2.3 gives rise to difficulties, because there are 
differences between the compilation methods in both groups and also between the 
judgement criteria of the results. In many cases the duration of follow-up is not 
mentioned. A follow-up period of four to six weeks is certainly too short to be 
able to make an accurate judgement of the effect of a treatment for tubal 
disorders. 
Studies with a control group 
Two controlled double blind investigations have been described on the clinical 
effects of the Crowe therapy. 
In !946 Fowler published a study on 34 American aviators who he had treated on 
account of barotrauma. He had treated one half using radium and the other half 
using a placebo applicator. Four of the 17 aviators treated with placebo returned 
to work, only one was without symptoms. Of the 17 irradiated aviators, 13 returned 
to work and only two had ntild complaints every so often (8). 
ln the study by Bordley & Hardy, already mentioned above, the effect of radium 
irradiation on the hearing was also exantined. A group of 385 children - half of 
whom had been irradiated, the other half had received a placebo treatment- under-
went an audiogram _every six months. For further details about selection criteria 
etc., see page 26. 
The most noticeable feature in the results is that there had been a general improve-
ment in hearing at all frequencies in both groups. The authors give three possible 
explanations: 
I) An age effect: as the children grow older the amount of adenoidal tissue in the 
nasopharynx decreases. 
2) A time effect: improved hygiene, which expresses itself in more effective treat-
ment of upper respiratory tract infections. 
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3) A habituation effect: the children become accustomed to the repeated 
audiometry and this increases their performance. 
A comparison of the hearing gains in both groups showed a slight advantage in the 
irradiated group. The difference was small and not significant, but consistent at 
each measurement. The size of the relative gain certainly suffered from the fact that 
six children from the control group disappeared owing to a progressive loss of 
hearing. 
The groups could be divided into three subgroups, characterized by 1) loss in the 
low tones, 2) loss in the high tones and 3) loss in both the high and low tones. The 
results in the latter group, characterized by a flat loss of hearing of 25 dB or more 
at two frequencies in the frequency range 125 to 1000 Hz and of 25 dB or more in 
the frequency range 2000 to 10,000 Hz, were the most interesting. Figure 2.4 shows 
the hearing gain on the last audiogram compared to the first. The irradiated group 
has a distinct advantage at all frequencies (43). 
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Figure 2.4 Hearing gain in the flat-hearing-loss subgroup five years after radium irradiation (n=43) 
and placebo (n ~ 29) (Bordley et al. 1955) (43). 
2.4.4 Distribution 
Nasopharyngeal irradiation using radium was introduced in 1926 by Crowe, who 
was working in the Otological Research Laboratory at the Johns Hopkins university 
in Baltimore. The therapy experienced a striking period of flourish and an equally 
striking period of decline. This reversal took place in the 1950s and 60s. 
Remarkably, in 1955 the therapy was recommended in an 'Editorial' in the British 
Medical Journal, partly on account of work by Bordley and Hardy (52), while in 
the same year a 'Redaktionele Kanttekening' (Editorial Marginalia) in the 
Nederlands Tijdschrift voor Geneeskunde (Dutch Medical Journal) warned against 
the application of the therapy (53). 
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Crowe estimated that during the Second World War 25,000 treatments were carried 
out by military doctors in the American Air Force and at the New London 
Submarine Base (33). At the request of the French lnstitut du Cancer, Debain 
travelled to America in 1949 to investigate the advantages and disadvantages of the 
tr.eatment. According to his reports there were 1400 applicators in use in America 
at that time. Medical teams with mobile clinics equipped with audiometers, 
nasopharyngoscopes and radium needles, visited primary schools and the children 
who needed treatment were dealt with on the spot. An advertisement appeared in 
the Saturday Evening Post: 'Will your child go deaf? ... Four million American 
children have something wrong with their ears ... But something can be done about 
it .. .' (54). Several years later a European ENT specialist accused his American 
colleagues of 'Kapitalisierungswiinschen' (35). 
Sounds of warning were also being struck in America against the unrestrained use 
of the therapy, pointing out the possibility of malignant degeneration (55) or an 
absence of therapeutic effect (34). As the use of tympanic tubes for middle ear 
drainage became more popular in the 1950s, the use of the Crowe therapy in 
America started to decline. In a survey conducted by Davison in !965 of 100 
American ENT specialists, only six of the 86 respondents were still using radium 
applicators. Twenty still applied external X-ray treatment to patients with lymphoid 
hyperplasia (49). This method is no longer in use in America (56). 
In France the therapy was introduced straight after the Second World War and 
spread throug.>10ut the whole country (49,50,57). In 1974 favourable results were 
reported at the university clinic in Bordeaux (57). But the method has now been 
abandoned owing to external pressure (58). 
In Germany nasopharyngeal irradiation made its entrance in 1951. Not only radium 
was used but also intratubal P32 and later Sr90 and Y90 (35). intratubal irradiation 
is still being carried out in Wiirzburg using Sr90 for the treatment of stenoses of the 
eustachian tube and epipharyngitis (36). 
In England nasopharyngeal irradiation using radium was conducted on a large scale 
during the Second World War. The method is no longer used nowadays (59,60). 
Fairly recent research on the 'betatherapie tubaire' using Strontium90 has been 
carried out in Belgium (38,61,62). The method was introduced shortly after the 
Second World War and is still being used in Liege (63) and Verviers (64). 
In the Netherlands the Crowe therapy was introduced in 1945 by Van Dishoeck. In 
I 950 he reported on his experience of using this form of radiation therapy on 200 
children. His advice was to use 25 mg instead of 50 mg of radium and to examine 
the effect after each session in order to cut short the course of treatment if the results 
were favourable. In further investigations after the completion of treatment he 
observed that the otitis serosa had cleared up and the hearing had improved, but 
that there was still an under-pressure in the middle ear. He was under the impression 
that the source of infection had been removed with the adenoidal tissue, but that 
in such patients the hypertrophic mucous membrane was still responsible for the 
stenosis. Owing to the fact that the radium irradiation did not reach this mucous 
membrane effectively enough, he advised external X-ray treatment via the neck in 
these cases (65). ln 1951 several results from the ENT clinic in Utrecht were 
published (47) (see Table 2.3). 
A survey held in 1982 under a number of Dutch ENT specialists brought to light 
that the therapy had been applied on a large scale throughout the country. It passed 
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through its most prosperous period in the 1950s and 60s. From the data received 
from each respondent on the duration of practice and the numbers of patients 
treated per year, it can be estimated that about 24,000 patients underwent this treat-
ment (See Appendix 1). 
The fear of tumour induction through radiation, the renewed invention of tympanic 
tubes by Armstrong in !954 and the activity of the inspectors from the Ministry of 
Health all contributed to making the method obsolete. In the Netherlands the 
method became extra discredited due to a notorious accident which occurred in 
1958, whereby the contents of a Crowe applicator found its way into the environ-
ment (see Appendix 2). 
2.5 EXTERNAL IRRADIATION OF THE NASOPHARYNX 
Before the advent of applicators containing radioactive substances for use within the 
nasopharynx, external X-ray treatment of this area was being conducted. The f"rrst 
news of this came from Szasz in 1922 (66). This form of irradiation was also applied 
via the mouth (67). In 1924 Witherbee compared radiotherapy with surgical treat-
ment and spoke in favour of the former in cases where there were surgical or 
anaesthesical contra-indications or where complications, such as bleeding or infec-
tion, needed to be avoided (68). 
On the assumption that an applicator placed in the nasopharynx could not irradiate 
the whole length of the eustachian tube, Dickson and McGibbon transferred to 
external 'deep' X-ray therapy. In 64 cases of barotrauma, 28 improved to such an 
extent that they were able to return to flying, without any symptoms (69). 
Besides the above mentioned disadvantage of nasopharyngeal application, Baarsma 
and De J ong also pointed out some other drawbacks: radium irradiation did not 
reach the lymphatic tissue of W aldeyer' s ring and the operator was exposed to high 
radiation doses. They applied X-ray therapy at a dosage of 3 x 150 to 200 rads, 
usually repeated once. In this way they treated 193 patients with a hearing loss due 
to tubal disorders. There were 147 patients belonging to the 4 to 16-year-old age 
group; in 700Jo the hearing became normalized. The results were not as good in the 
older age groups. This study did not involve a control group. They calculated the 
maximum exposure for several organs: nasopharynx 1150 cGy, processus 
zygomaticus 630 cGy and hypophysis 350 cGy (70). 
Bull and McKelvie treated a small series of 19 children with otitis serosa using 220 kv. 
Although they did not observe a uniform effect (only five children were cured), they 
believed that the large-scale studies from the past should not be ignored and that the 
therapy was probably of use in cases where conventional therapies had failed (71). 
ln a German university radiotherapy institute external Telecaesium irradiation is 
still being applied today using a dosage of 3 x 60 cGy with two day intervals. The 
indication is reported to be recurrent otitis media (72). 
2.6 ADVERSE EFFECTS 
In 1949 Robbins and Schulz warned about the danger of malignant degeneration 
resulting from radium irradiation of the nasopharynx. Although they only gave 
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examples of complications which arose from the treatment of haemangiomas on the 
skin and the use of X-ray treatment, they were afraid that nasopharyngeal radium 
irradiation too, would lead to damage in the long-run (55). 
Eighty-five patients treated by Samuel Crowe himself were subjected to a 
nasopharyngoscopic examination an average of 8.9 years after treatment, to inspect 
this area for abnormalities. Four cases of increased vascularization of the mucous 
membrane were observed and two cases of crustal atrophy (73). 
ln a non-concurrent prospective study by Hazen et al. on 417 people 14.6 years after 
irradiation, two malignant and five benign tumours were found, which coincided 
with the expected values (1). 
In a similar investigation by Sandler on 904 irradiated subjects an average of 25 
years after treatment, she observed significantly more brain tumours and cases of 
thyrotoxicosis than in a non-irradiated control group. One of the malignant head 
and neck tumours in the irradiated group was an undifferentiated anaplastic 
carcinoma of the palatum molle (39). 
Fairly recently, in case studies, two different authors have reported on a cystic 
adenocarcinoma of the palatum durum and vomer, observed 30 and 23 years after 
Crowe therapy, respectively (74, 75). 
2.7 SUMMARY 
Summarizing, it can be stated on the basis of data from the literature that irradia-
tion of the nasopharynx using a radioactive applicator causes the lymphatic tissue 
to atrophy. The effect persists for many years. It is possible that this form of irradia-
tion has a favourable effect on mucositis. In animal experiments no adverse effects 
on ciliary activity have been observed following contact irradiation of the mucous 
membrane. 
Many studies have been conducted on the clinical effect of the Crowe therapy, but 
very few involved a control group. In the light of these investigations, the effect of 
the therapy on various disorders appears to have been demonstrated. Its effect is 
greater in cases of light and moderate tubal dysfunction than in those with serious 
tubal dysfunction and greater in the young than in the old. The effect seems to be 
dependent on the cause of the tubal dysfunction: reversible lymphoid hypertrophy 
and mucosal swelling. 
The therapy spread widely in the 1940s, when irradiation was an accepted form of 
treatment, also for benign disorders. In America and Western Europe the therapy 
was applied on a large scale for barotrauma, otitis media serosa and recurrent ear 
infections. 
Fear of tumour induction and greater surgical possibilities on account of the 
reintroduction of tympanic tubes and the appearance of the operation microscope 
started to drive the therapy into obsolescence as from the 1950s. 
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CHAPTER 3 
HEAD AND NECK TUMOURS INDUCED 
BY IONIZING RADIATION 
3.1 INTRODUCTION 
It has been known for a great many years that ionizing radiation can induce tumours 
after a long or short latency period. In 1902, seven years after the discovery of 
rontgen irradiation, Frieben described the existence of a malignant skin tumour in 
a worker exposed to irradiation (1). In 1929 Martland reported on an osteogenic 
sarcoma following radium ingestion (2). 
In later years a relationship between the origination of a tumour in almost every 
organ in the head and neck area and previous exposure to radiation was suggested 
in casuistic publications (see Table 3.1) (3-!2). The first one concerned an induced 
larynx tumour in 1936 (3). 
In epidemiological studies dose-effect relationships have been demonstrated for 
radiation induced tumours of the thyroid gland, the brain (13) and the salivary 
glands (14,15). 
Table 3.1 First records of radiation induced head and neck tumours 
Author Publ. year Ref. Organ 
Lossen 1936 ( 3) larynx 
Kruchen 1937 ( 4) pharynx 
Duffy 1950 ( 5) thyroid gland 
Deller 1951 ( 6) tongue 
Aub 1952 (7) mastoid and nasal sinuses 
Mann 1953 ( 8) meninges 
Zillch !956 ( 9) brain 
Bab1ik 1959 (10) tonsil 
Saenger 1960 (11) salivary glands 
Rosen 1975 (12) parathyroid glands 
3.2 MEANS OF EXPOSURE 
3.2.1 Occupational 
Occupational exposure, besides that mentioned by Frieben, was especially well-
known in radiologists when radiation therapy was first introduced. Before radiation 
safety measures were enforced, leukaemia could be regarded as an occupational 
disease in radiologists (16). 
Epidemiological studies on workers in the watch industry, where dials were painted 
with luminous paint, showed an increased incidence of carcinoma of the mastoid 
and nasal sinuses. Alpha particle radiation in the radon gas released was probably 
responsible for these tumours (17,18). 
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The examination of groups of workers in nuclear ship building and nuclear power 
stations did not uncover an increased tumour induction or lead to definite conclu-
sions (quoted 16). 
3.2.2 Medical 
Most of our knowledge on radiation induced head and neck tumours is derived from 
investigations on people who have been exposed to irradiation for medical-
diagnostic or therapeutic purposes. 
When radiotherapy was first introduced, it was not only used for treating malignant 
processes but also for benign and often trivial complaints. In 1907 Friedlander 
propagated irradiation of the thymus gland in young children for treating malaise 
and breathing difficulties and to prevent cot death (19). Table 3.2 shows a number 
of benign disorders which were treated with radiotherapy. 
In America it is estimated that, in the past, one million youngsters were irradiated 
for acne vulgaris (22). In two Dutch publications estimations were also made. About 
!00,000 Dutch people are thought to have been irradiated for benign disorders (23). 
Nasopharyngeal radium application was carried out on about 25,000 (usually) 
young people (24). 
All· the indications mentioned in Table 3.2 concern external irradiation using 
rontgen radiation. Radium, used in the form of a closed source for several different 
types of application, was also thought to be associated with tumours which 
developed at a later date. These cases consisted of skin treatment for haemangioma 
planum (25) and of naso-pharyngeal application for ear disorders (26). 
Table 3.2 Benign disorders previously treated with radiotherapy in the head and neck region 
Category 
Lymphatic system 
Skin (20) 
Inflammatory I degenerative 
Disorder 
larged thymus gland (19) 
hypertrophic tonsils and adenoid 
hirsutism 
acne vulgaris 
greasy skin and large pores 
haemangioma 
psoriasis 
keloid 
tuberculotic lymphoma 
tinea capitis (21) 
arthrosis 
mastoiditis 
sinusitis 
The internal use of iodine (1 130, I131 and ! 125) for the treatment of thyrotoxicosis 
meant a particularly high radiation dose to the thyroid gland and is also associated 
with tumour induction (27-31). 
ln the first half of the century, the oral administration of radium (Ra224, Ra226) was 
recommended for many types of disorder. lt was used in the form of radium drink 
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cures, radium bread or injections, often without the mediation of a doctor 
(97,18,32). 
Contrast media containing thorotrast, instilled into the maxillary sinus often 
resulted in local or remote tumour induction (33-35). It has been reported that an 
extravasate of the medium, the result of a problematic carotis angiography, caused 
a malignancy in the neck (36). 
3.2.3 Atom bomb explosions 
Radiation induced head and neck tumours were also observed following exposure 
to radioactive dust resulting from atom bomb explosions in Hiroshima (gamma 
radiation and a large amount of neutron radiation) and Nagasaki (gamma radiation 
and a small amount of neutron radiation) and atomic tests near the Marshall Islands 
(gamma radiation and various isotopes) and in the deserts of Utah and Nevada. 
3.3 RISK FACTORS 
3.3.1 The tumour induction rate 
The chance of developing a radiation induced tumour is often expressed in figures: 
the tumour induction rate. In the UNSCEAR report in 1977 (37), this rate was 
defined as the number of radiation induced tumours which developed per l 00 
persons per rad during a certain observation period (n.J0·6.rad"1). 
This tumour induction rate ignores a number of characteristics concerning the 
people exposed, such as age on exposure, sex and ethnical factors, plus a number 
of characteristics concerning the ionizing radiation itself, such as the type of radia-
tion, fractionation and dose rate. It also suggests the existence of a linear relation-
ship between the dose and the number of induced tumours as well as between the 
observation time and the number of induced tumours. Besides the tumour induction 
rate, it is also possible to establish a tumour mortality rate on the basis of the 
number of tumours which prove to be fatal. This value varies considerably from 
organ to organ (see Table 3.3). 
It is important to bear these limitations in mind when employing these rates. The 
figures, with the exception of one or two cases, were compiled on the basis of a small 
Table 3.3 Tumour induction and mortality rates for head and neck organs per 106 persons per cGy 
(UNSCEAR) (37) 
Organ 
Thyroid gland 
Brain 
Salivary glands 
Sinus mucosa 
Bone 
Skin 
All other organs 
Tumour induction rate 
100 
10-15 
10-15 
2- 5 
2- 5 
5 
*All organs, including leukaemia, for doses >100 cGy 
Tumour mortality rate 
10 
10-15 
5 
? 
? 
0 
100* 
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number of studies and on exposure to moderate or high radiation doses. The risks 
involved with exposure to low doses of radiation have been estimated by extrapola-
tion. Longer observation times in the epidemiological studies still being conducted 
and future epidemiological investigations will possibly lead to alterations in these 
figures and produce more precise data. Tumour induction rates and tumour 
mortality rates are used to estimate the risks involved in radiation exposure during 
medical treatments and during nuclear disasters. 
3.3.2 Characteristics of the exposed organism 
Sex 
Women appear to be more sensitive to radiation induced thyroid tumours than men. 
Van Daal observed a ratio of 2:1 after a thorough review of the literature (38). In 
the judgement of the differences, it should be borne in mind that non-radiation 
induced thyroid tumours are also more common in women. 
In a study on survivors of the atom bomb in Hiroshima, Ohkita observed a higher 
incidence of salivary gland tumours in the women in a non-exposed control group 
and a higher incidence in men in the exposed group (39). 
Age on exposure 
In persons who were exposed to irradiation antenatally, it has appeared that 
tumours can be induced by very low doses of radiation (40). In many studies, it has 
been indicated that younger individuals are generally more sensitive to tumour 
induction via radiation than older people (41-43). In old age the sensitivity has been 
found to increase again (44). 
Ethnical factors 
In a controlled cohort study, in which 2,872 young adults who had been treated with 
rontgen radiation in their youth were compared with 5,005 non-irradiated family 
members, it appeared that radiation induced thyroid tumours occurred 3.4 times 
more often in Jewish children than in non-Jewish children. In the irradiated group, 
24 malignant en 52 benign thyroid tumours were observed, whereas these figures in 
the non-irradiated group were six and nought, respectively (45). 
In an American controlled cohort study on 2,200 children who had been irradiated 
for tinea capitis compared to a group of 1 ,400 non-irradiated children, it appeared 
that skin tumours had occurred exclusively among the white children, particularly 
those from Ireland, while the study group comprised 250Jo coloured children. In the 
irradiated group there were 41 people who developed one or more skin tumours, 
whereas in the control group only three skin tumours were observed (46). 
Genetic factors 
It is probably possible to designate groups of individuals who have a genetically 
increased chance of developing a radiation induced tumour. It has been brought 
forward by several authors that the high incidence of tumours which arose after 
irradiation in patients with multiple cases of retinoblastoma in their family, can be 
attributed to a radiation induced second mutation in cells which are genetically 
predisposed to neoplastic transformation (47,48). An increased risk is also thought 
to exist in patients with multiple paragangliomas (49) and in patients with the nevoid 
basal cell carcinoma syndrome (50). 
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Schneider et a!. established that persons who were irradiated in their youth for 
benign disorders in the head and neck region and who later developed neurogenic 
and salivary gland tumours, ran more risk of also developing a thyroid tumour than 
those who did not develop such tumours. They concluded from this there were 
subgroups within the total irradiated population who had a different sensitivity to 
developing radiation induced tumours. Genetic factors, among other things, were 
indicated as a possible cause (42). 
In their study on radiogenic skin tumours, Shore et al. also found evidence of more 
and less sensitive subgroups (46). 
Metabolic circumstances 
Irradiation of the thyroid gland causes - depending on the dose - a disturbance in 
the hormone balance which leads to an increase in the secretion of TSH by the 
pituitary gland. Animal experiments have shown that over-stimulation of the 
thyroid cells by TSH can induce thyroid tumours (quoted 51). 
Belsky et al. were of the opinion that the origination of salivary gland tumours in 
survivors of the Japanese atom bomb explosions was probably assisted by the poor 
state of nourishment owing to the war. This was based on the suggestion that the 
high incidence of salivary gland tumours in Eskimos is due to a chronic vitamin A 
deficiency from which they suffer (52). 
Finally, several authors have pointed out the possibility that radiotherapy has an 
increased tumour inducing effect in patients who are being treated with cytotoxic 
drugs at the same time (53-55). 
3.3.3 Characteristics of the pllysical agent 
Radiation type 
Animal experiments have shown that in the low dose region, high LET radiation 
(alpha and neutron radiation) has a greated tumour inducing capacity than low 
LET radiation (gamma and rontgen radiation) per dose unit (56). This was also 
shown for the induction of leukaemia caused by the atom bomb explosions in 
Japan (41). 
Radiation energy level 
A few authors have suggested that high energy radiation, such as megavolt and 
cobalt radiation, carries less risk of inducing tumours than low energy radiation, 
such as orthovolt radiation (57,58). As possible causes they indicated the greater 
radiation exposure of healthy tissues, inherent of the lower energies themselves 
(irradiation of the skin, scatter) (57) and a greater likelihood that the patient will 
move due to the longer irradiation times involved with orthovolt treatment (42). 
Lund et al., however, observed eight cases of secondary tumours in patients who 
had undergone cobalt radiotherapy, whereby the treatment data had been 
documented very carefully. He found five in the region which had received the 
highest dose and three in the periphery of the irradiated area (59). The expectation 
that proton radiation will carry less chance of tumour induction also seems to be 
unfounded (60). 
The short latency times observed by Lawson et al. using megavolt irradiation 
compared to orthovolt radiation, which they attributed to the difference in 
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biological effect, are more than likely the result of the study methods used (case 
reports vs. cohort studies) (61). 
Finally, Taylor suggested the possibility that the more modern and more effective 
radiotherapy methods, megavolt and cobalt radiation, will lead to a larger number 
of induced tumours in the long run, owing to the longer survival rates (57). 
Dose rate and fractionation 
Animal experiments have shown that longer radiation times for low LET radiation 
have a sparing effect on the origination of tumours (62). Fractionation was seen to 
have the same effect on the induction of pituitary tumours in animals (56). ln an 
experiment concerning the origination of radiogenic skin tumours in animals, no 
difference was observed either between single or fractionated doses of radiation 
(63). 
In man, fractionation is thought to reduce the risk of thyroid tumour induction (64). 
No differences were found with regard to the risk of the induction of breast tumours 
following fluoroscopy and the induction of leukaemia (quoted 41). 
Dose 
The lowest radiation doses after which induced head and neck tumours have been 
observed are recorded as being 6 or 7 cGy for the thyroid gland, 39 cGy for the 
parotid gland and 140 cGy for the brain (21,65). 
On the basis of several studies, a linear dose-effect curve has been drawn up between 
6 to 7 cGy and 1500 cGy for the induction of thyroid tumours (45,65-67). For this 
gland it is assumed that the tumour inducing capacity decreases strongly above a 
dose of 2000 cGy because, together with the destruction of thyroid tissue, the chance 
that malignant degeneration will take place becomes proportionally smaller (cell-
death function) (22). 
In the study on the effects of the Japanese atom bomb explosions on salivary gland 
tumours, a dose-effect relationship has been established in terms of: the chance of 
tumour induction in exposed persons increases as their distance from the hypocentre 
decreases (15,39). 
Seydel! suggested that a high dose of radiation (more than 5000 cGy), such as the 
dose given during the radio-therapy of malignant processes, carries a relatively 
smaller chance of secondary tumour induction than moderate or low doses. 
However, his own retrospective case-control study of the five year survival rates 
following the radiotherapy treatment of, among others, oropharynx tumours, which 
he conducted on the data at a cancer registration office, did not provide any convin-
cing proof of this (68). 
3.3.4 Latency time 
The latency times, between the exposure to irradiation and the manifestation of a 
tumour, differ considerably. For instance, for skin tumours the shortest and the 
longest latency times are assumed to be 3 and 64 years, respectively (20). In the case 
of parotid tumours, a minimum latency period of 2 years has been proposed (69). 
ln his study concerning radiogenic thyroid tumours, based on data from the 
literature, Van Daal showed that the average latency period increases as the observa-
tion time increases. This may be due to the fact that the period in which the tumours 
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Figure 3.1 Relation between the time of exposure and the tumour manifestation time. 
are likely to express themselves, after a certain minimum latency period, is unlimited 
(see Figure 3.1) (38). 
3.3.5 Dose-response curve 
In general, it is not possible to determine the exact course of the dose-response curve 
because epidemiologic data are lacking. An estimate can be made on the grounds 
of extrapolation of high to low doses and from animal to man. It can be assumed 
that, in the light of ioni2ation distribution in space and time, the interaction between 
ionizing events in tissue in tlte very low dose range are negligible. The dose response 
at molecular and cellular level will, therefore, be linear. Although quantitative 
extrapolation from animal to man is unfeasible, it is possible to apply the shape of 
the dose-response curve from animals to man because the mechanism of cancer 
induction is the same for animals and human beings that have been exposed to low 
radiation doses (see Figure 3.2) (41). 
3.3.6 Summary of the risk factors 
In summarizing the risk factors, it is possible that sex may have some influence on 
the sensitivity of the origination of radiation induced head and neck tumours. 
However, we should keep in mind here, that sex can also predispose to the 'spon-
taneous' appearance of tumours. For instance, non-radiation induced thyroid 
tumours occur more frequently in women than in men. 
The age on exposure, ethnical and genetic factors also seem to be of influence to 
radiation sensitivity. In the long run, it might become possible to indicate more 
groups within the population who are more at risk due to certain heredity factors, 
besides persons with multiple familial retinoblastomas, multiple paragangliomas 
and the nevoid basal cell carcinoma syndrome. 
There are clear indications that the interior environment has an influence on the 
radiation sensitivity with regard to the induction of tumours. A high TSH level, a 
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Dose (cGy) 
Figure 3.2 General dose-response model for radiation carcinogenesis, based on radiobiological 
experiments and epidemiological studies. I, tumour incidence; D. radiation dose: ao. spontaneous 
incidence of tumours in the population; a" linear component; a 2, upward-curving quadratic compo-
nent; {31 and {32, downward-curving components, defining cell-killing function. 
According to: Fabrikant J .I. (41). 
poor nutritional state and simultaneous treatment with cytotoxic drugs have been 
mentioned in this respect. 
It has been shown that high LET radiation carries a higher tumour inducing capacity 
than low LET radiation. Some authors have suggested that therapeutic megavolt 
and cobalt radiation carries less risk of inducing tumours than orthovolt radiation. 
If this appears to be true, it will not be the result of the difference in energy, but 
to the radiation methods used: better skin sparing and less scatter. In the future, 
a larger number of radiation induced tumours can be expected because the modern 
high energy radiotherapy treatment methods will be more effective in curing the 
primary tumour and, therefore, the patients will live longer. 
On the grounds of animal experiments and epidemiological studies, it is not possible 
to make a definite judgement on the influence of dose rate and fractionation. Both 
possibly have a sparing effect. 
For every organ, the latency time of radiation induced tumours can differ 
considerably from person to person. The average latency time for radiation induced 
leukaemia is about 10 years and for solid tumours several decades. The manifesta-
tion time for radiation induced thyroid and salivary gland tumours seems to be 
limitless after a certain minimum latency period. 
A dose-effect relationship has been established for the thyroid gland. It is assumed 
that there is a linear relationship for doses between 6 to 7 cGy and 1500 cGy. Above 
2000 cGy the tumour inducing capacity decreases due to the destruction of thyroid 
tissue. A dose-effect relationship has also been demonstrated for salivary gland 
tumours. 
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3.4 STUDY DESIGNS 
Initially, the relationship between the origination of tumours and prior irradiation 
was suggested in the light of case histories. 
Duffy et a!. (1950) established in their case-control study that in 28 cases of thyroid 
carcinoma, 9 cases had undergone irradiation of the thymus gland in their youth (5). 
Similar studies concerning the development of other tumours were carried out by 
Ju (1968) (73) on the salivary glands, by Martin eta!. (1970) (20) on the skin and 
by Sakamoto eta!. (1979) (74) on the pharynx. 
The first non-concurrent cohort study was conducted by Simpson et a!. (1950) on 
people who had been treated with rontgen irradiation to the thymus gland (75). 
Hazen et a!. (1966) carried out a similar study on people who had been irradiated 
in their youth for abnormalities in the head and neck region (51). Madan et al. 
(1974) (21) examined a group of Jewish immigrants who had been irradiated on 
account of tinea capitis and Belsky et al. (1975) (46) investigated a group of people 
exposed to the Japanese atom bomb explosions. 
A real health problem proved to be the radiation induced thyroid carcinoma: the 
'Chicago endemic' (64). Screening for thyroid abnormalities was carried out by 
Pincus in 1967 (7 6). 
ln the 1970s, so-called Recall Clinics were set up in America, whereby people who 
had been irradiated in their youth were called up, examined and possibly operated 
on for thyroid abnormalities (77-79). 
In the Netherlands follow-up investigations for thyroid abnormalities were also 
carried out via random sampling on people who had been irradiated in the head and 
neck region in their youth, in order to see whether it was necessary to examine all 
the people with this anamnesis (23). 
3.5 SAUV ARY GLANDS 
Induced salivary gland tumours were observed in non-concurrent cohort studies 
following irradiation for benign ENT abnormalities (13,51), tinea capitis (21) and 
in the survivors of the Japanese atom bomb explosions (43.,52). 
From casuistic literature it is known that occupational exposure, 1131 therapy for 
the treatment of thyroid carcinoma (80,81) and nasopharyngeal radium application 
to reduce hypertrophic adenoid tissue (81) have been held responsible for the induc-
tion of neoplasms of the salivary glands. Saksela et al. observed three cases of 
parotis carcinoma following the irradiation of benign mixed tumours of the same 
gland (quoted 82). 
The phenomenon of increased sensitivity in younger age groups reported in 
Japanese research, was toned down in a later publication (43,52). 
In a series of 31 possible radiation induced salivary gland tumours, Katz et al. 
discovered a woman-man ratio of 3:1. However, they also observed that women 
were exposed to radiation treatment (for keloids and ! 131 for thyroid abnormalities) 
more often than men (81). No differences were observed between the sexes in cohort 
studies on people who received external rontgen irradiation for benign ENT abnor-
malities (83), or in case-control studies on a group of people exposed to radioactive 
fall-out (14,15). 
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Table 3.4 Literature survey: radiation related salivary gland tumours 
Author (ref.} Year Study Type N/n• Dose Latency Age m/f Malignant'/ Lo~alisation Histology Remarks 
type exposure (cGy)U (yrs)•• exp.u Benign 
Ju (73) 1968 case X-ray 1 200-300 15-25 18.5 4/3 4/2 parotis 5 mucoepiderm. ca. 2 
(radium or more (I bilat.) submandib. 2 mixed tumours 2 
workers) other 3 
Smith (84) 1974 case X-ray 2 25 5-10 Ill Ill parotis mucoepiderm. I -family history positive 
mixed tumour I -father radiologist 
Wiseman (80) i982 case OIJ 2 350/675 3/10 2/0 parotis non-Hodgkin -one c:ase also thyroid care. 
me lymphoma 
llacha (53) 1983 case X-ray I 2,400 5 12 0/1 0/1 parotis mucoepidermoid ca. -suggested co-factors: comtitu-
(for leukemia) lion and immunosuppression 
by medication 
Takeichi (14} 1976 case- A-bomb 36/ 211 19/17 19/17 mucoepiderm. t'a. 6 -benign tumours mostly mixed 
control (Hiroshima} malig. mix, ca. 5 tumours 
other malignant 8 
Walker (69) 1981 l'USC· X-ray 6/ 72 3,820 9 33 J/3 6/0 parotis mucoepiderm. ca. 2 -induced tumours behave like 
control mixed malignant 2 spontaneous tumours 
other 2 
Takeichi (15) 1983 case- A-bomb 621 208 31/31 parotis 43 mtxed malig. II -benign mixed tumours 22 
control (Hiroshima) submandib. 14 mucoepid, ca. 7 -RR = 11.0 
other 19 other 13 
Katz (81} 1984 case- X-ray, 
control radium, 1311 31/ 275 800-1200 11-66 3-29 8/23 11120 parotis 24 mucocpiderm. ca. 6 -4 patients had multiple le~ions 
other II adenoid cyst. ca. 3 -6 patients also had thyroid 
other 2 tumours 
-I patient had tonsillar radium 
treatment 
Saenger (II) 1960 cohort X-rny 21 2,230 450-600 7-11 1-7 Ill 2/0 mucoepiderm. ca. I 
adenocarcinoma I 
Hazen (51) 1966 cohort X~ray, 
radium 2 I 971 575/862 5-9 7-8 1/1 'mixed 
tumours' 
lkhky (43) 11)72 ~·ohort A-bomb 12/44,471 1->JOO 
" 
26 6/6 5/7 paroti~ 7 mu~o·ocpiderm. ca. 2 -po<;itive dLHt'·eff('d rdation<;]lip 
(Hirmhimu) -~ubmandib. 3 <~cink cell ca. I -younger age, higha rhk 
(Nagasaki) minor glands 2 other 2 
1\lodan (21) 1974 cohort X-ray 17/11,000 140 Ill 4/3 paroti' 
Bd~ky (52) 1975 ~·olwrt A-bomb 16/41,797 1~>300 26 S/S 5/11 l'f Bchki (1972) cf Bebki (1972) -pos~ible peak bemcen '61 and 
(1-liroshima) paroth J benign 4 '65 
(Nagasaki) ~ubmandib. 
Shore I 1101 1976 cohort X-ray 4/ 2,215 39 20 7 3/1 1/3 parotis mhed tumours 2 -4oo:o (';o.ce'is p,ychiatrk 
pap. c~stadtno, I disorders among white expmcd 
acinic cell ca. I persons 
s~·hm•idn (1'13) 11)77 cohort X-my 27/ 1,1)22 suo 22 4.5 IH/9 (in lVII) parutb 21 mhed bcnign 17 -control group mb,ing 
pop. ~ubmandib. 2 mueoepidcrnl. ca. 7 -inl'idcnee does not decline 
2: I) minor gland~ 2 other 3 after JS yrs 
Colman (13) 1978 cohort X-ray J7/ 5,166 SOl 22 6.) 10127 parotis 31 -no dus~.·-dfcct relationship 
submam1ib. 
unknown 2 
Schneider (70) 19S5 cohort X-ray 67/ 5,37'} 16/51 -inddence does not dedine 
in casuistry: number of eases 
in case-control studies: irradiated cases/ total number of cases 
in mhort swdie<o: eases I total study group 
+* one figure indicate~ the absolute or mean number, otherwise the range h gi\·cn 
;\5 
Three quaners of the salivary gland tumours are found in the parotis gland; the 
remaining ones are found in the submandibular or small salivary glands. One half to 
two thirds are malignant. In many cases multiple localizations are observed (81,84). 
In 1942 Friedman discovered that the ductal epithelium of the salivary glands is very 
sensitive to irradiation (85). Histological examination of salivary gland tissue several 
months after exposure, revealed pleomorphism and atypia of the ductal epithelium 
(86). Other researchers succeeded in inducing a neoplastic cell line in nude mice 
using tissue from an. irradiated human submandibular salivary gland (87). 
Most of the malignant tumours are muco-epidermoid carcinomas (69). Other types 
which have been observed are malignant mixed tumours, adena-cystic carcinomas, 
acinous cell tumours (83) and malignant lymphomas (80,81). By far the most benign 
induced salivary gland tumours are mixed tumours (15,43). 
The latency times observed vary between 10 and 25 years (43,77). The shonest 
latency time recorded is 2 years (69), the longest 66 years (81). 
The lowest doses to have been known to induce salivary gland tumours are 39 cGy 
(65) and 140 cGy (21). 
There are too few data available to be able to draw up a dose-response curve. The 
examination of a population of Japanese who were exposed to the atom bomb 
explosions revealed evidence that the chance of people developing a salivary gland 
tumour depended on their distance from the explosion: the closer they were, the 
higher the risk (15,39). 
Takeichi et a!. carried out a case-control study on 208 patients with a histologically 
confirmed salivary gland tumour. Sixty-two were survivors of the atom bomb explo-
sion in Hiroshima and 146 had not been exposed. An RR of 11.0 was established 
on the basis of the total number of exposed and non-exposed persons. They 
suggested that the incidence had reached its peak and was on the decrease, because 
the incidence in the five year interval, between 1967 and 1971, did not reach the 
same level as between 1957 and 1961 (15). 
The study results per author are shown in Table 3.4. 
3.6 BRAIN AND MENINGES 
Irradiation of the neuro-cranium is not only likely to cause necrosis of the brain 
tissue but, in the long term, it can also lead to tumour induction in the brain and 
meninges. 
These radiation induced tumours are usually the result of the medical-therapeutic 
treatment of malignancies, such as retinoblastoma (88), esthesioneuroblastoma (89) 
and pituitary adenoma (90), or of benign conditions, such as haemangioma planum 
of the skin (25), tubal disorders (26) and tinea capitis (91). 
Also medical-diagnostic procedures, such as ventriculography using thorotrast, 
have been brought into association with brain tumours which developed later (92). 
Recently, research has been carried out into the occurrence of brain tumours in 
occupationally exposed persons (93,94). 
In the judgement of a second tumour, occurring after a latency period following 
irradiation, it is useful to note that multiple tumours arise in cases with 
phakomatoses, such as m. Recklinghausen. Sometimes double spontaneous brain 
tumours are observed, but this is very rare (95). 
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The most frequently observed radiation induced tumours are meningiomas (8), 
sarcomas (96) and astrocytomas (97). 
In their report on 38 cases of radiation induced meningiomas, Iacono et al. made 
a distinction between tumours which arose following a low dose of radiation and 
those which appeared following a high dose, The group exposed to a high dose of 
radiation (2300-7200 cGy) displayed a shorter latency time (20.8 year:s) than the low-
dose group (less than 800 cOy; 3L3 years). There also appeared to be a difference 
in the man-woman ratio: in the case of radiation induced meningiomas the ratio was 
19:15 and in 'spontaneous' meningiomas 5:9 (98). 
Madan et al. found four meningiomas in a cohort of 10,912 people who had been 
irradiated on account of tinea capitis and one case in a control group of equal size. 
These figures are too small to draw definite conclusions (21). 
Animal experiments have shown that meningiomas can be induced by Co60 (99). 
According to Powell et al., 15 cases of post-radiation sarcoma were described till 
1977, located in or around the sella turcica in patients irradiated for brain or 
pituitary tumours. These tumours consisted of twelve fibrosarcomas and three 
osteogenic sarcomas. The radiation doses varied between 2400 and 7800 cGy and 
the latency times between 2.5 and 21 years (100). 
Three years later Martinet al. gave an overview of 18 sarcomas: 14 fibrosarcomas, 
one osteosarcoma, one malignant fibrous histiocytoma and two undifferentiated 
sarcomas. They noted an average latency time of 10 years (101). Case reports have 
continued to appear since then. 
Metastasising meningeal sarcomas could be induced in animal experiments by injec-
ting the offspring of pregnant rats with Sr90 on the 18th day of gestation (103). 
Piatt et al. published a complete review of the literature on astrocytomas which were 
thought to be radiation induced. Seventeen cases were involved, the first was 
described by Jones in 1960 (97). Thirteen of the patients had been irradiated on 
account of brain tumours and four for benign disorders. The average latency time 
was ll.l years, the doses varied between 400 and 6000 cGy (104). 
In animal experiments it was possible to induce ependytnomas in monkeys (105) and 
glioblastomas in monkeys (106) and rats (107). 
A more unusual radiation induced tumour is the schwannoma (108-110), which has 
also been induced in animal experiments (107). One case of acoustic neuroma was 
described which arose following radiotherapy (110). 
In a group of 2,215 people who had been irradiated for tinea capitis in their youth, 
Shore et al. found an incidence ratio of 2.8:1000 for benign and malignant brain 
tumours together. No such tumours were found in the control group (110). Modan 
eta!. observed a ratio of 1.4:1000 in a group of 10,912 people treated in the same 
way, a significant difference with two control groups (21). In the treatment method 
for tinea capitis the pituitary gland received a dose of 50 cGy and the brain 120 to 
140 cGy (65). 
Sandler et a!. found three brain tumours (two astro-cytomas and one unspecified) 
in a group of 904 persons who had been treated using nasopharyngeal radium 
(average 4.208 mgmin) after a mean follow-up period of 25 years. The incidence 
ratio was 3.7:1000. In a control group of 2,021 people treated in a different way no 
brain tumours were observed. 
The difference was significant. The brain received 44 to 177 cGy in the exposed 
group (26). 
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v. Table 3.5 Literature survey: radialit•n related tumours brain and meninges 
"' 
Author (ref.} Year Study Type N/n• Dose Latency Age m/f Malignant! Localisation Histology Remarks 
type exposure (cGy)U (yrs)•• exp.u Benign 
Reller (91) 1972 case X-ray tinea capitis 16 22-45 7.6 10/6 0/16 meninges meningioma 
Gonzalez- (90) 1976 case X-ray pituitary I 5,000 II 1/0 1/0 malignant fibrous -presents literature survey 18 
Vit.1le tumour histioc~·toma fibrosar~·onlas after 
radiotherapy for brain tumours 
Powell (100) 1977 ca~e X-ray I 5,000 13 52 1/0 l/0 hypophysis fibrosarcoma -presents literature data: 
dose~ 2400-7800 cOy 
latency 2.5 - 21 years 
Robinson (!OS) 1978 case X-ray 3 3,400 24.5 19 211 211 astrocytoma 2 
ustrocytoma I 
Sogg (109) 1978 case X-ray I 6,007 5 9 0/1 1/0 a~trocytoma -radiated craniopharyngioma 
craniopharyngioma enhance~ risk for radiation~ 
induced tumours 
Coppcto (60) 1979 ~·usc Proton radiation I 10,000 7 •16 1/0 1/0 fibrom hi~tincytoma 
acromegaly 
Prcissig {49) 1979 case X-ray glomus I 4,480 8 43 1/0 l/0 cerebellum a~trocytoma 
jugulare 
Martin (101) 1980 case X-ray pituitary I 4,500 5 18 0/1 1/0 hypophysis pituitary -presents literature data pmt-
tumour fibrmarcomu irradiation pituitary sarcomas: 
median latency 10 years 
Cohen (95) 1981 case X-ray I 8,000 14 4 0/1 1/0 frontal lobe astrocytorna 
medulloblastoma 
J,Kono (98) 1981 case X-ray I 5,000 27 J 0/1 1/0 multiple meningiomas -for post-irradiation meningio-
medulloblastoma lesions mas applies: afler low-dose 
radiation latency i~ longer (30 
years) than after high dose (20 
years) 
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The differences in incidence ratio between these three studies can be explained by 
the differences in observation time. 
Colman et aL conducted an investigation on 5,166 subjects who had been exposed 
to rontgen irradiation in their youth. Eighty per cent had been irradiated on the 
tonsils and adenoid. In the 3,108 people traced, 23 tumours of neural origin were 
observed, including nine brain tumours (a ratio of 2.9:1000 was established). The 
six malignant tumours found were 32 times higher than would have been expected 
on the grounds of the incidence in the American population. The average age on 
exposure was 3.8 years. After the division of the 23 tumours according to the 
amount of radiation received, a positive dose-effect relationship was observed. 
Unfortunately, this study did not involve a control group (13). 
Table 3.5 shows the study results per author. 
3.7 PHARYNX AND LARYNX 
Radiation induced tumours of the pharynx and larynx have only been described 
following medical treatment with ionizing radiation. Nearly all the cases were 
associated with rontgen (initially orthovo1t, later also megavolt) or cobalt irradia-
tion (61). One single case has been described following internal 1221 application 
(31). 
The tumour inducing irradiation was usually given for benign complaints, such as 
tuberculotic lymphomas (!11), thyrotoxicosis (!12), tubal disorders (74) and larynx 
papillomas (113-115). 
Malignant (55, 74) and benign (116) head and neck tumours formed other indica-
tions for irradiation, particularly the first stage of larynx carcinoma (57 ,59,61, !17). 
The radiation treatment doses varied between 450 (ll8) and 1100 (ll9) to 20,000 
(74,111) cGy. 
By far the most induced tumours of the pharynx and larynx are squamous cell 
carcinomas. Only very few fibrosarcomas have been described (68,120,121). 
Sporadic tumour types, such as angiosarcoma (122), acinous cell carcinoma (123), 
adenocarcinoma (124) and malignant fibrous histiocytoma (116), have also been 
described. 
In 1965 Goolden et al. published an overview of 67 pharyngeal tumours, from the 
literature up till then, which were thought to be radiation induced. The reasons for 
exposure were usually tuberculotic glands or thyrotoxicosis. In most cases the 
origination of the pharynx tumour was preceded by a radiation induced skin tumour 
in the irradiated area. The average latency time of the pharynx tumours was 30 
years. The post-cricoid region appeared to be the most sensitive (125). 
The fact that the hypopharynx is sensitive to radiation induced tumours is also 
evident in case-control studies in groups of cancer patients. In 1967 Van Dishoeck 
found that 80Jo of the patients who he had treated on account of hypopharynx 
tumours had a radiation treatment in their anamnesis (126). Similarly, Beekmans 
discovered that in a group of 328 patients with a larynx or hypopharynx tumour, 
21 of them had undergone radiation treatment an average of 20 years previously 
owing to benign disorders in the head and neck region. Eight of these tumours were 
localized in the hypopharynx (quoted 127). 
A study by Lawson et al., in which they examined the division of 45 post-irradiation 
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tumours of the larynx, pharynx and oesophagus, also provided evidence that the 
hypopharynx is more sensitive to radiation induced tumours than the larynx. The 
average latency time was 27 years. Thirty-three of the tumours appeared to be 
localized in the hypopharynx (61). 
Sakamoto et a!. supported these results in a patient-control study on 2,030 patients 
with a malignancy of the pharynx, larynx or thyroid gland. Seven out of the 584 
pharyngeal tumours (1.20"7o), two out of the 1208 larynx tumours (0.17"7o) and six 
out of the 202 hypopharynx tumours (2.97"7o) had developed following radiation 
treatment. The number of hypopharynx tumours which arose following irradiation 
was even higher than for the thyroid gland (6 out of 238 = 2.52"7o)! In the 
epipharynx carcinoma patients, no radiation treatment was mentioned in the 
anamnesis. The latency time for the induced hypopharynx carcinomas was 30.2 
years (74). 
Goolden's finding that the post-cricoid region is predisposed to developing radiation 
induced tumours was supported in a recent study by Stell. He observed that 18 of 
the 385 patients with a hypopharynx tumour had been irradiated in the past on 
account of benign disorders, usually thyrotoxicosis. In II of these cases the process 
originated from the post-cricoid region. The average latency period was 35 years. 
The fact that 15 of the 18 tumours were found in women was explained by the obser-
vation that thyrotoxicosis and post-cricoid carcinoma are more frequent in women 
(119). 
The relationship between the irradiation of an early stage larynx carcinoma and the 
origination of a second primary tumour in the irradiated area has been studied in 
several cohort studies. The first reports on tumour induction in the irradiated region 
appeared in 1955 (128). 
Lawson et a!. followed 535 patients for 5 to 25 years after treatment for a Tla or 
Tlb larynx carcinoma. The treatment had consisted of surgery or radiotherapy. 
Thirty patients developed a second primary tumour of the larynx or hypopharynx, 
9"7o belonged to the irradiated group and 3.9"7o to the surgical group. They also 
studied all the known cases of radiation induced tumours of the larynx or pharynx 
and made a striking observation. The latency period for the development of larynx 
or hypopharynx carcinoma following orthovolt radiotherapy, on account of benign 
neck disorders, appeared to be 27 years. This latency time decreased to 12 or 15 
years if the radiation beam had been aimed at the larynx for the treatment of larynx 
papillomas and fell further, to 7 years, after megavolt radiotherapy for larynx 
carcinoma. On these grounds they assumed that megavolt irradiation had a higher 
radiobiological effect. The short latency period following megavolt therapy together 
with an increase in life expectancy caused them to advise against applying this treat-
ment in persons younger than 50 years of age (61). In their comparison of the 
latency times, the authors did not take two factors into consideration which could 
influence the latency time. In the first place it is possible that the short latency time 
of the tumours induced following the irradiation of juvenile papillomas, was due 
to the young age at which the children were irradiated. Secondly, the latency times 
in the various studies were calculated in different ways. Case reports were used for 
radiation induced tumours following radiotherapy for benign neck disorders and 
juvenile papillomas and a cohort of persons was followed for tumours induced after 
radiotherapy for larynx carcinoma: if the observation time had been longer the 
average latency time would have probably increased. 
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v. Table 3.6 Literature survey: radiation related malignant tumours larynx and pharynx 
"' 
Author (ref.) 't'car Study Type N/n• Dose latency Age m/f Localisation Histology Remarks 
type exposure (cGy) .. (yrs)u exp. •• 
Los sen (3) 1936 case X-ray 2 10 2/0 larynx -Patient sued radiotherapist for 
lymph glands damages 
Kruehen (4) 1937 o:asc X-ray I 20 45 1/0 hypopharynx carcinoma simplex 
thyroid gland 
Den Hoed (Ill) 1946 case X-ray tuberculous 2 20,000 27-28 16 Ill larynx carcinoma -In one patient also .~kin tumour 
glands 
Holinger (123) 1953 case X-ray 3 25 31 112 larynx 2 carcinoma I -Literature survey: 12 cases 
tuberculous glands hypopharynx I fibrosarcoma I -3 men, 9 women 
-latency 16-32 years 
Goolden (125) 1965 case X-ray 4 40 36 0/4 oesophagus 2 carcinomas -Indicates post cricoid region of hypo-
thyrotoxicosis hypopharynx 2 pharynx as a sensitive area 
Mt.:Graw (Ill) 1965 case X-ray J 3,000 36 17 112 oesophagus I carcinomas -All patients also have another 
larynx I tumour in the irradiated field 
laryngophar _ynx 
Gerlings (112) 1969 case X-ray 
' 
3,000 33 25 2/J larynx 3 carcinomas 
hypopharynx I 
oesophagus I 
Taylor (57) 1977 t.:ase X-ray larynx II tumour II 5I 912 larynx cart.:inomas -Author questions course of second 
carcinoma dose tumour: radiation, carcinogenic 
behaviour or immunologic predestina-
tion 
Donaldson (121) 1978 case X-ray larynx I 5,600 II 68 1/0 larynx fibrosarmma 
carcinoma 
, 
t\fl'Killop (JI) 1978 case X-ray I 2x30mCi 8 44 0/1 laryn)( sarcoma 
thyrotoxicosis 
v. 
__, 
Reibel (123) 1981 case X-ray I 450 46 
thyroto.xkosis 
Narula (122) 1986 case X-ray 2 5,200 21-25 
Ueekrnans 1966 case X-ray 211 328 20 
(cited 127) control benign diseases 
Sakamoto (74) 1979 case X-ray 14/ 2,015 6,600 2& 
control 
Stell (119) 1984 case X-ray 181 385 I, 100-3,200 35 
control 
Seyde\1 (68) 1975 cohort X-ray 91 611 6,800 2·32 
malignancies 
Lawson (61) 1975 cohort X-ray 201 225 tumour 5-25 
larynx carcinoma dose 
Glanz (117) 1976 cohort X-ray 251 60 tumour 9.9 
larynx carcinoma dose 
Lund (59) 1982 cohort X-ray 10/ 266 tumour 12 
larynx carcinoma dose 
in casuistry: number of cases 
in case control studies : irradiated cases/ total number of cases 
in cohort studies: cases I total study group 
u one figure indicates the absolute or mean number, otherwise the range is given 
10 011 subglottic acinic cell carcinoma 
tracheal 
16-35 210 nasopharyn.x angiosarcoma 
larynx 13 
hypopharynx 8 
20 4/10 pharynx 7 carcinomas -Epipharynx relatively resistent 
larynx 2 to radiation induced tumours 
thyroid 6 
(double) 
3/15 hypopharynx carcinomas 
postcrkoidal 
(I double) 
oropharynx epidermoidcar· High dose radiation bears lower 
cinoma 8 risk than low or medium doses 
fibrosarcoma 
hypopharynx 2 carcinomas -Lilerature survey: 45 cases 
larynx 18 hypopharynx 33, larynx 12, 
oesophagus 2 
mean latency 27 years 
51.3 24/ I larynx carcinomas -Ten cases were taken from other 
studies 
911 larynx 10 carcinomas· Discusses smoking habits: concludes 
pharynx I radiation induction 
Glanz found 15 second primary tumours in 60 patients who had been treated 
successfully for T1a and T1b larynx carcinoma and survived longer than 5 years 
(25 OJo). In the analysis she also added 10 patients with similar tumours from other 
clinics, 9 men and 1 woman. The latency times varied from 5 to 18 years, average 
9.9 years. According to her, the following observations proved that these tumours 
were radiation induced: 
- The interval matched that of a radiation induced tumour. As a rule tumour recur-
rence occurs within the f"rrst two years following treatment. 
- The second tumour developed in the irradiated area. 
- In patients treated exclusively by surgery, secondary tumours are extremely rare 
(1117). 
- Histological examination revealed that the second tumour originated from the 
. irradiated surface epithelium ·and not from deeper lying 'nests' of tumour cells 
which had survived the irradiation (117). 
In 450 cases of larynx and hypopharynx carcinoma, Taylor found 11 patients in 
whom the tumour recurred more than 5 years after irradiation. He brought forward 
three possible causes for the recurrence: 
- The second tumour resulted from the same carcinogenic influence (smoking) as 
the f"rrst. 
The second tumour developed from cell groups which were not destroyed by the 
radiotherapy. 
- The second tumour was induced by irradiation. 
He also wondered whether the radiation method, orthovolt, megavolt or cobalt, had 
any effect on the pattern of tumour induction (57). 
Finally, in their patient material, Lund et al. found 10 (3.80Jo) second primary 
tumours in 266 patients who had been irradiated on account of T1 or T2 larynx 
carcinoma after a mean latency time of 11.8 years. On the grounds of the observa-
tion that a second primary tumour arose just as frequently in patients who smoked 
as in those who did not, she concluded that the tumours had been induced by 
irradiation. From data in the literature, she calculated that second primary tumours 
developed in 50Jo of the cases irradiated on account of early larynx carcinoma (59). 
The study data per author are shown in Table 3.6. 
3.8 THYROID GLAND 
The organ in the head and neck region which gained the greatest clinical meaning 
with regard to tumour induction is the thyroid gland. A monograph on this subject 
was published in 1977 (129). 
Winship et al. conducted a survey on thyroid cancer in children in many hospitals 
throughout the world. More than 800Jo of the children with a thyroid malignancy 
appeared to have been exposed to radiation in one form or another in their very 
young years (130). 
It has been alledged that induced thyroid carcinoma occurs twice as frequently in 
women as in men (38). Socio-cultural factors also appear to have some influence: 
Jewish children seem to be the most predisposed (45). 
The portion of thyroid cells that are sublethally damaged after irradiation may give 
rise to malignant growth during further cell division. The hypofunction of the 
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thyroid gland, resulting from the irradiation, can lead to a higher production of 
TSH by the pituitary gland due to the feed-back mechanism. Animal experiments 
have shown that a raised TSH level in itself increases the chance of tumour induc-
tion (131). Moreover, thereis evidence that the simultaneous exposure of the thyroid 
and pituitary gland involves a greater risk of tumour induction than irradiation of 
the thyroid gland alone (51,56). 
Eighty-five per cent of induced thyroid gland tumours are of the papillary or mixed 
type and 15"7o are of the follicular type. At diagnosis 30 to 80% have already 
metastasised locally (38, 77). The abnormality following induction is more likely to 
be multifocal than in non-induced carcinomas (30-50%) (38). 
The average latency time, the time between irradiation and the diagnosis of the 
tumour, increases with the length of the observation periods. Twenty-eight years is 
mentioned in a fairly recent study (77). The minimum limit is given as 5 years (66). 
The lowest doses thought to be responsible for thyroid tumour induction are 6.5 
(21), 20 (!32), 90 (13) and !50 (133) cGy. Between these values and ca. !500 cGy 
there appears to be a linear relationship between dose and effect. Hempehnann et 
al. (45) gave the following figures for this: 2.5 ± 0.5 . !0-6 . cGy-1 • yr·1 and Maxon 
et al. (67): 4.2 . 10·6 • cGy-1 • yr·1• The tumour inducing capacity probably 
decreases sharply above 2000 cGy, due to thyroid tissue destruction, which is also 
the case with the capacity for malignant degeneration (22). Recently, attention has 
been focused on the fact that high radiation doses, for abnormalities in the region 
of the thyroid gland, can give rise to radiation induced thyroid tumours. The 
amount of scatter received by the thyroid gland during treattnent may well lie in the 
sensitive dose area for this organ (134). 
3.9 SKIN 
The first tumour thought to be radiation induced concerned a skin tumour in a 
labourer at a factory which manufactured X-ray tubes (!). Skin tumours resulting 
from irradiation as an occupational disease have been reported in radiologists (16) 
and workers in uranium mines (!35). Skin tumours following medical treattnent, for 
tinea capitis, have also been observed (46). 
At the beginning of this century, when nearly all of the radiation induced skin 
tumours were acquired occupationally, most of the cases concerned epitheliomas of 
the hands. Later on, when it became the fashion to irradiate dermatoses particularly 
in the head and neck region (on account of over-productive sebacous glands), most 
of the tumours were found to be basal cell carcinomas (20). A radiation induced 
sarcoma has also been described (!36). 
The fact that radiation induced skin tumours are not mentioned in some of the 
studies where use has been made of death statistics or tumour registration data, is 
probably the result of the very small number of people who die of skin tumours and 
under-registration at tumour registration offices (46). 
Martin et a!. reviewed the files of patients at their dermatology clinic to see how 
many of them had an anamnesis of radiation exposure. They observed that 19% of 
those with a skin tumour had been exposed, against only 5% of the other patients. 
There was a woman : man ratio of 3: I. The chief indication for irradiation in 
women was hirsutism, in men acne. Haemangioma planum also formed an indica-
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tion. The latency period varied from 3 to 64 years, the average was 21 years. There 
was a basal cell carcinoma : epithelioma ratio of 4: I. The multicentricity of the 
lesions and the higher tendency to metastasise than tumours from other origins was 
striking. The mortality rate was also higher in the tumour patients who had been 
exposed to irradiation, reaching 10"7o - of whom two thirds within 5 years. They 
found evidence that the chance of tumour manifestation is maintained for the whole 
of the patient's life (20). 
Shore et al. compared a population of 2200 persons who had been irradiated on 
account of tinea capitis with a control group of 1400 people who had been treated 
in a different manner. The scalp received a dose of 300 to 600 cGy during 
radiotherapy. The average follow-up period was 26 years. The minimum latency 
period was 20 years, the average was 32.2 years. In the irradiated group 41 patients 
were found to have a skin tumour, some of them had multiple lesions. Only three 
cases were observed in the control group. All the tumours were basal cell 
carcinomas. 
It was thought that ultraviolet light from sunlight was a contributing factor because: 
- The tumours were chiefly localized in areas of the head and neck which were 
exposed to sunlight. 
- The tumours were particularly common in people with fair skin. 
- Tumours were only found in white people, although 25"7o of the study group 
comprised coloured people. 
The fact that an increased skin tumour incidence has not been observed in survivors 
of the Japanese atom bomb explosions is attributed to the high level of skin pigmen-
tation in Japanese people. The authors concluded that the estimations of skin 
sensitivity to radiation induced tumours up till then had been too low and they 
recommended that the ICRP norm (50 rem/year) be reduced (46). 
Howell observed that the latency period in people with a certain disposition to 
developing skin tumours (the nevoid basal cell carcinoma syndrome) was 
considerably shorter (0.5 to 3 years) than in 'normal' irradiated people. He 
concluded from this that the mechanism of carcinogenesis in these basal cell 
carcinoma$ takes place in at least two stages (50). 
Van Daal et al. recently published the results of a cohort study on 605 persons who 
had been irradiated 16 to 46 years previously for benign disorders in the head and 
neck region. A clinical examination was carried out on 257 people, in whom 20 skin 
tumours (one epithelioma, the remainder were all basal cell carcinomas) and 7 
thyroid tumours were found. In the light of the figures expected according to the 
UNSCEAR scale, these results meant a higher incidence of skin tumours (factor 7) 
and a lower incidence of thyroid tumours (factor 4). Possible causes were stated as 
being differences in patient selection, study methods and treatment time (137). 
Reanalysis of the study data revealed a tumour induction rate of 40 skin cancers per 
!06 persons per cGy. On account of these late radiation effects they concluded that 
benign skin disorders should not be treated by radiotherapy (13 8). 
3.10 PARATHYROID GLANDS 
In 1975 Rosen et al. described a parathyroid adenoma which had developed 40 years 
after irradiation for hirsutism (12). 
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Several years later a report appeared on 27 operations which had been performed 
for hyperparathyroidism in people who had been irradiated in their youth for benign 
disorders in the head and neck region. In 13 cases a parathyroid adenoma was 
observed. In 4 cases additional malignant and in 6 cases additional benign thyroid 
tumours were found (139). 
In 1979 Russ et al. brought out a report of a retrospective investigation in which 
the anamneses of 74 patients with a histologically confirmed diagnosis of 
parathyroid adenoma were examined for radiation exposure. Medical-diagnostic or 
therapeutic irradiation appeared in 250Jo of the cases, as opposed to 7.90Jo in a 
control group. The average age on exposure was 16 years. The interval between 
exposure and surgical removal of the adenoma was 24 to 47 years, the mean latency 
was 30 years. The major portion of the irradiated patients with parathyroid 
adenomas also developed other induced tumours, for example of the thyroid, 
breast, parotis and skin ( 140). 
Van Daal eta!. found a clear relationship between irradiation in the head and neck 
region and the development of functional or morphological abnormalities 
(adenomas) of the parathyroid glands in their study on 257 previously irradiated 
persons. They advise preoperative screening for hyperparathyroidism and extensive 
exploration of all parathyroid glands in patients who are to undergo surgery for 
radiation related thyroid nodules (141). 
Tumours of the parathyroid glands have also been induced by ionizing radiation in 
animal experiments (142). 
3.11 MASTOID AND NASAL SINUSES 
In 1952 Aub et al. described three epidermoid carcinomas of the nasal sinuses and 
petrous bone in people who had been exposed to internal irradiation, via radioactive 
substances a few decades earlier. The people (usually women), had either been 
employed in the watch-making industry where they had used paint containing 
radium, in laboratories, or had been given oral or intravenous radioactive 
substances as medicine (7). 
In a group of 5058 people who had been exposed in this manner, 21 mastoid 
carcinomas and II malignant tumours of the nasal sinuses were found. The latency 
time varied between 20 and 50 years, with an average of 33 years. More than a third 
of the malignancies were mucoepidermoid tumours, which are very rarely observed 
among non-radiation induced tumours of the mastoid and nasal sinuses. The lowest 
dose calculated was 605 cGy. Thirteen per cent of the people who had been exposed 
to more than 1000 cGy developed a malignant mastoid or paranasal sinus tumour. 
The predisposition of the mastoid and nasal sinuses for developing radiation 
induced tumours was explained through the observation that radon gas- a daughter 
product of radium- accumulates in poorly ventilated body cavities (17,18). 
Mastoid tumours have not only been observed following internal exposure to 
radioactive substances but also following external irradiation for the treatment of 
recurrent cerebellar astrocytoma (143) and thyroid carcinoma (144). 
It has been reported that carcinoma of the maxillary sinus can develop after a 
latency period of 12 to 24 years following thorotrast instillation. Since !980, 18 such 
tumours have been mentioned in case reports (33,35). 
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One case of ethmoid adenocarcinoma has been described, 30 years after exposure 
to a high dose of radiotherapy on account of a bilateral retinoblastoma (145). 
3.12 OTHER HEAD AND NECK ORGANS 
The first osteogenic sarcoma was described by Cahan et al. in 1948. It had developed 
following radiotherapy for retinoblastoma (4). Such tumours have also been 
discovered in the orbita (146), os temporale (147) and the brain (see brain sarcoma). 
Sixty-two secondary tumours of varying natures were observed recently in a group 
of 693 patients, an average of 10.4 years after irradiation for bilateral 
retinoblastoma (48). 
In a case report, a patient with fibrosarcoma of the mandibula was described who 
had also undergone radiotherapy for retinoblastoma (148). 
The following more or less wen· documented tumours have also been described: 
dumb-bell sarcoma of the foramen jugulare (149), carcinoma of a sebaceous gland 
on the eyelid (150), odontoma of the jaw (151), several malignancies of the tongue 
(6,152), sarcoma of the lip (153) and neoplastic lymphangitis (154). 
3.13 MULTICENTRJICITY AND PLURALITY 
On the basis of the physical properties of ionizing radiation, it is possible for a 
number of tumours to develop simultaneously at various locations in the irradiated 
tissue. In an organ this manifests itself in the form of multicentricity and in an organ 
system in plurality. 
A genetically determined increased sensitivity to developing radiation induced 
tumours may play a part here (42,46). 
In 1946 Den Hoed described a patient who had developed a basal cell carcinoma 
of the skin and a larynx carcinoma, 25 years after radiation treatment for tuber-
culotic lymphomas (lll). Since then, several - chiefly casuistic - publications have 
appeared on multiple radiation induced tumours (74,77,109). 
Triple radiation induced tumours -a 'hattrick' -have been described in the head and 
neck region (ll3,156). 
Multiple tumours have also been revealed in retrospective case-report (140) and 
cohort (42) studies. 
Animal experiments have proved that it is possible to induce double tumours (103). 
Scanlon stated that if a radiation induced tumour appears in a gland, the risk of 
other glands developing tumours in the irradiated region is significantly increased. 
He called this 'polyglandular neoplastic potential' (77). 
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CHAPTER 4 
THE DESIGN OF THE STUDY 
4.1 INTRODUCTION 
The most important question in this study concerned the long-term influence of 
nasopharyngeal radium irradiation on people's health. The principal considerations 
were tumour induction in the head and neck region and disturbances in processes 
which are influenced by hormones. In view of the possibility that these effects are 
relatively rare and for the sake of the statistical evidential value, we endeavoured 
to identify as many people as possible who have been treated using nasopharyngeal 
radium irradiation in the past. 
Owing to the fact that the latency time of solid tumours can be several decades or 
more, it was necessary to allow a fair period of time to elapse between the treatment 
and the person's participation in the present study. 
With the goal of, among other things, tracing a suitable study population, a ques-
tionnaire was sent to ENT specialists in the sununer of 1982. Members of the Dutch 
Ear Nose and Throat Society were invited to take part in the survey, but bearing 
in mind the period in which the therapy was applied, only those who had become 
members before or in 1960 and whose names appeared in the annual report of 1980 
received a request. This involved 110 ENT specialists (see Appendix 1). 
On the basis of the results of the questionnaire, ENT specialists in the Netherlands 
and Belgium were approached by letter or telephone with a number of specific ques-
tions. 
In order to find out whether the data in patients' records formed a suitable source 
of information, a study was carried out in the archives of eight ENT clinics and one 
radiotherapy department. Assessments were made of the possibility of finding suffi-
ciently large numbers of irradiated persons as well as non-irradiated control 
subjects. Obviously, factors such as time, manpower and cost played a part in this. 
It was finally decided that the records in five Dutch ENT archives were suitable for 
study purposes. 
See Table 4.1 for a chronological presentation of the data collected. 
Table 4.1 Data collection in chronological rank order 
Collection method 
Survey of 110 ENT specialists 
Study group from 5 ENT archives 
Controls from 5 ENT archives 
Follow-up of 500 non-selected subjects 
Follow-up whole group of 4922 persons 
Health surveys of 4457 subjects 
Asking patient's permission to verify 644 'tumours' 
Verification of 505 'tumours· via the specialist concerned 
Period 
Summer 1982 
Sept. '82 -June '83 
Jan. '83 -Dec'83 
July'83- Dec. '83 
July'84- Feb. '85 
Feb.'85- Aug. '85 
Jan.'86- Mar. '86 
Apr .'86- Aug. '86 
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4.2 THE STUDY GROUP 
People born between 1910 and 1965 were eligible for inclusion in the study. 
The tracing of data in the records of irradiated and control subjects was carried out 
by the secretarial staff of the ENT clinics concerned. The diagnosis was always 
taken from the record cards by the same ENT specialist - the author. 
4.2.1 The irradiated group 
The record cards of the irradiated subjects were traced systematically. The following 
data were noted: surname, christian name(s), address, date of birth or age, type of 
health insurance, date of first consultation, diagnosis, data when the irradiation 
took place, the number of exposures and the duration of treatment. Where possible, 
the name of the patient's g.p. at that time was also noted. Each irradiated person 
was given an identification and clinic number (see Appendix 3). 
For the purpose of compiling a control group, the data per clinic were expressed 
according to the year of birth (5 year groups) and the year of the first consultation 
(5 year groups). 
4.2:2 Control persons 
The control group was compiled on the basis of the data collected on the irradiated 
group per clinic. At each ENT clinic the records of random potential control persons 
were taken from the archives. If it appeared that their sex and years of birth and 
treatment matched those of a person in the irradiated group they were included in 
the control group. This process was repeated until the control group was complete. 
An example of the way in which a control group was compiled (clinic 2) is shown 
in Appendix 4. 
The same data was noted for the control persons as for the irradiated persons. The 
groups only differed with regard to whether or not they had been exposed to radia-
tion and the diagnosis. 
4.2.3 Results 
In three clinics the subject's sex could only be deduced on the grounds of the chris-
tian name. As the christian names did not always give a definite answer, a number 
have been noted as 'sex unknown'. Erroneously, the irradiated subjects in whom the 
sex was unknown were not included in the rendering of the irradiated groups, so 
a deficit arose in the control groups from three clinics. See Table 4.2 for the results 
of the compilation of the study group. 
4.3 FOLLOW-UP 
Follow-up methods were tested in 500 persons -about one tenth of the total study 
group -from clinic 3 as from July 1983. For each person, a request was made to 
the Registry of Births, Deaths and Marriages in the municipality mentioned on the 
record card, in order to acquire the following information: 
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Table 4.2 The number of exposed and non~exposed study subjects per sex and clinic 
Males Females Total 
Clinic Exp NExp Exp NExp Exp NExp 
1 723 648 477 463 !200 1lll 
2 188 184 140 142 328 326 
3 388 373 346 333 734 706 
4 83 85 60 59 143 144 
5 88 58 49 35 137 93 
Total 1470 1348 1072 1032 2542 2380 
- Is the person still living at the same address? 
- If the person has moved, what is the new address? 
- If the patient is deceased, what is the date of death and the death certificate 
number? 
The form and accompanying letter used for this purpose are shown in Appendix 5. 
lf the person had moved, the new municipality /municipalities was/were approached 
until the new address was found or it was discovered that the person was deceased. 
In many cases the forms were forwarded automatically by the record offices. 
As the results of this test were considered to be satisfactory, it was decided to 
conduct the follow-up for the total study group in this manner. The procedure was 
started in July 1984. 
4.3.1 Emigrated 
When previously emigrated Dutch people return to the Netherlands, this event is 
recorded at the Government Inspection Department of the Public Registry Offices 
for Births, Deaths and Marriages in The Hague. In order to persue the follow-up 
in cases where the people had remigrated, the data of 241 emigrated persons were 
sent to this registry office. In this way it was possible to trace 46 of the emigrated 
people for follow-up. 
4.3.2 Moved, present whereabouts unknown 
A number of people appeared to have moved without the record office in the 
municipality concerned knowing the new address. However, it was possible to 
persue the follow-up in the case of 45 out of the 175 'untraceables'. The new 
addresses of 43 people were found in the archives of the Ministry of Defence. Two 
people had died, which was revealed by the Central Bureau of Genealogy. 
Attempts to find untraceable people via the general patient archives of the hospital 
where the patient was treated at that time, produced little result. It was only possible 
to track down one of the 25 untraceables from clinic 2. 
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4.3.3 Deceased 
In the event that study subjects were found to have died, information about the 
cause of death was requested and obtained from the Central Statistical Office 
(CSO). The applications went via the chief medical officer. ln 144 out of the !50 
deceased (96"7o) it was possible to find out the cause of death. ln five cases this was 
not possible because the people had died abroad; in one case the information could 
not be found. 
4.3.4 Results 
At the end of the follow-up phase in February 1985, it appeared that from the total 
study group of 4922 persons 4607 (93 .6%) had been traced. See Table 4.3 for a 
summary of the follow-up. 
Table 4.3 Follow-up status study group 
Status Number (%) 
Traced 4607 93.6 
Alive. of whom 4457 90.6 
Respondents 3855 78.3 
Non-respondents 602 12.2 
Deceased ISO 3.0 
Untraceable, of whom 315 6.4 
Emigrated 196 4.0 
Lost 119 2.4 
Total 4922 100.0 
4.4 THE QUESTIONNAIRE 
In February 1985 a health questionnaire and accompanying letter was sent to 4457 
study subjects (see Appendix 6) whose current address was known. ln several dozen 
cases the people concerned were living in Belgium or Germany, very close to the 
treatment district of clinic !. In the address, only the initials and surname were used; 
in the case of married women only the maiden name. 
After three weeks the 2167 non-respondents (48.6%) were sent a reminder consisting 
of the same health survey and an accompanying letter. After this reminder the 
follow-up was continued with the assistance of the Institute for Social Scientific 
Research in Tilburg. 
Interviewers from this institute were informed about the aim and design of the 
study. The 1178 remaining non-respondents (26.4%) were approached by telephone 
or if they were not on the telephone were visited at home. (A small number of people 
living in remote places and without a telephone were not followed-up). ln 576 of 
the cases it proved possible to obtain answers which were suitable for processing. 
The final non-response consisted of 602 persons (!3.5%). 
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The interviewers noted the reason for non-response for 555 non-respondents (92"7o). 
It usually comprised a refusal without motives being given. Quite often the people 
concerned could not be contacted owing to an unlisted telephone number, or were 
always out or did not answer the door. Promises to still send back the form or 
announcements that the form was already on its way were heard frequently. In a 
few cases the people did not respond as a matter of principle or for reasons of 
privacy. Further grounds for non-response were mental deficiency, psychiatric treat-
ment or long trips abroad. See Table 4.4 for a detailed list of reasons for non-
response. 
Table 4.4 Reasons for non-response (N = 602) 
Reason 
Flat refusal 
Form already sent back 
Moved 
Never home 
Promise to return the form 
Address unknown 
Unreachable by phone 
Reasons of privacy 
No telephone. lives remotely 
Unlisted address/telephone number 
Opposed in principle 
Personal details incorrect 
Long trips abroad 
HI at home 
Did not answer the door 
Undergoing psychiatric treatment 
Admitted to hospital 
Mentally deficient 
Divorced, moved away 
Died recently 
Drug addiction 
In prison 
Reason unknown 
Total 
N 
211 
90 
51 
47 
42 
19 
18 
16 
12 
II 
6 
5 
5 
4 
4 
4 
3 
2 
2 
47 
602 
During the survey it appeared that a number of health questionnaires had not been 
filled in by the study person intended but by a relative with the same name. This 
was partly the result of the brief data used in the address. After comparing the date 
of birth which had been filled in on the questionnaire with that of the intended study 
subject it appeared that this had taken place in 177 cases. 
The study subjects were approached once again, with an adapted version of the 
accompanying letter and using a more detailed address (including the date of birth). 
This method proved to be successful in 141 (79.7"7o) of the cases, sometimes 
following a reminder per telephone or post. 
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4.4.1 Results 
A total of 3855 completed questionnaires were returned (86.5"7o of those sent), see 
Table 4.3. 
4.5 VERIFICATION OF A POSITIVE TUMOUR ANAMNESIS 
In January 1986 a start was made to verify the positive tumour anamneses suspected 
on the grounds of the answers filled in on the health questionnaires. No verification 
was carried out in cases where it - almost - certainly concerned a benign complaint. 
In order to limit the number of cases requiring venfication, those in whom it was 
likely that a hysterectomy had been performed on account of menometrorrhagia 
and those in whom cervix cytology had taken place, were not followed-up. (See 
Chapter 5 Coding questionnaire information). 
4.5.1 Asldng lhe study subjects for permission 
In the 644 suspected cases of neoplastic disorders, an attempt was made. to acquire 
the· person's original clinical or pathological diagnosis from the specialist who had 
treated the patient at that time. 
These members of the study group were sent a letter in which we requested their 
permission to approach the specialist concerned. An appropriate text was chosen, 
depending on whether the suspicion was based on the answer to question 2,4 or 5 
of the heaith questionnaire (see Appendix 7). A copy of the person's answer to the 
question was enclosed. Specific questions were asked about the hospital, the 
specialist and the year in which the treatment had taken place. 
People in whom multiple tumours were suspected received a request for each 
suspected tumour. In this way it was possible for the people to make their own 
choice as to whether they wished to give their permission for one tumour but not 
for another. Non-respondents were approached three weeks later by telephone and 
asked if they would proceed with their answers. 
4.5.2 Tbe request to lhe doctor who treated the patient 
The letters of request were provided with a sticker on which the clinical or 
pathological diagnosis could be written. They were sent with an accompanying letter 
(see Appendix 8) to the doctor whose name had been written on the request form 
by the study subjects. If it appeared from the Medical Address List 1985-1986 that 
the specialist concerned was no longer working at the hospital mentioned by the 
study person, the letter was sent to another doctor at the same department. If the 
specialist's name was unknown. the request was sent to a doctor at a department 
thought to be most suitable for the complaint concerned. The non-respondents were 
approached three weeks later by telephone. 
4.5.3 Results 
Only 68 (11%) of the 644 written requests sent out were not answered (see Figure 
4.1). 
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644 (100) permission asked 
576 (89) no answers 68 (11) no answer 
505 (78) permission 71 {11) no permission 
95 (15) no information 410 (64) information 42 (7) misinterpretation 29 (5) refusals 
370 (57) pathology 40 (6) no pathology 
141 (22) neoplasms 229 {36) other diseases 
Figure 4.1 Results verification procedure. Verification was carried out when, on the basis of inquiry, 
a neoplastic disease was suspected. Percentages in brackets. 
Permission could not be obtained from 71 (II 'lo) of the 576 people who answered 
the request. In 42 the coder had misinterpreted the answer on the questionnaire: 
either there never had been a tumour or the 'suspicion of a tumour' had been based 
on a symptom or it had healed spontaneously. 
There were also reports that the patient had not visited the doctor for that particular 
complaint or that there had been a mistake. In the remaining 29 cases (5%) it was 
a matter of flat refusal. 
The specialists who had treated the 505 cases (78%), from whom we received 
permission, were approached for information concerning these study subjects. No 
information was available on 95 patients (15%). The reason was usually related to 
the long period of time which had elapsed since the presentation of symptoms: the 
records had been lost, or the hospital had been closed, or the specialist was 
unknown, retired or deceased. 
Forty (6%) of the 410 cases of suspected tumours (64%) on which we did obtain 
information, did not appear to involve a pathology, or involved only the examina-
tion of symptoms or normal findings (biopsy of the stomach mucosa, liver punc-
ture). 
The remaining 370 (57%) comprised diagnoses of 141 neoplasms (22%) and 229 
(360Jo) other disorders. 
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5.1 DOSIMETRY 
CHAPTERS 
DATA COLLECTION 
The radiation doses received by the pituitary gland, the thyroid gland and the 
parotid gland were calculated for the three different radium applicators used for 
treatment at the five ENT clinics which participated in this study. Depending on the 
age and treatment method, which varied per cliuic with regard to the applicator and 
treatment duration, the following doses were calculated: 10-36 cGy for the pituitary 
gland, 2-7 cGy for the thyroid gland and 4-19 cGy for the parotid gland. The doses 
received by the tissues in immediate contact with the needle were much higher: 
3,500-23,000 cGy. See Appendix 9 for a detailed calculation. Reviewing the dose 
values calculated in our own study, it has been established that the relationships 
between the doses absorbed by the various organs are in agreement with those 
mentioned in the literature. In the Netherlands the doses per organ are generally 
lower than those calculated by other authors because lower activity radium 
applicators were used (10 mg and 25 mg) as well as 50 mg radium applicators, and 
the treatment duration was usually shorter (see Chapter 2 'Dosimetry'). 
5.2 THE DATA FORM 
A data form was filled in for every person in the study group. (See Appendix 3). 
The first page, on which the christian and surname, address, date of birth, iden-
tification (ID) and cliuic numbers - necessary for the status vitalis · were noted, was 
used for follow-up purposes. 
On the second page the data necessary for establishing and classifying the study 
groups were recorded. These included the ID and clinic number, sex, date of birth 
and the type of health insurance. The date of the first contact with the patient was 
also set down in order to be able to select a control group later on. Finally, the 
diagnosis and radiation therapy data were noted. 
5.2.1 Coding 
Copying the data from the record cards gave rise to some amount of difficulty on 
account of the brief notations which had been used. This was the result of the fact 
that the specialists involved had set up the filing system purely for their own use. 
Very often the information was limited to one word or abbreviation which 
summarized the ENT examination, diagnosis or treatment. 
Each person was given an ID number, beginning with number 000!. The members 
of the irradiated group were numbered first, followed by the control group. It was 
possible to ascertain the sex in most cases, but if the christian name was fitting for 
both sexes or if the study person was referred to as 'child' the person was coded as 
'sex unknown'. 
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The date of birth had been recorded for practically everyone, but sometimes only 
the age in years had been noted. In the latter case the age and corresponding year 
were coded. If possible the type of health insurance was also recorded. The clinic 
number indicated which of the five archives the patient had been selected from. The 
date of the first consultation was regarded as the first contact with the study person. 
The following rules were used in the coding of the diagnosis: 
l) Otitis media serosa (OMS) included all possible synonyms, such as 'glue ears' 
and 'tubal catarrh'. Also the finding 'withdrawn tympanic membranes' and the 
notation 'deaf' followed by treatment for OMS, were included in this category. 
2) Recurrent ear injection included acute otitis, chronic otitis, mastoiditis, status 
after mastoidectomy or radicalization and 'ear ache'. 
3) Other tubal dysfunction was usually used in the case of adults. These included 
·tinnitus (without loss of perception) and 'crackling noises in the ears'. 
4) Adeno-tonsillectomy also referred to as hypertrophic tonsils, hypertrophic 
adenoid or adenotomy and 'blocked nose'. 
5) Sinusitis included rhinitis and allergic rhinopathy. 
6) Perceptive hearing loss 
8) Other disorders 
9) Diagnosis unknown 
5.3 THE HEALTH SURVEY 
In the health survey (see Appendix 6) questions were asked which, on the grounds 
of data in the literature, were known or assumed to be relevant to the topic: the 
effects of ionizing radiation on man. Suffering from cancer or having suffered from 
cancer in the past formed the central theme. Every effort was made to reduce the 
chance of missing a positive tumour anamnesis by formulating the questions in 
different ways. Questions: 2 (admissions to hospital), 4 (tumours) and 5 (biopsies) 
were formulated with this goal in mind. 
Questions were also asked about hormone regulated disturbances. These were aimed 
at detecting possible abnormalities related to the influence of radiation on the func-
tion of the pituitary gland. Questions 3 and 6 dealt specifically with totally or 
partially hormone regulated disorders or their medical treatment, such as diabetes, 
anaemia, dysfunction of the thyroid gland and hypertension. Questions 10 and ll 
on fertility, were also asked with a view to detecting hormonal disturbances resulting 
from the influence of the pituitary gland. Question l concerning height and weight 
was asked in association with possible growth disturbances. 
The answers to questions 7 and 8 provided information on radiation exposure other 
than nasopharyngeal radium irradiation; and 8 and 9 on other carcinogens. Finally, 
the date of birth was requested in question l as a means of checking that the correct 
person had filled in the form. See Table 5 .I for an overview of the topics included 
in the health survey. 
5.3.1 Coding questionnaire information 
A data-input form was used to code the answers given in the health survey (see 
Appendix l 0). The answers to questions 2,4 and 5 concerning the tumour anamnesis 
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Table 5.1 Overview of the topics in the health survey 
Topic Question(s) 
Tumour induction 
Hormone balance 
Other radiation effects 
Exposure to other irradiation 
Exposure to other carcinogens 
2,4,and 5 
1,3,6,10 and 11 
3 
7 and 8 
8 and 9 
were coded by an ENT specialist (the author) with the cooperation of an internist-
oncologist. All the other answers were coded by three fifth-year medical students; 
a quality control was also carried out. 
Tumours 
A positive tumour anamnesis, suspected on the grounds of the answers to questions 
2, 4 and 5, was coded according to its localization and nature (see Table 5.2 and 
5.3). 
Table 5.2 Coding of the tumour anamnesis on the grounds of questions 2, 4 and 5, according to 
localization 
01 brain 
02 thyroid gland 
03 parathyroid glands 
04 pituitary gland 
05 salivary glands 
06 oesophagus 
07 lip 
08 mouth 
09 paranasal sinuses 
10 throat 
ll ear 
12 vocal cords 
13 eye 
14 lymph glands head & neck 
15 lymph glands unspecified 
16 skin head & neck region 
17 skin unspecified 
18 bone head & neck region 
19 bone unspecified 
20 leukaemia 
21 breast 
22 penis 
23 prostate 
24 testes 
25 vagina 
26 uterus 
27 ovary 
28 lungs 
29 adrenal gland 
30 other abdominal organs 
31 other head & neck region 
32 other unspecified 
33 head & neck surgery 
indicating possible tumour 
A maximum of three possible tumours per study person could be coded. See 
Appendix ll for examples of coding according to localization and nature. 
Table 5.3 Coding of the tumour anamnesis on the grounds of questions 2, 4 and 5, according to nature 
l definitely benign 
2 probably benign 
3 possibly benign - possibly malignant 
4 probably malignant 
5 definitely malignant 
6 unknown, no classification possible 
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Carcinogens 
The answers to question 8 concerning occupational exposure to carcinogens were 
coded according to a list of poisonous substances from occupation, according to 
Verberk and Zielhuis (Appendix 12) (!). 
Three groups were classified: 'none', '(probably) very little' and 'a great deal'. 
Respondents who had been employed for less or more than 10 years in an occupa-
tion involving risk, were classified under '(probably) very little' and 'a great deal', 
respectively. 
5.4 CAUSES OF DEATH 
It was possible to trace the cause of death in 144 of the !50 people (96"7o) who had 
died. The causes of death were obtained from the Central Statistical Office and 
coded according to the Revision of the Manual of the International Statistical 
Classification of Diseases, Injuries and Causes of Death, valid for the year of death. 
Due to the fact that considerable differences can exist between the various Revisions 
with regard to the coding of diseases, injuries and causes of death, all the codes for 
the. causes of death were compared with, and where necessary made to conform 
with, the SMR edition of the 'Classificatie van Ziekten 1980' (2). The causes of 
death are presented in Chapter 7. 
S.S CAUSES OF DISEASE 
On the grounds of the study subject's answers to questions 2, 4 and 5 of the health 
survey, which gave rise to 644 suspected tumours, we tried to obtain supplementary 
information from the former specialist. In this way it was possible to verify the 
diagnoses in 370 cases: 141 were related to neoplasms and 229 to other complaints. 
All 370 diagnoses were coded according to the 'Classificatie van Ziekten 1980'. 
These codes were divided into a number of groups of interest. These are presented, 
together with the causes of death in Chapter 8. 
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CHAPTER 6 
DESCRIPTION OF THE STUDY POPULATION 
ACCORDING TO CHARACTERISTICS 
The control group is slightly smaller than the irradiated group. This is due to the 
fact that no control persons were selected for irradiated persons classified under 'sex 
unknown' in the first phase of the study (see Chapter 4 'The study group'). 
6.1 AGE 
The average age of the study subjects at the time of treatment was I 0.1 years. The 
majority were between six and ten years old (see Table 6.1). 
Table 6.1 Mean age at the start of treatment per clinic. Irradiated group only 
Clinic 
Age 
2 3 4 5 all .,, 
0-5 345 28 102 4 26 505 20.4 
6-10 609 !87 365 69 43 1273 51.3 
ll-15 125 61 ll6 23 25 350 14.1 
16-20 22 20 45 3 16 106 4.3 
21-25 12 5 32 3 6 58 2.3 
26-30 8 4 24 2 4 42 1.7 
31-35 19 ll 20 2 6 58 2.3 
36-40 ll 0 13 6 4 34 1.4 
41-75 20 2 2 28 2 54 2.2 
Total 1171 318 719 140 132 2480 100.0 
Missing observations: 62 
In our study group it appeared that children with otitis media serosa, the most 
frequent indication for naso-pharyngeal irradiation, consulted anENT specialist for 
treatment at this age, which corresponds with the ages reported in the literature. A 
random survey of the population showed that the most common age for otitis serosa 
is slightly lower: between three and six years (1). 
6.2 SEX 
There were more males than females in the study group (57.30Jo vs 42.70Jo, see 
Chapter 4 Table 4.2). This is in agreement with expectations because the most 
frequent indication for irradiation, otitis media serosa, is diagnosed more often in 
boys than in girls. In a study conducted by Kokko, a group of children with otitis 
serosa was described with a boy:girl ratio of 59:41 (quoted !). Lildholdt found a 
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similar relationship (56.7% vs 43.30Jo), however, this difference was not significant 
after comparison with the male: female ratio in the local population (51.3% vs 
48.7%) (2). 
6.3 CLINIC 
Control patients were only selected for irradiated patients in whom the sex was 
known. Therefore, a small deficit has arisen in the control group (see Chapter 4, 
Table 4.2). 
6.4 DIAGNOSIS 
In the irradiated group otitis serosa, recurrent otitis and 'other tubal disorders' 
formed the diagnoses in 93.7%. These were also the most important indications for 
irradiation. The control group consisted mainly of children who had undergone an 
adeno-tonsillectomy (42.1 %) and sufferers from recurrent otitis (27.2%). The 
indications for irradiation differed between clinics: in clinic 2 a hypertrophic 
adenoid was a frequent indication for radium treatment (see Table 6.2). 
Table 6.2 Diagnostic indications per clinic for exposed and non-exposed subjects 
Clinic 
Diagnosis 
2 3 4 5 All 
Exp NExp Exp NExp Exp NExp Exp NExp Exp NExp Exp 
"" 
NExp % 
Serous otitis 706 57 208 15 468 40 89 6 53 2 1524 60.5 120 5.0 
Recurrent otitis 457 473 54 47 223 101 16 19 66 7 816 32.4 647 27.2 
Tubal dysfunct. 4 3 6 2 6 2 19 0.8 4 0.2 
Adenotonsillect. 10 280 53 233 l 381 54 13 53 77 3.1 1001 42.1 
Rhinosinusitis 4 82 6 l7 8 13 3 36 3 6 24 1.0 !54 6.5 
Perceptive loss 18 8 3 2 l 0.0 3! !.3 
Other 3 196 2 15 4 !58 26 21 !0 0.4 416 17.5 
Unknown 13 3 2 4 27 2 48 1.9 4 0.2 
Total 1197 1109 328 327 7!5 704 142 144 137 93 2519 100 2377 100 
Missing observations: 26 
6.5 RADIUM TREATMENT 
Depending on the clinic and age of the patient, the radiation doses varied between 
250 and 4000 mgmin. The average was !197 .8 mgmin and the standard deviation 
was 718.4 mgmin. In Figure 6.1 the number of exposed subjects (N is ;;;; 10) have 
been set out against the dose received. 
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Figure 6.1 Number of subjects exposed to nasopharyngeal radium irradiation. per dose (mgmin x 
1000). Only groups of at least ten are recorded. accounting for 2.458 persons. Groups of less than ten 
accounted for 79 persons. In five persons the radiation dose was unknown. 
6.6 EXPOSURE TO IRRADIATION 
Question 7a of the health survey, concerning exposure to irradiation during 
diagnostic X-ray examination, did not show any clear differences between the 
irradiated an.d control groups. However, question 7b, regarding possible 'other' 
exposure, gave rise to a number of different and interesting answers (see Table 6.3). 
Table 6.3 Exposure to 'other' irradiation per clinic for exposed and non-exposed subjects 
Clinic 
Radiation 
2 3 4 5 All 
Exp NExp Exp NExp Exp NExp Exp NExp Exp NExp Exp % NExp 
"" 
Cobalt 45 7 8 19 I I 2 75 3.9 8 0.5 
ROntgen 62 86 14 21 36 38 8 6 2 5 122 6.4 156 9.2 
Radium 236 5 48 4 151 3 30 1 22 487 25.6 13 0.8 
Diverse 43 5 7 13 1 6 I 4 73 3.8 8 0.5 
Unknown !II 40 18 10 35 20 5 2 12 181 9.5 72 4.2 
None 477 746 137 193 274 389 38 72 40 46 966 50.7 1446 84.9 
Total 974 889 232 228 528 452 88 82 82 52 1904 100 1702 100 
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The exposed group expressed in their answers that they were very much aware of 
the radium irradiation in their past. A quarter of the respondents could even 
remember the name radium; also the name cobalt~ various and unknown were often 
mentioned. 
6.7 EXPOSURE TO CARCINOGENS 
The coding of exposure to occupational irradiation gave rise to such a small number 
of positive answers that a meaningful comparison was not possible (see Table 6.4). 
The coding of occupational exposure to other carcinogens showed no differences 
between the irradiated and non-irradiated persons at clinics 1,2 and 3 (see Table 
6.4). The number of subjects in clinics 4 and 5 were too small to draw conclusions. 
When the populations at the various clinics were compared, a striking difference 
was observed between clinic 1 (situated in the south of the province Limburg) and 
clinic 2 (situated in the province Drenthe). In the area surrounding clinic l, where 
there is a large amount of petrochemical industry, exposure to carcinogens (other 
than ionizing radiation) was coded in 20.9%, whereas for clinic 2, in an area with 
considerably less industry, this was only 15.5o/o. 
Table 6.4 Occupational exposure to radiation and carcinogenic substances per clinic for exposed and 
non-exposed subjects 
Clinic 
Expos.ure 
2 3 4 5 All 
Exp NExp Exp NExp Exp NExp Exp NExp Exp NExp Epx NExp 
Radiation 
none 947 888 235 222 522 445 82 85 85 52 1871 1692 
little 73 1 2 10 5 
much 2 3 
Carcinogens 
none 761 700 200 188 425 361 74 82 63 41 1523 1372 
little 130 124 17 20 53 46 8 2 7 4 215 196 
much 65 67 18 16 45 39 17 7 146 130 
6.8 ALCOHOL AND TOBACCO 
No differences were found between the irradiated and non-irradiated gronps with 
regard to the use of alcohol and tobacco. However, it appeared that people from 
the southern clinics (l and 3) drank more beer: and the men generally smoked more 
cigarettes than the women (see Table 6.5). 
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Table 6.5 Use of stimulants per clinic and sex for exposed and non-exposed subjects 
Clinic 
Stimulant 
2 3 4 5 
Exp NExp Exp NExp Exp NExp Exp NExp Exp NEXp 
m f m f m f m f m f m f m f m f m f m f 
Beer 11.3 3.4 12.8 2.9 10.3 0.4 8.1 1.8 10.4 1.0 12.5 1.2 8.0 0.6 9.5 1.2 9.9 1.1 8.5 0.9 
weekly 
Wine 1.3 3.4 1.3 3.6 1.4 6.0 1.3 4.4 2.4 6.8 2.0 5.5 4.0 5.8 5.0 6.0 L7 5.6 1.4 4.2 
weekly 
Dutch gin 1.1 0.5 1.1 0.5 2.3 1.3 3.3 1.2 2.7 1.3 2.7 0.9 3.3 0.8 4.2 0.2 4.4 0.7 4.6 1.1 
weekly 
Cigarettes 14.5 1.3.7 16.213.7 14.712.8 15.113.6 15.613.3 17.3 13.4 13.911.4 13.810.7 14.01 L6 15.712.8 
daily 
Pipe 0.2 0.1 0.2 0.0 0.3 0.0 0.3 0.0 0.2 0.1 0.2 0.0 0.6 0.0 0.9 0.1 0.8 0.0 0.9 0.0 
daily 
Cigars 0.4 0.2 0.3 0.1 0.5 1.0 0.4 0.0 0.6 0.1 0.6 0.2 0.7 0.0 2.0 0.5 0.7 0.0 1.6 0.0 
daily 
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CHAPTER 7 
MORTALITY AFTER NASOPHARYNGEAL RADIUM 
IRRADIATION TREATMENT 
7.1 INTRODUCTION 
Nasopharyngeal irradiation using radium226 was introduced by Samuel Crowe in 
1924 (1). This therapy was designed to improve the function of the eustachian tube 
by shrinking lymphoid tissue in and around the tubal orifice. It has appeared to be 
effective in children suffering from secretory otitis media (2) and in airmen suffering 
from barotrauma (3). 
Nasopharyngeal radium irradiation became routine medical practice in America and 
Europe in the 1940s and 50s. The therapy was made practically obsolete as a result 
of the realization that radiation treatment involved a potential cancer risk (4) and 
through the availability of other forms of treatment (5). 
Two studies conducted in America on small groups of people (6, 7) con!rrmed that 
children treated for various conditions using the nasopharyngeal application of 
radium226 run the risk of developing cancer in the long-term. Owing to the interest 
in studies on subjects exposed to low-dose irradiation, we carried out the present 
study on a large group of Dutch people who had been treated using nasopharyngeal 
radium226 irradiation in their youth. 
7.2 MATERIALS AND METHODS 
7.2.1 Study population 
A group of 2,542 persons who were born after 1909 and treated using 
nasopharyngeal radium irradiation between 1945 and 1965 were selected from the 
medical records of five ENT clinics in the Netherlands. These people comprised the 
exposed group. The large majority (92.9"7o) had been treated for secretory otitis 
media (60.4%) or recurrent otitis (32.5"7o). 
A group of control subjects were also selected at random from the same medical 
records until equal numbers of exposed and non-exposed people had been assembled 
for each clinic, matched for sex, year of birth (5 year age groups) and year of first 
contact (5 year intervals). The non-exposed group had been treated without the use 
of radium for a variety of ENT disorders, including hypertrophic tonsils and 
adenoids (42.1 %), recurrent otitis (27.2%), rhinosinusitis (6.5%), secretory otitis 
media (5.0%) and perceptive deafness (1.3%). The non-exposed group consisted of 
2,380 subjects. The number of exposed and non-exposed persons per clinic are 
shown in Table 7.1. 
To the reader: 
Chapter 7 has been accepted for publication in the Annals of ORL, in a modified form. The sections 
'Introduction' through 'Follow-up' have been presented in the previous chapters. The section 
'Dosimetry' has been dealt with extensively in Appendix 9. 
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Table 7 .I The number of exposed and non-exposed study subjects per sex and clinic 
Clinic Males Females Total 
Exp NExp Exp NExp Exp NExp 
I 723 648 477 463 1200 1111 
2 188 184 140 142 328 326 
3 388 373 346 333 734 706 
4 83 85 6() 59 143 144 
5 88 58 49 35 137 93 
Total 1470 1348 1072 1032 2542 2380 
At clinics l ,3 and 5 the sex of the patient was not specified on the records and was 
subsequently defined on the basis of the christian name. In cases where the christian 
name was not gender specific, the subject was coded as sex unknown. As the result 
of an oversight, no control subjects were selected for the exposed persons classified 
under sex unknown. This is the reason why the exposed and non-exposed groups 
are of unequal size. In the course of the follow-up the sex of all the exposed persons 
became known. In Table 7.2 the numbers of exposed and non-exposed subjects are 
shown according to age, sex and year of first contact. The numbers of exposed and 
non-exposed persons are fairly well balanced with regard to age and sex. 
Table7.2 Number of exposed and non-exposed individuals according to year of first contact*, age* and 
sex 
Year of Sex Age** 
first 
contact 0-5 6-10 I 1-15 16-25 26-75 Total 
Exp NExp Exp Nexp Exp NExp Exp NExp Exp NExp Exp NExp 
1946-50 M 64 56 54 49 15 15 19 !3 10 7 162 140 
F 70 52 51 43 14 9 15 9 8 !3 !58 126 
1951-55 M 177 170 127 l!7 27 26 29 29 41 33 401 375 
F 132 128 104 108 38 35 24 27 17 15 3!5 313 
1956-60 M 241 210 127 108 47 47 8 22 29 30 452 417 
F 175 159 100 84 31 32 13 18 12 15 331 308 
1961-65 M !51 137 136 136 24 52 19 20 39 40 369 385 
F so 91 93 90 28 47 7 14 16 17 224 259 
Total M 633 573 444 410 113 140 75 84 119 110 1384 1317 
F 457 430 348 325 Ill 123 59 68 53 60 1028 1006 
* Age or year of first contact unknown for 130 exposed and 57 non-exposed persons. 
** Age at the time of first contact 
7 .2.2 Follow-up 
The cohort was followed from the time of the first contact until death, emigration 
or, for those still alive and resident in the Netherlands, until I February 1985. The 
subjects were traced by various means, for example via municipal and state registry 
offices, conscription mes and telephone directories. A separate search was made for 
90 
Table 7.3 Follow-up status of the total study population 1 February 1985 
Status Exposed Non-exposed Total 
n ('lo) n ('lo) n (OJo) 
Located 2390 94.0 2217 93.2 4607 93.6 
Alive 2315. 91.1 2142 90.0 4457 90.6 
Deceased 75 2.9 75 3.2 150 3.0 
Not located 152 6.0 163 6.8 315 6.4 
Emigrated 98 3.9 98 4.1 196 4.0 
Untraceable 54 2.1 65 2.7 119 2.4 
Total 2542 100 2380 100 4922 100 
the untraceables in the death registry files at the Central Bureau of Genealogy. A 
summary of the follow-up status is shown in Table 7.3. In total it was possible to 
trace 94.0"1o of the exposed (male 93.3%, female 94.2%) and 93% of the non-
exposed persons (male 94.1 "lo, female 92%). Of the 6.4% lost to follow-up, 4% 
were known to have emigrated and 2.4% could not be traced. 
Information concerning the deceased was obtained from the Chief Inspector of 
Public Health. It was possible to establish the cause of death in 144 of the 150 
persons known to have died (96%). For five people who had died outside the 
Netherlands the cause of death could not be determined and in one subject the death 
certificate could not be found. 
7 .2.3 Dosimetry* 
The radiotherapy treatment was carried out in a similar way to that described by 
Crowe (I). A cylinder containing radium sulphate was inserted into the nostril and 
positioned close to the orifice of the eustachian tube. It was then left in place for 
several minutes. The type of applicator used (mg radium) and the number and dura-
tion of the applications differed for each ENT clinic. These data had been carefully 
recorded for every irradiated subject (see Table 7 .4.). The subjects from clinic I 
(n= 1200) were irradiated using a nickel-alloy applicator containing 25 mg in four 
sessions. The treatment time for subjects under 16 years of age was seven minutes, 
for those over 16, fifteen minutes. The radiation doses received by the tissues in the 
head and neck region depended on the distance from the radiation source, the size 
of the subject at the time of treatment and the position of the applicator. Dose 
estimations were made for selected sites in each age group using the isodose curve 
for the applicator employed and the 'average' measurements per age group as taken 
from the skull films of 25 individuals between three and sixteen years of age. The 
dose rates (in cGy /h) were estimated for the thyroid, parotid and pituitary glands 
for all the applicators used at the five ENT clinics. Depending on the clinic and age 
of the subject, the absorbed doses were estimated to be between 2 and 7 cGy for 
*This part of the study was executed under the supervision of A.G. Visser, PhD, radiophysicist of the 
Rotterdam Radiotherapeutic Institute. 
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Table 7.4 Radiation treatment methods per clinic and estimated doses (cGy) received at different 
anatomical sites 
Clinic n Treatment parameters Estimated dose (cGy) 
mg Ra Time (min)* Sessions Thyroid Parotid Pituitary Adjacent tissue 
1200 25 2S-60 4 2-3 6-8 12-14 4,480- 9,600 
2 32S 50 36- 72 3 5-7 14-19 29-36 11,520-23,040 
3 734 25 40- 80 4 3-4 8-11 16-20 6,400-12,800 
4 143 10 60-240 1-4 2-3 4-13 11-18 3,555-14,220 
5 137 25 26- 52 3 2-3 5-7 10-13 4,160- 8,320 
All 2542 10-50 26-240 1-4 2-7 4-19 10-36 4,160-23,040 
* Total exposure time age dependent 
the thyroid gland, between 4 and 19 cGy for the parotid gland and between 10 and 
36 cGy for the pituitary gland. The doses estimated to have been absorbed by the 
adjacent tissues at the orifice of the eustachian tube and by the nasopharyngeal 
mucosa are considerably higher (see Table 7.4). 
7 .2.4 Method of analysis 
The mortality rates per 10,000 person years for the exposed and non-exposed groups 
and for males and females separately were compared per cause of death. 
For the calculation of follow-up periods, the date of first treatment (exposed) or of 
first consult (non-exposed) were taken as the start of follow-up. However, in several 
cases this data was unknown. Our study population also comprised patients whose 
f'rrst consultation took place before the period in which treatments were applied at 
the clinics. These subjects were excluded from the study, leaving 2,510 exposed and 
2,199 non-exposed persons for analysis (see Table 7.5). The end of the period of 
follow-up for all cases was either the date of death or loss to follow-up or I February 
1985. 
The statistics presented in the next sections of this chapter concern these selected 
populations. Confidence intervals for the risks were calculated (8). 
Table 7.5 Selection of subjects for whom period of follow-up is exactly known, per sex for exposed 
and non-exposed subjects 
Male Female Total 
Exp nexp exp nexp exp nexp 
Study subjects with known period of follow-up 1448 1257 1062 942 2510 2199 
Study subjects with unknown period of follow-up 22 91 10 90 32 181 
Total no. subjects 1470 1348 1072 1032 2542 2380 
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7.3 RESULTS 
As shown in Table 7.6, the mortality rate for all causes for both sexes combined was 
almost equal in the exposed group (11.5/104 person years) and in the non-exposed 
group (11.0/104 person years). For males the rate in the exposed (15.4/104 person 
years) is about ll80Jo of the rate in the non-exposed (13.1/104 persons years), 
whereas for females the rate in the exposed (6.3/104 person years) is about 750Jo of 
that in the non-exposed (8.3/104 person years). 
There were no remarkable differences between the exposed and non-exposed groups 
for causes of death other than cancer. In the exposed group three times as many 
males died of cancer (at all sites) than in the non-exposed group; for exposed 
females about half the number of the non-exposed were found. However, neither 
of these findings are statistically significant. 
In Table 7. 7 the number of deaths per specific cancer site are shown. The numbers 
for any one site are small, thus limiting the conclusions which can be drawn. In four 
exposed males lymphatic or haematopoietic tumours were found (two were 
leukaemia), whereas none were found in non-exposed males. The 950Jo confidence 
interval (8) showed no significant difference between groups, however. In females 
there were fewer deaths from cancer in the exposed group than in the non-exposed 
group. 
These malignancies did not appear to be concentrated at any particular site. Smaller 
numbers of brain, breast, lymphatic a.'ld haematopoietic malignancies were found 
in the exposed females compared to non-exposed females. Only one death due to 
brain cancer of unspecified nature was found in the exposed group~ whereas two 
were found in the non-exposed group. None of these differences are statistically 
significant. Twenty-four malignancies were classified under 'other' sites. These 
included four cases of cancer of the lung (only males, two had been exposed), eight 
of the digestive tract and six of the urogenital system. 
7.4 DISCUSSION 
Irradiation of the head in persons suffering from tinea capitis has been associated 
with an increased risk of their developing leukaemia (9,10). This observation is 
consistent with findings after larger portions of the bone marrow have been exposed 
to radiation, such as is the case during radiotherapy of the spine for ankylosing 
spondylitis in adults and following irradiation of the chest in children (l!). It has 
also been reported that children who have been irradiated on account of tinea capitis 
run an increased risk of developing tumours of the central nervous system (9, I 0) and 
persons who have frequently been subjected to full-mouth dental X-ray examina-
tions run an increased risk of developing meningiomas (12). The radiation exposures 
thought to be associated with an increased risk of developing leukaemia or tumours 
of the central nervous system in these studies were 30 and !50 cGy, respectively. The 
risks were generally two to three and a half times higher than expected. However, 
in the study by Ron et a!. (10) the increase in risk for leukaemia only reached 
marginal levels of significance. 
During nasopharyngeal radium therapy, the tissues immediately adjacent to the 
applicator receive very high doses of radiation due to beta and gamma irradiation. 
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Table 7.6 The number (n) of deaths, the cumulative mortality rate (per 10,000 person years, 1945-1985) for exposed and non-exposed subjects, the relative risks ..,. 
(RR) and confidence intervals (95Q/o) associated with exposure, per sex. 
Male Female Total 
---
exposed non-exp exposed non-exp exposed non-exp 
-
n rate n rate RR 95"1oCI II rate II rate RR 95%CI II rate n rate RR 95%CI 
Total (all causes) 56 15.4 44 13.1 1.18 (.77-1.80) 17 6.3 21 8.3 0.75 (.37-1.52) 73 11.5 65 11.0 1.04 (.73-1.51) 
Cancer 15 4.1 5 1.5 2.78 (.96-9.36) 6 2.2 10 4.0 0.56 (.17-1.69) 21 3.3 15 2.5 1.30 (.64-2.71) 
Cardiovascular 12 3.3 15 4.5 0.74 (.32-1.72) 4 1.5 3 1.2 1.24 (.22-8.38) 16 2.5 18 3.1 0.82 (.19-1.72) 
Accidents/Suicide 17 4.7 15 4.5 1.05 (.49-2.21) 3 1.1 2 0.8 1.40 (.16-17.7) 20 3.2 17 2.9 1.09 (.55-2.22) 
Other 9 2.5 7 2.1 1.19 (.40-3.70) 4 1.5 6 2.4 0.62 (.1 3-2.65) 13 2.0 13 2.2 0.93 (.40-2.17) 
Unknown 3 0.8 2 0.6 1.39 (.16-17.6) 0 0 ' • 3 0.5 2 0.3 1.39 (.16-17.6) 
N in group 1448 1257 1062 942 2510 2199 
person years 36387 33680 27048 25202 63435 58882 
* impossible value (not defined) 
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Table 7.7 The number (n) of cancer deaths, the cumulative mortality rate (per 10,000 person years, 1945-1985) for exposed and non-exposed subjects, the relative 
risks (RR) and confidence intervals (95<t/o) associated with exposure, per sex. 
Male Female Total 
~~~ 
exposed non-exp exposed non-exp exposed non-exp 
-
n rate 11 rate RR 95o/oCI 11 rate 11 rate RR 95%CI 11 rate 11 rate RR 95%CI 
Total (all sites) 15 4.1 5 1.5 2.78 (.96-9.36) 6 2.2 10 4.0 0.56 (.17-1.69) 21 3.3 15 2.5 1.30 (.64-2.71) 
Drain I 0.3 0 • 
' 
0 2 0.8 0 ( 0 ·4.96) I 0.2 2 0.3 0.46 (.01-8.73) 
Head and Neck 0 0 • • 0 0 • • 0 0 • 
L/H+ 4 1.1 0 • (.61- ' ) I 0.4 2 0.8 0.47 (.01-8.77) 5 0.8 2 0.3 2.32 (.38-23.5) 
Breast 0 0 • • 0 2 0.8 0 ( 0 ·4.96) 0 2 0.3 0 ( 0 -4.94) 
Other 10 2.7 5 1.5 1.86 (.58-7.12) 5 I.S 4 1.6 1.16 (.25-5.72) 15 2.4 9 1.5 1.55 (.63-4.09) 
N in group 1448 1257 1062 942 2510 2199 
person years 36387 33680 27048 25202 63435 58882 
* impossible value (not defined or infinitely high) 
+ Lymphatic and hematopoietic system 
Tissues further than one em away from the source are only exposed to gamma radia-
tion, the intensity of which decreases inversely with the square of the distance (see 
Table 7.4) (13). 
Two prior studies on subjects who have been treated using radium applicators for 
ENT conditions have been carried out. Hazen et al. (1966) followed-up 4!7 children 
- who had been treated with a 25 mg radium applicator (usual dose per treatment 
300-600 mgmin)- for an average of 14.6 years. Only two malignant and five benign 
neoplasms were identified in the exposed group compared to 10 and 23, respectively, 
in 2, 746 siblings. No increased risk was found in this small study group (6). 
More recently, Sandler et al. (!982) followed-up 904 persons- who had been treated 
using a 50 mg radium applicator (usual dose 4,208 mgmin) -for !8 to 35 years. She 
compared tbe subsequent incidence of cancer to that in 2,021 non-exposed persons. 
Three brain tumours and an anaplastic tumour of the soft palate were observed in 
the exposed group, whereas no cases of cancer in the head and neck region were found 
in the non-exposed group (p < .05). No other areas showed an increased risk (7). 
The present study was similar in design to that of Sandler et al. (1982). Our study 
group was, however, considerably larger (2,542 exposed, 2,380 non-exposed) and 
the average dose was lower (average 1,198 mgmin). In the Netherlands, unilateral 
irradiation was the standard treatment procedure, whereas in Sandler et al.'s study 
(1980) the population had been subjected to bilateral treatment (14). 
For each exposed person on our study group tbe probability that he/she would still 
be alive at the end of tbe stndy period was calculated, using age, sex and period 
specific death rates for the Netherlands. This led to an expected number of deaths: 
51 males and 18 females out of 2287 persons. These figures are very close to the 56 
males and 17 females we observed in our population (Table 7 .6). 
Therefore, tbe conclusion can be drawn that the death rate in the exposed and non-
exposed groups is comparable to the death rate in the Dutch population as a whole. 
There were five persons in our study group for whom we could not establish the 
cause of death. Table 7.6 shows 15 deaths from cancer out of a total of 56. This 
leads to the assumption that at least one of these five subjects can be expected to 
have died of cancer as well. 
In the present study no overall significant increase in mortality due to cancer was 
fonnd. When the study population was examined according to sex, no notable 
differences in mortality due to all causes or causes other than cancer were found 
between the exposed and non-exposed persons. In the case of mortality due to 
cancer, a marginal increase was noted for lymphatic and haematopoietic 
malignancies in males only. 
However, it is not justified to conclude that there is a causal relationship between 
malignancies of the lymphatic and haematopoietic system and radiation here, 
because of the small numbers of tumours observed, the inconsistencies in the 
incidence of tumours between men and women and the much longer latency periods 
(see Table 7.8) than are usually observed for radiation associated malignancies of 
the lymphatic and haematopoietic system. We did not find an increased incidence 
of brain cancer in this group. Considerable statistical variability resulted from the 
low incidences, therefore, the observation of an increased incidence of cancer in 
some areas in exposed males and a decrease in exposed females does not lead to a 
ready interpretation. We are continuing our follow-up efforts to identify subjects 
who are still alive, which may help to clarify our results. 
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Table 7.8 Individual data of deaths due to tumours of lymphatic and haematopoietic system and brain 
per sex for exposed and non-exposed subjects 
Sex Exposure !CD9 Diagnosis Yr birth Dose Yr l/C* Yr death Latency 
status (yrs) 
Male Exposed L/H** 202.8 Malignant lymphoma 1953 700 1963 1980 17 
205.1 Chron. myeloid 
leukemia 1934 1500 1956 . 1976 20 
205.0 Acute myeloid leukemia 1947 750 1953 1977 24 
202.1 Mycosis fungoides 1917 1200 1954 1963 9 
Brain 239.6 Non-specified brain tum. 1913 1500 1962 1971 9 
Non-exposed L/H 
Brain 
Female Exposed LIH 205.1 Chron. myeloid 
leukemia 1943 1500 1955 1983 28 
Brain 
Non-exposed L/H 205.0 Acute myeloid leukemia 1947 1951 1978 27 
206.0 Acute monocytic 
leukemia 1915 1962 1980 !8 
Brain 191.6 Malig. tumour 
cerebellum 1958 1959 1982 23 
191.9 Malig. brain tumour 1950 1953 1981 28 
* Year of irradiation or first contact 
** Lymphatic and haematopoietic system 
In the exposed group no deaths as a result of breast cancer were observed, whereas 
there were two cases in the non-exposed group. Hazen et al. (6) found no cases in 
their exposed subjects and three in the siblings. Sandler et al. (7) suggested that the 
decreased incidence of breast cancer in their population might be related to altera-
tions in pituitary function following nasopharyngeal radium treatment. The present 
study findings agree with this suggestion. 
Summarizing, no increased incidence of cancer at any site associated with the Crowe 
therapy was observed in the present study. Sandler et al.'s (1982) (7) findings 
relating to an increased incidence of cancers in the head and neck region were not 
confirmed in our study. The average radiation exposures were lower in the 
Netherlands, which may have contributed to this finding. Also, the small incidence, 
even in our relatively large study group, makes precise comparisons between studies 
difficult. 
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CHAPTER 8 
TUMOUR INCIDENCE AFTER NASOPHARYNGEAL 
RADIUM IRRADIATION 
8.1 INTRODUCTION 
In 1896, one year after the appearance of the first X-ray films, radiation damage 
to various human tissues and to vision was mentioned by the Italian F. Batelli (1). 
The first report of a malignancy was published in 1902 by Frieben: a skin cancer 
in a radiation worker (2). Since then the tumour inducing properties of ionizing 
radiation have been well established (3). 
Almost all tissues in the head and neck region have been shown capable of 
developing neoplasms after radiation exposure. Particularly sensitive organs are the 
thyroid gland (4), the salivary glands (5), the brain (6) and the hypopharynx (7). The 
tendency of radiation related neoplasms to show multicentricity and plurality is in 
concurrence with the physical properties of radiation (8). Irradiation of the head 
and neck region has also given rise to non-neoplastic disease, such as necrosis of 
brain tissue, cataracts and thyreotoxicosis. Psychiatric disorders were suggested to 
be radiation related in a study concerning children irradiated for tinea capitis (9). 
Irradiation therapy was in common practice between 1920 and 1960 for benign 
conditions, such as hypertrophic tonsils and adenoids, thymus enlargement, acne, 
tinea capitis, thyreotoxicosis, keloid and haemangioma planum. 
In 1926 Crowe introduced irradiation of the nasopharynx as a treatment for diseases 
of the ear caused by malfunction of the eustachian tube (10). The treatment 
consisted of the application of a cylinder containing radium sulphate near the 
nasopharyngeal orifice. This therapy was carried out on a large scale in school 
children suffering from serous otitis media (II) and in airmen suffering from 
barotrauma (12). Fear of cancer induction (13) and the availability of alternative 
therapies (14) have made the therapy practically obsolete. 
Two authors described an adenocystic carcinoma of the palatum durum and vomer 
30 and 23 years after the Crowe therapy, respectively (15,16). 
Sandler et al. (1982) reported the results of a U.S. non-concurrent prospective study 
in which 904 persons who had been exposed to nasopharyngeal irradiation were 
compared to 2,021 non-exposed control subjects. The person-years of observation 
were 22,500 and the mean individual radiation dose was 4,208 mgmin. A 
significantly higher incidence of brain tumours and thyreotoxicosis was reported in 
the exposed subjects. One of the malignant head and neck tumours in the exposed 
group was an undifferentiated anaplastic carcinoma of the palatum molle (17). 
We selected a large population of 2,542 persons who had been treated using the 
Crowe therapy from the records in Ear, Nose and Throat clinics in the Netherlands. 
To the reader: 
Chapter 8. in modified form, has been submitted for publication. The sections 'Introduction' through 
'Follow-up' have been presented in the previous chapters; the section 'Dosimetry' is presented extensively 
in Appendix 9. 
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The mean individual radiation dose was approximately half of that reported by 
Sandler et a!. (1982). The morbidity in this group and in a non-exposed control 
group are described below. 
8.2 MATERIALS AND METHODS 
8.2.1 Study population 
The exposed population consists of all the subjects (2,542) selected from the files 
at five Dutch ENT clinics who were born after 1909 and treated in the years 1945-
1965 using nasopharyngeal radium irradiation. The reasons for radiation therapy 
were primarily secretory otitis media and recurrent otitis, together accounting for 
92.9o/o of the indications in the exposed study subjects. 
The control population (n = 2,380) was selected from the records at the same clinics 
in such a way as to correspond with the exposed subjects with respect to clinic, sex, 
birth year (5 year age groups) and the year of f"rrst contact (5 year time periods). 
The non-exposed subjects had been treated without the use of radium for a variety 
of ENT disorders, including hypertrophic tonsils and adenoids (42.1 o/o), recurrent 
otitis (27.2%), rhinosinusitis (6.5%), secretory otitis media (5.0%) and perceptive 
deafness (1.3 o/o ). Persons with a previous history of malignant disease were excluded 
from the study. 
8.2.2 Follow-up 
The entire cohort of exposed and non-exposed subjects was followed-up until death, 
emigration or February 1 1985. Tracing efforts were carried out by various means, 
including searches in municipal registries, state registries, conscription files and 
telephone books. For those lost to follow-up a search was made in the death registry 
nles of the Central Bureau of Genealogy. A summary of the follow-up is presented 
in Table 8.1. 
Each individual traced received an explanatory letter and a questionnaire to be 
completed by the subject. The questionnaires were identical for the exposed and 
non-exposed persons, without any indication of prior irradiation. 
Table 8.1 Study population. Follow-up status up till February 1985 
Status Exposed (OJo) Non-exposed (o/o) Total (Oi'o) 
Located 2390 (94.0) 2217 (93.2) 4607 (93.6) 
Alive 2315 (91.1) 2142 (90.0) 4457 (90.6) 
Survey yes 2022 (79.6) 1833 (77 .0) 3855 (78.3) 
no 293 (11.5) 309 (13.0) 602 (12.2) 
Deceased 75 ( 2.9) 75 ( 3.2) 150 ( 3.0) 
Not located 152 ( 6.0) 163 ( 6.8) 315 ( 6.4) 
Emigrated 98 ( 3.9) 98 ( 4.1) 196 ( 4.0) 
Lost 54 ( 2.1) 65 ( 2.7) 119 ( 2.4) 
Tot. populat. 2542 (JOO"Io) 2380 (IOO"Io) 4922 (IOO"Io) 
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Five main topics were emphasized in the questionnaire: tumour history, conditions 
potentially related to pituitary gland function, radiation history, occupational 
exposure to carcinogens and smoking and drinking habits. 
Non-respondents were sent a second questionnaire. Persons who did not return a 
questionnaire were approached by an interviewer who obtained the data over the 
telephone. Interviewers were not informed of the exposure status of the study 
subjects. Except in cases where prohibitive efforts would be required, non-
respondents were visited at home when telephone interviews were not possible. For 
deceased persons the data on the death certificate were obtained from the Chief 
Inspector of Public Health in order to determine the cause of death. 
Tumours or suspected tumours reported in the questionnaires were classified into 
one of five categories according to their assumed nature, (certainly benign, probably 
benign, possibly benign/possibly malignant, probably malignant, certainly malig-
nant) or classified as 'nature of tumour unknown'. Categories I (certainly benign) 
and 2 (probably benign) were not followed-up. Owing to the large number of uterus 
extirpations reported (over 100), which were probably mainly performed for 
menometrorrhagia, follow-up for this organ was only carried out for categories 4 
(probably malignant) and 5 (certainly malignant). 
An attempt was made to obtain a clinical or histological diagnosis from the physi-
cian who treated the subject at the time, in the case of suspected malignant disease. 
We asked the study persons for permission to verify the suspected disease. The ques-
tions concerned hospitalization, year of treatment and the name of the physician 
who had treated the subject. When more than one malignant disease was suspected, 
requests were made for each of the diseases. So it could happen that permission was 
given to verify only one out of several suspected malignancies. 
Requests for clinical or histological diagnosis were sent to the physician, with an 
explanatory letter and the written permission of the subject. If the physician had 
retired or no longer worked in the hospital, the information was requested via a 
physician of the same discipline. If the name of the physician was unknown, the 
information was requested via a representative of the most appropriate discipline. 
This part of the study was impeded because some hospital flles had been disposed 
of and some of the hospitals had closed down. Pathology specimens were not 
reviewed. In order to minimize reporting bias, only illnesses diagnosed to the date 
of the first study letter were included in the analysis. 
8.2.3 Dosimetry* 
The study group was selected from five different ENT clinics. The radium source, 
number of sessions and exposure times differed between clinics, but these 
parameters had been recorded accurately for every irradiated individual (Table 8.2). 
Estimates for various tissue doses were made for 'average persons' in each group. 
Measurements were taken from skull films of individuals, not in the study popula-
tion, aged between three and sixteen years of age. The dose rate was measured in 
cGy /h for all applicators employed as a function of age, for target organs such as 
the thyroid, parotid and pituitary glands. 
• This part of the study was executed under the supervision of A. G. Visser, PhD, radiophysicist of the 
Rotterdam Radiotherapeutic Institute. 
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Table 8.2 Radiation methods and estimated radiation doses (cGy) received at different anatomical sites 
for each of the five participating clinics 
Clinic Treatment parameters Estimated dose (cGy) 
n mg Ra Time (min)* Sessions Thyroid Parotid Hypophysis Adj. tissue 
1200 25 28- 60 4 2-3 6-8 12-14 4,480- 9,600 
2 328 50 36- 72 3 5-7 14-19 29-36 I 1,520-23,040 
3 734 25 40- 80 4 3-4 8-11 16-20 6,400-12,800 
4 143 10 60-240 1-4 2-3 4-13 11-18 3,555-14,220 
5 137 25 26- 52 3 2-3 5- 7 10-13 4,160- 8,320 
All 2542 10-50 26-240 1-4 2-7 4-19 10-36 4,160-23,040 
* Total exposure time age dependent 
The absorbed doses for the entire irradiated population, depending on clinic and 
age, varied from 2-7 cGy for the thyroid, from 4-19 cGy for the parotid and from 
10-36 cGy for the pituitary gland. The doses absorbed by the nasopharyngeal 
mucosa and the immediately adjacent tissues were considerably higher. 
8.2.4 Metl!ods of analysis 
The cumulative incidence rates per 10,000 person years and for males and females 
separately were compared per tumour site. For the calculation of follow-up periods, 
the date of first treatment (exposed) or of first consult (non-exposed) were taken as 
the start of follow-up. However, in several cases this data was unknown. Our study 
population also comprised subjects whose first consultation took place before the 
period in which treatments were applied at the clinics. 
These persons were excluded from the study, which left 2,510 exposed and 2,199 
non-exposed subjects for analysis (see Table 8.3). The end of the period of follow-
up for all cases was the date of death or loss to follow-up or 1 February 1985. The 
statistics presented in the following sections concern these selected populations. 
Confidence intervals for the risks were calcuiated (18). 
Practically every case of cancer was registered in the mortality data. However, data 
on incidence are incomplete due to non-response to the questionnaire or in the 
verification procedures. To correct for both deficits, we derived correction factors 
based on the assumption that the non-response group (either questionnaire or 
verification) would have shown the same cancer rates. 
Table 8.3 Selection of subjects for whom period of follow-up is exactly known, per sex for exposed 
and non-exposed subjects 
Male Female Total 
Exp nexp exp nexp exp nexp 
Study subjects with known period of follow-up !448 1257 !062 942 2510 2199 
Study subjects with unknown period of follow-up 22 91 10 90 32 181 
Total no. subjects 1470 1348 1072 1032 2542 2380 
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8.3 RESULTS 
We were able to locate 91 "lo of the entire study population and ascertain 3"7o to be 
dead (Table 8.1). Tracing efforts were equally successful for exposed and non-
exposed persons. Located individuals were similar to those not located with respect 
to age at first contact. year of birth, sex and diagnosis. The total number of person 
years of follow-up was 63,435. Exposed subjects were followed-up for an average 
of25.3 years, non-exposed subjects for an average of26.8 years (see Table 8.4). This 
difference is the consequence of the different starting points of tbe follow-up 
periods between both groups. 
Of the study subjects who were located alive, 86.5"7o completed a questionnaire, 
either by mail, telephone or via home interviews; 60"7o of the completed question-
naires were returned after the first request and 23"7o after the second and in !7"7o 
data was obtained by telephone and home interview. A slightly greater portion of 
the exposed group completed the questionnaire (87 .3"7o) than the non-exposed group 
(85.6"7o) (Table 8.1). 
Permission for verification of suspected malignant diseases was obtained for 78.4"7o 
of the requests. Information from tbe physician or hospital records revealed the true 
nature of the disease in 81.2"7o of the requests. 
Table 8.4 Characteristics of the study population, only subjects with known period of follow-up 
Male Female Total 
Characteristics Exp nexp exp nexp exp nexp 
No. of subjects 1448 1257 1062 942 2510 2199 
Mean no. person-years follow-up 25.1 26.8 25.5 26.8 25.3 26.8 
No. of respondents only 1125 988 870 737 1995 1725 
Mean No. person-years follow-up respond. only 26.0 26.7 26.4 27.1 26.1 26.9 
8.3.1 Malignancies 
As shown in Table 8.5, there were some differences in total cancer mortality. In the 
exposed group three times as many males died of cancer (of all sites) than in the non-
exposed group; for exposed females about half the number of the non-exposed was 
found. 
Lymphatic or haematopoietic tumours were found in four exposed males (two were 
leukemias), whereas none were found in non-exposed males. 
In exposed females, no deaths as a result of breast cancer were observed, whereas 
there were two in the non-exposed group. These fmdings have been discussed in 
more detail in Chapter 7. 
Differences were noted in total cancer incidence between the respondents to the 
questionnaire. In the exposed group twice as many verified malignant tumours were 
found as in the non-exposed group. A striking difference was found in the occur-
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Table 8.5 Number of deaths and incident cases of malignant tumours for exposed and non-exposed 
study subjects. per sex. 
Incidence based on verification of suspected malignant disease . 
Cancer site Mortality Incidence* 
Male Female Total Male Female Total 
Exp Nexp Exp Nexp Exp Nexp Exp Nexp Exp Nexp Exp Nexp 
Total (all sites) I5 5 6 IO 2I I5 II 6 10 4 2I IO 
Brain** I 0 0 2 I 2 2 0 I 2 2 
Head and neck 0 0 0 0 0 0 4 2 0 6 
L/H**"' 4 0 I 2 5 2 I 2 0 0 2 
Breast 0 0 0 2 0 2 0 0 4 2 4 2 
Other IO 5 5 4 I5 9 4 2 4 8 3 
Non respondents excluded 
** Histologically benign brain tumours (one fatal) included 
*** Lymphatic and haematopoietic system 
renee of head and neck tumours: six in the exposed, only one in the non-exposed 
group. 
In Table 8.6 a specification of the head and neck cancer incidence is presented. 
Three organs in the head and neck region showed an increased tumour incidence in 
the exposed: the larynx, the thyroid and the skin. However, the numbers were very 
small. 
Two laryngeal carcinomas and three head and neck skin carcinomas were found in 
exposed males, whereas only one head and neck skin carcinoma was found in non-
exposed males. In exposed females, two thyroid carcinomas were observed, against 
none in non-exposed females. 
In Table 8.7 the mortality and incidence data have been combined to produce a 
cumulative incidence. 
The only confidence interval that does not include the value 1.00 is that for the 
relative risk for all malignant tumours combined and for both sexes (Cll.Ol-2.83). 
The excess risk is mainly caused by 'head and neck tumours' and 'other tumours' 
(lung, digestive tract and urogenital system). However, if taken separately, there is 
no significant excess risk for any of these tumour sites in the exposed group. 
Table 8.6 Malignant head and neck tumour incidence for exposed and non-exposed study subjects. per 
sex. Based on verification of suspected malignant disease 
Male Female Total 
Cancer site (lCD) Exp N-exp Exp N-exp Exp N-exp 
Larynx (I6I) 2 0 0 0 2 0 
Skin (I73.0-4) 2 I 0 0 2 I 
Thyroid (193) 0 0 2 0 2 0 
Total 4 2 0 6 
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Table 8.7 Cumulative incidenceA and cumulative incidence rates (per 10,000 years, 1945-1985) per cancer site for exposed and non-exposed subjects, the relative 
risks (RR) and confidence intervals (950Jo) associated with exposure, per sex. 
Male 
exposed non-exp exposed 
--
II rate II rate RR 95'1oCI n rate 
Total (all sites) 36.8 10.1 18.9 5.0 2.01 (.96-4.44) 23.7 8.8 
Brain 5.0 1.4 2.0 0.6 2.32 (.25-57.1) 0.0 
Head and neck 7.9 2.2 2.0 0.6 3.68 (.36-40.9) 3.5 
Larynx 4.0 I. I 0.0 • (.20- • ) 0.0 
Skin 4.0 I. I 2.0 0.6 1.86 (.II- 125) 0.0 
Thyroid 0.0 0.0 • • 3.5 1.3 
L/H"'* 6.0 1.7 4.0 1.2 1.39 (.23-5.77) 1.0 0.4 
Breast 0.0 0.0 
' • 7.1 2.6 Other 17.9 4.9 9,0 2.7 1.84 (.69-5.42) 12.1 4.5 
Correction factor 1.978 1.990 1.770 
(due to 
response+ I (1.23/ (1.25/ (1.20/ 
verifications+ +) 1.60) 1.59) 1.47) 
N in study group 1448 1257 1062 
person-years 36387 33680 27048 
Cumulative incidence is mortality plus corrected incidence among Survivors 
* impossible value (not defined or infinitely high) 
• • lymphatic and hematopoietic system 
Female 
non-exp 
n rate 
16.3 6.5 
3.6 1.4 
0.0 
0.0 
0.0 
0.0 
2.0 0.8 
5.2 2.1 
5.6 2.2 
1.582 
(1.27/ 
125) 
942 
25202 
first part of the correction factor: 1/(response on questionnaire); for male exposed: 1.23. 
Total 
exposed non-exp 
RR 95%CI n rate II rate RR 95%CI 
1.35 (.79-3.19) 60.5 9.5 33.2 5.6 1.69 (1.01-2.83) 
• ( 0 -2.28) 5.0 0.8 5.6 1.0 0.83 ( .23-10.6) 
• (.20- • ) 11.4 1.8 2.0 0.3 5.29 ( .61- 109) 
• • 4.0 0.6 0.0 • ( .20- • ) 
' • 4.0 0.6 2.0 0.3 1.85 (.11-125) 
• (.20- • ) 3.5 0.6 0.0 • ( .20- • ) 
0.46 (.01-9.35) 7.0 1.1 6.0 1.0 1.08 ( .26-5.13) 
1.26 (.15-4.15) 7.1 1.1 5.2 0.9 1.26 ( .15-4.15) 
2.00 (.58-8.14) 30.0 4.7 14.6 2.5 1.91 ( .93-4.13) 
2510 2199 
63435 58882 
+ + second part of the correction factor: requested number of verifications/received number of verifications; for male exposed: 1.60 
Total correction factor is the product; for male exposed: 1.23 x 1.60 = 1.978 
all Cl's are calculated with (18) 
The differences in mortality from lymphatic or haematopoietic tumours in males 
(see Table 8.5) were almost compensated for by the incidences in the part of the 
population that was still alive. In females, differences in breast cancer mortality 
were almost nullified when incidence data were added. 
8.3.2 Benign tnmours 
In comparing benign tumour incidence, overall and for specific sites (Table 8.8), no 
differences were noted between exposed and non-exposed groups. Striking was the 
almost threefold over-reporting of benign tumours by the female population 
irrespective of the state of exposure. 
Table 8.8 Benign tumour incidence for exposed and non-exposed study subjects, per sex 
Male Female Total 
Tumours (ICD) Exp Nexp Exp Nexp Exp Nexp 
Digestive tract (211) 0 1 0 2 0 3 
Skin (214,216)• 5 6 17 11 22 17 
Breast (214.1;217) 3 3 19 12 22 15 
Head and neck 1 2 2 5 3 7 
Lips, mouth, pharynx (21 0) 0 2 1 2 4 
Skin (214.0;216.0-4) 1 0 0 2 2 
Thyroid (226) 0 0 1 1 
UG tract (218-23) 2 0 3 3 5 3 
Other+ Haemangioma (228-9) 3 2 0 3 3 
Total 14 14 41 34 55 48 
8.4 DISCUSSION 
In the 1977 report of the United Nations Scientific Committee on the Effects of 
Atomic Radiation (UNSCEAR), tumour induction rates are given for different head 
and neck organs (3). The rate is defined as the number of induced tumours 
appearing in one million persons exposed to one cGy. A median latency is assumed 
of about 25 years, so that the total number of cancers diagnosed within this time, 
after exposure to radiation, may represent about half of all cancers likely to have 
been induced. This rate does not take variables such as age at exposure, sex or the 
kind of radiation into account and assumes a linear relationship between dose and 
the number of induced tumours. Based on these assumptions, the expected number 
of induced tumours at selected sites in our study group have been estimated and are 
shown in Table 8.9. The estimation of one expected induced tumour per site is only 
exceeded for the thyroid gland and the brain. 
In our study an excess of two malignant thyroid tumours and a deficit of one brain 
tumour was observed in the exposed group. 
In 1952 Loch and Fischer reported the first follow-up study of 85 persons who had 
been irradiated by Crowe a mean of 8.9 years before. Five persons showed enlarged 
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Table 8.9 Expected number of induced and observed malignancies of parotid gland, thyroid gland and 
brain in a population (n = 2,500) exposed to nasopharyngeal irradiation 
Organ 
Parotid 
Thyroid 
Brain 
Induction rate* 
.lQ-6.cGy-1 
20 
100 
20 
* As given by UNSCEAR (1977) (3) 
Dose (cGy) 
4-19 
2- 7 
10-36 
Number of tumours 
Expected Observed 
0.2-0.95 0 
0.5-1.75 2 
0.5-1.8 -1 
blood vessels and two persons showed slight crusting (19). In a non-concurrent study 
of 417 persons by Hazen et al., a mean of 14.6 years after irradiation, two malignant 
and five benign tumours were found, which did not differ from the expected values 
(20). In both investigations the follow-up period was short and control groups were 
either lacking (19) or difficult to assess (20). 
More recently, Sandler et al. (1982) carried out a study on 904 persons who had been 
treated with a 50 mg radium applicator, with a follow-up period of 18 to 35 years 
(usual dose 4,208 mgmin) and compared the subsequent cancer occurrence to that 
in a group of 2,021 non-exposed subjects. Three brain tumours and an anaplastic 
. cancer of the soft palate were identified in the exposed group, whereas no cancers 
of the head and neck were found in the non-exposed group (p<.05). No other 
increased incidences of cancer risk were found. A nearly significant reduction in 
breast cancer in exposed females was noted (17). 
The present study was similar in design to that of Sandler et al. (1982). The study 
group was, however, considerably larger (2,542 exposed, 2,380 non-exposed) and 
the average dose was lower (average 1,198 mgmin). In the Netherlands unilateral 
irradiation had been the standard form of treatment, whereas the Sandler et al. 
(1980) population had been exposed to bilateral treatment (21). 
In the present study we will have missed several types of cancer. We have already 
noticed deficits due to non-response to the questionnaire or verification procedure. 
Correction factors have been introduced to compensate for this (see Table 8. 7). 
However, these factors may be too high because existing incidences will have been 
reported more frequently than lacking incidences, i.e. the frequency of cancer cases 
in the non-respondents may have been lower. On the other hand, the number of 
people with cancer in the deceased group might have been higher than reported due 
to cancer being present in subjects who died of other causes and in the five missing 
observations (Table 7 .6). The incidence of cancer among the survivors will have 
been too low owing to misreco!lection in these subjects. We did not find significant 
differences between subjects in the exposed group who remembered being treated 
with the Crowe therapy and those who did not; this might lead to the conclusion 
that there was no over-reporting by subjects who remembered the radiation treat-
ment. 
There is no reason to suppose that these possible causes of under or over-reporting 
are any different in the exposed and non-exposed groups. In other words we expect 
the relative risks to be unbiased. 
Small but significant increases in the cancer incidence were found in the exposed 
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group. This was mainly the result of cancer in the head and neck region and at 
'other' sites remote from the irradiated area. The relative risk for these sites was not 
significantly different from 1.00. Small differences in mortality from cancer of the 
lymphatic or haematopoietic system in males and from breast cancer in females 
disappeared when the incidences were added. 
The two laryngeal carcinomas and two skin carcinomas in the head and neck region 
cannot easily be brought into connection with the low radiation doses received via 
nasopharyngeal radium irradiation. As regards the two thyroid carcinomas in 
exposed females, a relationship with previous irradiation is more obvious in view 
of the tendency of the thyroid gland towards radiation carcinogenesis. 
Although no statistically significant increases in cancer incidence in the head and 
neck region were established and although it would be hard to find an explanation 
for the (non-significant) higher cancer rates at other sites, we cannot ignore the 
increased overall cancer rate in exposed subjects. 
In our investigation of benign tumour incidence, women appeared to repori three 
times as many benign tumours as men, irrespective of whether or not they had been 
exposed to irradiation. 
Contrary to Sandler et al. (1982), we were unable to find a higher brain tumour 
incidence in the exposed group. Our breast cancer mortality did agree with their 
findings, but our cumulative breast cancer incidence did not; the latter incidence 
also disagreed with the findings in the population studied by Hazen et al. (1966), 
in which pituitary irradiation had taken place (19). 
Summarizing, our study does corroborate the hypothesis that there is some risk of 
tumour induction involved with nasopharyngeal radium irradiation at the dose level 
applied to this population. 
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CHAPTER 9 
HORMONAL AND OTHER EFFECTS OF 
NASOPHARYNGEAL RADIUM IRRADIATION 
In order to examine the possible induction effects of nasopharyngeal radium irradia-
tion on hormone balance, resulting from the inclusion of the pituitary gland in the 
treatment field, a number of specific questions were asked in the questionnaire. 
These questions were formulated with the aim of detecting hormonal disease as well 
as hormone-influenced processes, such as growth and fertility. The statistics in this 
chapter concern selected populations, as mentioned in Chapter 7 under 'Methods 
of analysis'. 
9.1 HORMONAL DISEASE 
Differences were observed with regard to hormonal disease between the exposed and 
non-exposed groups. This was also the case for the use of medications correspon-
ding to hormonal disease. It was striking that both thyroid disease (L9"1o vs 1.2%) 
and thyroid medication (1.3% vs 0.8%) were more frequent in the irradiated group. 
This was also true for diabetes mellitus (1.8% vs 1.1%) and antidiabetic medication. 
The fact that subjects were aware that they had been irradiated did not account for 
the larger number of reports (see Table 9.1). 
Table 9.1 Hormone-related disease and medication for exposed and non-exposed subjects. 
Hormone Exposed Non-exposed 
related: 
N % rate N % rate 
Disease 
Diabetes 36 1.8 7.3 19 Ll 4.2 
Anaemia 348 17.7 70.1 287 17.1 63.7 
Thyroid disease 38 !.9 7.7 21 1.2 4.7 
Hypophyseal 5 0.2 !.0 4 0.2 0.9 
Hormonal disease 58 3.0 11.7 48 2.9 10.7 
Medication 
Oral antidiabetics 12 0.6 2.4 8 0.5 !.8 
Insulin 23 !.2 4.6 16 1.0 3.6 
Antihypenensives 126 6.6 25.4 101 6.2 22.4 
Hormones 155 8.1 31.2 125 7.6 27.8 
Thyroid medication 25 1.3 5.0 14 0.8 3.1 
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9.2. HORMONE-INFLUENCED BODY FUNCTION 
The irradiation of the head and neck region did not have any clear effect on height 
or weight. Height was 174 ± 10 em and weight was 71.3 ± 13 kg for the exposed 
group compared to 173 ± ll em and 7!.2 ± l3 kg for the non-exposed group, 
respectively. 
There were no differences between the groups concerning the marital status (79.50Jo 
vs 78.1 OJo) and fertility, expressed in relation to the number of children. Parents in 
the exposed group had an average of 2.16 ± 1.01 children and in the non-exposed 
group 2.12 ± 1.06 children. Involuntary infertility occurred in 2.80Jo of the exposed 
and in 2.40Jo of the non-exposed subjects. No differences were observed with regard 
to the age of menarche, the regularity of the menses, the number of miscarriages 
and the age of menopause in the female respondents. 
9.3 OTHER HEALTH EFFECTS 
9.3.1 Hearing disorders 
As shown in Table 9.2, there is a higher incidence of hearing disorders and people 
with hearing aids in the exposed group. This is to be expected, because the most 
important reason for irradiating patients (otitis serosa) carries a risk of late hearing 
impediment which, even with optimum medical care, cannot be completely 
prevented. On the basis of similar findings in the population of Sandler eta!., which 
consisted solely of people who had been treated for hearing disorders in their youth, 
(see Chapter 7, 'Discussion') the assumption was made that nasopharyngeal radium 
therapy does not have any long-term effect on the prevention of deafness (1). 
However, it is possible that particularly the persistent cases of otitis serosa under-
went the treatment and in this way gave rise to a selection. 
Table 9.2 Other diseases of exposed and non-exposed subjects. 
Disease 
Hearing disorder 
Hearing aid 
Cataract 
Epilepsy 
Mental depression 
Psychiatric treatment 
9.3.2 Visual disorders 
N 
823 
133 
18 
22 
249 
159 
Exposed 
% 
42.1 
6.8 
0.9 
1.1 
12.7 
8.1 
Non-exposed 
N % 
256 15.2 
37 2.2 
15 0.9 
22 1.3 
192 11.4 
111 6.6 
The incidence of cataracts was the same in both groups. This is also unremarkable 
because the lens only becomes affected at higher radiation doses (200-600 cGy) (2). 
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9.3.3 Psyclliatric disorders 
In the study conducted by Shore eta!. (3), mentioned above (see Chapter 3, 'Brain 
and meninges') an increased incidence of- treated- psychiatric disorders (40"1o) was 
observed among white people in the irradiated group. Although the dose received 
by the brain in his study was much larger (70-170 cGy) than in our study, we still 
included questions concerning depression and treatment by psychologists or 
psychiatrists in our questionnaire. The incidence of treatment by the latter appeared 
to be higher (8.1 "1o vs 6.6%) in the exposed group. It seems that this difference is 
related to the higher incidence of hearing deficits among the exposed subjects. (See 
Table 9.3). 
Table 9.3 Occurrence of mental disorders compared to state of hearing. Number and percentage of 
total respondents. 
Mental disorder Hearing disorder 
no ('lo) yes ('lo) total ('lo) 
Depression 260 (10.2) 180 (16.7) 440 (!2.1) 
Psych. treatment 157 ( 6.2) 113 (10.5) 270 ( 7.4) 
Total respondents 255! ( 100) !075 ( 100) 3626 ( 100) 
9.4 DISCUSSION 
The radiation dose received by the pituitary gland during nasopharyngeal radium 
treatment was small (10-36 cGy). From radiotherapy practice it is known that 
disorders in pituitary function normally manifest themselves following much higher 
radiation doses. Moreover, the questions in our questionnaire were too broad to 
detect small function deficits of the pituitary gland which express themselves in the 
form of hormone imbalance. 
In conclusion, small differences were found with relation to hormonal disorders and 
hormone-influenced processes. The distinctly higher number of psychiatric 
disorders seems to be related to the greater number of hearing deficits in the exposed 
group. 
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CHAPTER 10 
DISCUSSION AND CONCLUSIONS 
lU DISCUSSION 
The motivation to carry out this study lay in the very great contrast of views which 
clinicians seem to have regarding the Crowe therapy, its effectiveness and its late 
side-effects. 
Despite the fact that some physicians are rather sceptical about the tumour inducing 
capacity of this therapy and others think that the chance of tumour induction is 
small, they will all still be incllned to carry out very careful examinations of patients 
-with an anamnesis of Crowe therapy- for tumours, 'just to be on the safe side'. 
With the additional realization that a diversity of opinions exist on the therapeutic 
effect of the Crowe therapy, our curiosity was more than sufficiently provoked. 
After all, wouldn't it be all the more regrettable if people ran an increased risk 
throughout their lives of developing cancer as the result of a treatment during their 
youth which appeared to be ineffective afterwards? 
A prospective non-concurrent design was chosen for the execution of this study, 
involving about 2,500 persons who had been exposed to irradiation. The population 
could have been larger if more funds had been available and if there had been more 
cooperation between colleagues. Some researchers in the field of radiation might 
think that, in view of the low radiation doses received by several of the organs, a 
study population of 2,500 subjects is too small. The number of radiation induced 
tumours which - on theoretical grounds - may occur in our population, is indeed 
not very large (see Chapter 8, Table 8.9). However, the dose received by the 
pituitary gland (10-36 cGy) was substantial and the dose received by the 
nasopharynx (3,500-23,000 cGy) was considerable. Moreover, the possible negative 
results can be used to establish the lower limit of the risk. 
The number of A-bomb and nuclear disaster victims (Chernobyl) and people who 
have been exposed to irradiation, via their occupation or for medical reasons, is 
small. But due to the prohibition to experiment on people, we are obliged to use 
such populations for research purposes. Comparisons of the results in similar 
studies can strengthen or weaken the meaning of the observed risks, even if they are 
not statistically significant in the separate studies. Moreover, one of the advantages 
in our study was that the radiation doses received by the various head and neck 
organs could be calculated accurately, which is not always the case with medical 
exposure and mostly impossible with regard to the A-bomb and nuclear disasters. 
In a similar study to ours, by Sandler eta!. (1982) (see Chapter 7, 'Discussion') an 
increased incidence of RES tumours and a decreased incidence of breast tumours 
were found in the exposed group, which we-re not statistically significant. Our results 
regarding mortality support these findings. In Sandler et al.'s study a statistically 
significant higher incidence of head and neck tumours and thyrotoxicosis was found 
in the exposed group. 
In our study on the cause of death no corresponding indications were found. 
However, on the basis of the answers in the questionnaire regarding the incidence 
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of disease, there appeared to be a higher (but not statistically significant) incidence 
in the total number of head and neck tumours. A higher incidence of thyroid disease 
was also noted. Contrary to the findings in Sandler et al.'s study, the higher all-
cancer incidence in our exposed group reached statistical significance. 
Owing to the fact that the radiation dose received by the larynx(;:;;; 7 cGy) and skin 
(;:;;; 20 cGY) was much lower in our study than is usually the case for radiation 
induced tumours, it is not easy to establish a relationship between the origination 
of these tumours and the previous nasopharyngeal irradiation. 
The thyroid gland is very sensitive to irradiation. Radiation-induced carcinomas of 
this organ have been seen to develop after low radiation doses, such as those 
received by our study group (;:;;; 7 cGy). 
It is notable that the high radiation exposure of the mucosal lining of the 
nasopharynx, in our study 3,500-23,000 cGy, did not result in the origination of 
radiation-induced nasopharyngeal tumours. This finding is in agreement with the 
results of Sandler et al.'s study. 
The results in our study do corroborate the hypothesis that some risk of tumour 
induction is involved with nasopharyngeal radium irradiation, although its validity 
is restricted due to the limited number of study subjects and the limited number of 
tumours found. 
What are the consequences of the results of this study regarding our judgement of 
the nasopharyngeal radium irradiation (Crowe therapy) as a medical treatment? 
Although it is very probable, on the basis of data from the literature, that irradia-
tion has a therapeutic effect on disorders resulting from dysfunction of the 
eustachian tube, it seems best to leave the therapy in its obsolete state. Physicians 
who are still practicing the Crowe therapy should reconsider possible alternative 
therapies for patients presenting with tubal problems. 
In the f"rrst place, there is probably some risk of tumour induction on the grounds 
of the results from this and other studies. Furthermore, we must remember that 
some radiation-induced tumours may manifest themselves after a longer latency 
time (30 or 40 years) than the observation period in our study, which adds to the 
risk. 
Those who wish to reserve the treatment for very persistent cases of tubal dysfunc-
tion would do well to remember that scarred eustachian tubes do not respond to 
irradiation. What are the consequences of the results of this study regarding the 
physician's attitude towards patients with nasopharyngeal radium treatment in their 
anamnesis? 
The risk of tumour induction is too small to justify exhaustive examination of 
symptom~ free persons. Extensive diagnostic measures are unnecessary and alarming 
and should therefore not be carried out. 
For the same reasons, recalling these persons and screening them for existing 
tumours should not be considered. The following conclusions are formulated as 
answers to the questions posed in Chapter l: 
10.2 CONCLUSIONS 
(!) During an observation period of a mean of 25.3 years in 2,542 persons who had 
been treated using Crowe's nasopharyngeal radiation method as applied in the 
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Netherlands, no increased mortality due to cancer was observed. However, a 
statistically significant increase in the cumulative incidence of all malignant 
tumours combined was found. Separation of the individual tumour sites did not 
produce a significant excess. No increased incidence of nasopharyngeal or brain 
cancer was found. 
(2) There were some indications that the Crowe therapy had affected hormone-
influenced processes. 
(3) Through comparisons with a similar American study (Sandler et al.), indications 
regarding the possibility of tumour induction in man in the exposure range 0-50 
cGy were strengthened. No data were obtained for establishing a dose-effect 
relationship. 
(4) Owing to the efficient registration of births, deaths and marriages in the 
Netherlands, it is possible to conduct successful epidemiological follow-up 
procedures (in this study 93.60Jo of the population could be followed-up). 
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SUMMARY 
The Crowe therapy - nasopharyngeal irradiation by means of radium application -
was a very popular form of treatment for ear disorders in children and for barotrauma 
in adults between about !925 and !975 in America and Europe. Nowadays this treat-
ment has more or less been abandoned owing to the fear of tumour induction and 
replacement treatments. It is necessary for a physician who is confronted with a 
patient who has been irradiated using the Crowe therapy in the past, to know the 
nature and degree of the risks. In this thesis a non-concurrent cohort study is 
described in which the effects of the Crowe therapy were examined with regard to 
the health of a population of persons who were irradiated in their youth. 
In Chapter l the aims of the study are formulated. The most important question 
is whether the Crowe therapy leads to the origination of tumours. Most of the atten-
tion is focussed on the head and neck region. The second question concerns the 
possible influence of the Crowe therapy on hormone balance, as a result of the 
pituitary gland being in the treatment field. Further, it is investigated whether infor-
mation can be obtained regarding dose-effect relationships in a dose range (0-50 
cGy) for which little is known in man. Finally, the study method - involving the 
follow-up procedures relevant to a non-concurrent cohort study in the Netherlands 
- forms a topic of investigation. 
Chapter 2 deals with the Crowe therapy in greater detail. Some attention is paid to 
the anatomy and physiology of the eustachian tube, as it is the ultimate goal of the 
Crowe therapy to improve the function of this organ. Owing to tbe fact that 
lymphoid tissue is pre-eminently sensitive to irradiation, the distribution of this 
tissue in and around the eustachian tube is described. Under normal circumstances 
there is no lymphoid tissue in the eustachian tube. The adenoid can have a negative 
effect on tubal function and adenotomy can have a positive one. 
Double blind controlled research has shown that the Crowe therapy affects the size 
of the adenoid as well as the degree of lymphoid overgrowth at the tubal orifice. 
Most studies on the effect of tubal function and the effect of tbe various clinical 
expressions of poor tubal function lack a control group. Effectiveness has been 
shown via double blind controlled research with regard to flat hearing loss, such as 
occurs in children with otitis serosa and with regard to adults with barotrauma. 
Chapter 3 gives an overview of the present state of knowledge on - ionizing - radia-
tion induced tumours in the head and neck region. Besides occupational exposure 
to radiation and exposure for medical reasons, a great deal of knowledge has been 
acquired on radiation induced tumours from the Japanese atom bomb explosion 
victims. The chance of a radiation induced tumour developing depends on many 
factors. These are associated with the characteristics of the individual and of the 
physical agent. 
Women are more sensitive to radiation induced thyroid tumours than men. 
Exposure at a young age and particularly antenatally leads to an increased risk of 
developing radiation induced tumours. 
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Ethnical factors also appear to be of influence. In one study Jews were found to 
be more predisposed to developing thyroid tumours and in another study white 
people were found to be more predisposed to developing radiation induced skin 
tumours than coloured people. 
Various studies have shown the existence of genetically determined sensitivity to 
radiation induced tumours. This was observed in patients with multiple familial 
retinoblastomas and in patients with the nevoid basal cell carcinoma syndrome. 
The patient's metabolic situation also appears to play a part. For example, a high 
TSH level, malnutrician and the use of cytotoxic drugs were found to involve an 
increased risk. 
The risk of developing a radiation induced tumour depends on the type of radiation. 
High LET radiation (alpha and neutron irradiation) has a higher tumour inducing 
capacity than low LET radiation (gamma and rontgen radiation) per dose unit. 
Moreover, it is possible that the energy level, dose rate and fractionation also 
influence the origination of radiation induced tumours. 
The lowest dose thought to have induced a tumour is 6 cGy. The risk increases with 
the dose to a certain level (2000 cGy for thyroid tumours) and decreases at higher 
levels because the number of cells which can become malignant decreases (cell death 
function). The minimum latency period is a few years, the maximum latency period 
appears to be unlimited. A description of tumour induction due to irradiation is 
given for a number of organs in the head and neck region. 
The salivary glands are receiving increasing attention as a site where radiation 
induced tumours can arise. In a population of people exposed to the atom bomb 
explosions in Japan, it was established that the chance of developing a salivary gland 
tumour increases as the distance of the exposed person from the explosion site 
decreases. 
Radiation induced salivary gland tumours can be malignant or benign and can have 
all kinds of histologies. Radiation induced tumours of the brain and meninges are 
particularly well known as 'second primary tumours' following the irradiation of 
retinoblastomas or pituitary adenomas. It is also believed that tumour induction is 
possible after low radiation doses, such as 120-140 cGy, given for tinea capitis. 
The first radiation induced tumours to be described in the head and neck region 
were localized in the pharynx and larynx. They are reported exclusively following 
medical treatment using ionizing irradiation. The fact that cohort studies have 
proved that 5"7o of the people who have been irradiated for an early stage larynx 
carcinoma develop a second primary tumour, has clear clinical implications. The 
thyroid gland is the most sensitive organ in the human body for radiation induced 
tumours. For this reason, most of the knowledge on the relationship between radia-
tion and cancer has been acquired via studies on radiation induced thyroid tumours. 
The skin is also very radiation sensitive. Basal cell carcinomas have been described 
following radiation for dermatoses (acne) on the face. The degree of skin pigmenta-
tion is an important risk factor. The clinical significance of radiation induced skin 
tumours is small: as a rule they can be treated adequately. 
The most striking forms of radiation induced tumours are those which develop at 
several different places in the same organ (multicentric) and those which develop in 
several different tissues simultaneously (pluritissular). This is associated with the 
physical nature of the ionizing radiation. 
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In Chapter 4 the design of the study is described. The exposed group, comprising 
2,542 persons, was selected from the records at five ENT clinics. The control group 
was selected on the basis of the characteristics of the subjects in the exposed group, 
i.e. the year of birth, the year of first contact and sex. During follow-up we tried 
to find out how many subjects were still alive and how many had died. This was 
accomplished in 93.6"7o of the cases. The cause of death was established for the 
deceased and the subjects who were still alive were surveyed with questions concer-
ning their health. The response to the survey was 86.5%. If it was suspected on the 
grounds of the questionnaire that a subject was suffering from or had suffered from 
a tumour, their specialist - at that time - was approached for verification of the 
diagnosis. 
The method of collecting data is described in Chapter 5. The radiation doses were 
calculated with the aid of antero-posterior and lateral skull X-ray films of children 
of various ages with a placebo applicator in situ. In this way it was possible to deter-
ntine the doses received by each organ in the head and neck region. The details are 
presented in Appendix 9. Depending on the age and clinic, the doses for the pituitary 
gland varied from 10-36 cGy, for the thyroid from 2-7 cGy, for the parotis from 
4-19 cGy and for the nasopharynx 3,500-23,000 cGy. 
All the necessary data for the follow-up exantination were obtained from the records 
at the five ENT clinics, including sex, insurance, date of first contact, diagnosis and 
radiotherapy treatment data. 
The health survey comprised questions concerning potential tumours, problems 
with hormone balance and other possible effects that the irradiation of the head and 
neck region might have had on the health of the subject. Finally, the way in which 
the various data were coded is described. 
In Chapter 6 a number of characteristics of the study population are presented. The 
average age of the subjects at the beginning of follow-up and the slight 
predontinance of males (57:43) corresponds with the pre-entinent age and sex at 
which otitis serosa is usually treated. Otitis serosa was the most frequent indication 
for the Crowe therapy. 
The mortality of the exposed group is compared to that of the non-exposed group 
in Chapter 7. No significant differences were observed with regard to the total 
mortality, deaths due to cancer or deaths due to cancer of specific organs. Four 
cases of lymphatic or haematopoietic tumours, two of which were leukemias, were 
identified as the cause of death in males in the exposed group, whereas none were 
observed in the non-exposed group). One brain tumour was found in the exposed 
group, against two in the non-exposed group. 
In Chapter 8 the cumulative tumour incidence is compared in exposed and non-
exposed subjects. Six head and neck tumours were observed in the exposed group, 
whereas only one was found in the non-exposed group. This difference is not 
statistically significant. For all cancers a significantly higher cumulative incidence 
was found in the exposed group. This significance is mainly caused by 'head and 
neck tumours' and 'other tumours' (lung, digestive tract and urogenital system). No 
differences were found between the exposed and non-exposed groups with regard 
to benign tumour incidence. 
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Chapter 9 deals with the influence of irradiation on the occurrence of hormonal 
disorders, such as diabetes mellitus and thyroid disorders and hormone-influenced 
processes, such as growth and fertility. Small differences were observed to the disad-
vantage of the exposed group. Notably, more reports of thyroid disease were found 
in the exp.gsed group. The higher incidence of mental depression and treatment by 
psychologists or psychiatrists seems to be related to the higher incidence of hearing 
deficits among exposed subjects. 
In conclusion, the results of our study show that some risk of tumour induction is 
involved with nasopharyngeal radium irradiation. No increased mortality due to 
cancer was observed. However, a statistically significant increase in the cumulative 
incidence for all cancers combined was observed. Separation of the individual 
tumour sites did not produce a significant excess. 
There were some indications that the Crowe therapy had affected hormone-
influenced processes. 
Indications regarding the possibility of tumour induction in man in the exposure 
range 0-50 cGy were strengthened. This study has shown that it is possible to 
conduct successful epidemiological follow-up procedures in the Netherlands owing 
to the efficient registration of births, deaths and marriages. 
The Crowe therapy, as a medical treatment, should be left in its obsolete state. 
In view of the small risk of tumour induction that irradiatied persons run, we 
consider that it is not necessary to pay special attention to symptom-free patients 
or to recall exposed persons for screening. 
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SAMENVATTING 
De therapie volgens Crowe, nasofaryngeale bestraling door middel van radium-
applicatie, werd veelvuldig toegepast tussen ± 1925 en ± 1975 in de V.S. en in 
Europa voor ooraandoeningen bij kinderen en barotrauma bij volwassenen. 
Thans is deze therapie vrijwel verlaten wegens angst voor tumorinductie en de 
beschikbaarheid van vervangende therapieen. Voor de medicus die geconfronteerd 
wordt met een patient die in het verleden volgens Crowe bestraald werd is het nodig 
te weten welke de aard en de mate van de risico's zijn. 
In dit proefschrift wordt een historisch cohort-onderzoek beschreven waarin de 
effecten van de Crowe-therapie op de gezondheid van een in het verleden bestraalde 
populatie worden nagegaan. 
In Hoofdstuk l worden de vraagstellingen geformuleerd. De be!angrijkste is of de 
Crowe therapie !eidt tot het ontstaan van gezwellen. De meeste aandacht heeft 
hierbij de hoofd-halsregio. De tweede vraagstelling betreft de eventuele inv!oed van 
de Crowe therapie op de hormoonhnishouding door het meebestraald zijn van de 
hypofyse. Vervo!gens wordt in dit onderzoek nagegaan of informatie kan worden 
verkregen over dosis-effectrelaties in een dosisgebied (0-50 cGy) waarover bij de 
mens nog weinig bekend is. Tenslotte is de methode van onderzoek, de follow-up 
procedures bij een historisch prospectief cohortonderzoek in Nederland, onderwerp 
van studie. 
In Hoofdstuk 2 wordt nader ingegaan op de Crowe therapie. Enige beschouwingen 
worden gewijd aan anatomie en fysiologie van de bnis van Eustachius we!ks func-
tieverbetering doe! is van de Crowe therapie. Omdat lymfoid weefsel bij uitstek 
gevoelig is voor straling wordt de verdeling van dit weefsel in en rond de buis van 
Eustachius besproken. Onder normale omstandigheden bevindt zich geen lymfoid 
weefsel in de buis van Eustachius. Het adenoid kan een negatieve en de adenotomie 
een positieve invloed hebben op de tubafunctie. In dubbelblind gecontro!eerd onder-
zoek werd aangetoond dat Crowe bestraling effect heeft zowel op de grootte van het 
adenoid als op de mate van lymfo1de 'overgroei'van de mond van de buis van 
Eustachius. De meeste onderzoeken naar het effect op de tubafunctie en het effect 
op de verschillende klinische uitingen van een slechte tubafunctie ontberen een 
controlegroep. Ten aanzien van v!akke gehoorverliezen bij kinderen, zoals gezien 
wordt bij otitis serosa en ten aanzien van barotrauma bij volwassenen werd in 
dubbelblind gecontroleerd onderzoek de werkzaamheid aangetoond. 
Hoofdstuk 3 geeft een overzicht van de bestaande kennis over door ioniserende 
straling ge1nduceerde hoofd-halstumoren. Behalve door b!ootstelling aan straling in 
het beroep en om medische redenen, is veel kennis over tumorinductie vergaard door 
blootstelling aan straling van slachtoffers van de atoombomexplosies in Japan. De 
kans op het krijgen van een stralenge1nduceerde tumor is van vele factoren 
afhankelijk. Deze betreffen zowel kenmerken van het blootgestelde organisme als 
kenmerken van het fysisch agens. 
Vrouwen zijn gevoeliger voor stralengelnduceerde schildkliertumoren dan mannen. 
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Expositie op jeugdige leeftijd en vooral antenatale expositie leidt tot een boger risico 
op het ontstaan van stralengelnduceerde tumoren. 
Ook etnische factoren bleken van invloed. In een onderzoek predisponeerde joods-
zijn tot het krijgen van stralengeinduceerde schildkliertumoren en in een ander 
onderzoek preclisponeerde blank-zijn tot het krijgen van stralengeinduceerde huid-
tumoren. 
In verschillend onderzoeken bleek een genetisch bepaalde gevoeligheid voor 
stralengeinduceerde tumoren te bestaan. Dit werd o.a. gezien bij patienten met 
multipele farniliaire retinoblastomen en patienten met het nevoid basal cell 
carcinoma syndrome. Ook bleek de metabole toestand een rol te spelen. Zo werden 
een hoog TSH -gehalte, ondervoecling en gebruik van cytostatica als risicoverhogend 
aangewezen. Het risico op het ontstaan van stralengeinduceerde tumoren is 
afhankelijk van de soort straling. Hoge LET-straling (alfa- en neutronenstraling) 
heeft een hoger tumorinducerend effect dan !age LET -straling (gamma- en 
rontgenstraling) per dosiseenheid. Daarnaast is het mogelijk dat het energieniveau 
van de straling, het dosistempo en het fractioneren van de dosis van invloed zijn op 
het ontstaan van stralengeinduceerde tumoren. 
De laagste dosis waarna tumorinductie werd aangenomen bedraagt 6 cGy. Het risico 
neemt toe met de dosis tot een bepaald niveau (2000 cGy bij schildkliertumoren) en 
neemt bij hogere niveaus weer af doordat het aantal cellen dat maligne kan 
transformeren steeds kleiner wordt (celdoodfunctie). De minimum latentietijd 
bedraagt enkele jaren, de maximum latentietijd lijkt onbegrensd. Voor een aantal 
hoofd-halsorganen afzonderlijk wordt de tumorinductie door straling beschreven. 
De speekselklieren krijgen in toenemende mate aandacht als plaats waar stralengein-
duceerde tumoren kunnen optreden. In een aan een japanse atoombomexplosie 
blootgestelde populatie werd vastgesteld dat de kans op speekselkliertumoren groter 
werd naarmate de geexponeerde zich clichter bij de plaats van explosie bevond. 
Ge!nduceerde speekselkliertumoren kunnen goed- of kwaadaardig zijn en van 
velerlei histologische aard. 
Stralenge!nduceerde tumoren van hersenen en hersenvliezen zijn vooral bekend als 
'tweede primaire tum oren' na bestraling voor retinoblastoom of hypofyseadenoom. 
Ook voor lagere stralingsdoses, zoals 120-140 cGy gegeven voor tinea capitis, wordt 
de mogelijkheid van tumorinductie aangenomen. 
De eerste beschreven stralengeinduceerde hoofd-halstumoren waren gelocaliseerd in 
farynx en larynx. Zij zijn uitsluitend vermeld na medische behandeling met 
ioniserende straling. Omdat in cohort-onderzoek is aangetoond dat zich bij 
personen clie bestraald zijn voor een klein larynxcarcinoom in 5o/o der gevallen in 
het bestraalde gebied een tweede primaire tumor ontwikkelt, heeft dit een duidelijke 
klinische betekenis. 
De schildklier is voor tumorinductie door straiing het gevoeligste orgaan van het 
menselijk lichaam. Om die reden is de meeste kennis over de relatie straling en 
kanker vergaard door bestudering van de stralengeinduceerde schildkliertumor. 
De huid is eveneens een gevoelig orgaan. Basaliomen werden beschreven na 
bestraling voor dermatosen (acne) in het gelaat. De mate van huidpigmentatie is een 
belangrijke risicofactor. De klinische betekenis van stralengeinduceerde huid-
tumoren is gering: in de regel zijn zij goed behandelbaar. 
De meest treffende vorm van tumorinductie door straling is het op meerdere 
plaatsen (multicentrisch) of het in meerdere organen tegelijkertijd (meervoudig) 
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ontstaan van de afwijking. Dit hangt samen met de fysische eigenschappen van 
ioniserende straling. 
In Hoofdstuk 4 wordt de opzet van bet onderzoek beschreven. De bestraalde groep, 
2542 personen, werd uit vijf KNO-archieven geselecteerd. De controlegroep werd 
samengesteld uit dezelfde archieven op grand van een weergave van de bestraalde 
groep, overeenkomend in geboortejaar, jaar van eerste contact en geslacht. Bij de 
follow-up werd nagegaan of de personen uit beide groepen nog in Ieven waren of 
overleden waren. Dit gelukte in 93,60Jo van de gevallen. Van de overledenen werd 
de doodsoorzaak opgespoord en de nog levenden werden geenqueteerd met vragen 
betreffende de gezondheid. De respons op de enquete bedroeg 86,5%. Indien op 
grond van de enquete vermoed werd dat de betreffende respondent aan een 
gezwelziekte leed of geleden had, werd getracht de diagnose bij de destijds 
behandelende arts te verifieren. 
In Hoofdstuk 5 wordt besproken op welke wijze de gegevens verzarneld werden. Met 
behulp van voorachterwaartse en dwarse schedelfoto's met een placeboapplicator in 
situ werden dosisberekeningen uitgevoerd bij kinderen van verschillende leeftijden. 
Voor elk hoofd-halsorgaan konden zo ontvangen doses berekend worden. In 
Appendix 9 worden de details hiervan gepresenteerd. Afhankelijk van leeftijd en 
kliniek varieerde de dosis voor de hypofyse van 10-36 cGy, voor de schildklier van 
2-7 cGy, voor de gl. parotis van4-l9 cGy en voor de nasofarynx van 3.500 tot23.000 
cGy. 
Uit de archieven van de verschillend KNO-klinieken werden de personalia en andere 
gegevens benodigd voor de follow-up overgenomen alsmede geslacht, verzeke-
ringsvorm, datum eerste contact, diagnose en bestralingsgegevens. 
De gezondheidsvragenlijst, gebrnikt bij de enquete, bevatte vragen over mogelijke 
gezwe!ziekten, vragen betrekking hebbend op de hormoonhuishouding en enige 
vragen betreffende andere mogelijke effecten op de gezondheid van bestraling van 
bet hoofd-halsgebied. Tenslotte wordt in dit hoofdstuk de wijze van codering van 
de verschillende gegevens besproken. 
In Hoofdstuk 6 worden enkele kenmerken van de onderzoeks-populatie 
gepresenteerd. De gemiddelde leeftijd bij het begin van de follow-up en het in 
geringe mate overwegen van het mannelijk geslacht (57:43) komt overeen met de 
voorkeursleeftijd en het geslacht waarbij otitis serosa wordt behande!d. Otitis serosa 
was de be!angrijkste indicatie voor de Crowe therapie. 
in Hoofdstuk 7 wordt de sterfte van de bestraalde groep vergeleken met die van de 
controlegroep. Geen significante verschillen werden aangetoond in totale sterfte, 
sterfte aan kanker of sterfte aan kanker van bepaalde organen. Vier gevallen van 
lymfatische of haematopoietische tumoren, waarvan twee leukamie, werden bij 
bestraalde mannen als doodsoorzaak vastgesteld, terwijl er geen bij de niet 
bestraalde groep werden gevonden. In de bestraalde groep werd een hersentumor 
gevonden, tegen twee in de niet-bestraalde groep. 
In Hoofdstuk 8 is het voorkomen van tumoren tussen bestraalde en niet bestraalde 
personen vergeleken. Zes maligne hoofd-hals tumoren werden bij de bestraalde 
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groep gevonden, terwijl er bij de niet bestraalde groep slechts een werd ontdekt. Dit 
verschil is statistisch niet significant. Voor alle maligne tumoren tesamen, werd een 
statistisch significant verhoogde cumulatieve incidentie vastgesteld in de bestraalde 
groep. Dit verschil werd vooral bepaald door 'hoofd-halstumoren en 'andere 
tumoren' (long, maag-darm-stelsel en tractus urogenitalis). Met betrekking tot het 
optreden van benigne tumoren werden er geen verschillen gevonden tussen de 
bestraalde en de niet bestraalde groepen. 
In Hoofdstuk 9 word! de invloed van de bestraling nagegaan op het voorkomen van 
hormonale aandoeningen zoals diabetes mellitus en schildklieraandoeningen en 
hormonaal be1nvloedbare processen zoals groei en vruchtbaarheid. Er werden kleine 
verschillen vastgesteld ten nadele van de bestraalde groep. Met name werden 
vermeldingen van schildklieraandoeningen vaker waargenomen. De hogere 
incidentie depressies en psychologische of psychiatrische behandeling lijken in 
verband te staan met de hogere incidentie van gehoorstoornissen onder bestraalde 
personen. 
Op grond van deze studie mogen we concluderen dat er enig risico van tumorin-
ductie bestaat door nasofaryngeale radiumbestraling. Een verhoogde sterfte aan 
kanker werd niet waargenomen. Wel kon een statistisch significante verhoging van 
de cnmulatieve incidentie van alle maligne tumoren tesamen worden vastgesteld. 
Gekeken naar de afzonderlijke organen, werden geen significante verschillen gezien. 
Er werden enige aanwijzingen gevonden dat de therapie volgens Crowe invloed heeft 
op het voorkomen van hormonaal bepaalde aandoeningen. 
Bestaande aanwijzingen dat ioniserende straling in het dosisgebied 0-50 cGy bij de 
mens tumoren kan induceren werden bevestigd. 
Deze studie heeft aangetoond dat een historisch cohortonderzoek in Nederland met 
succes kan worden uitgevoerd dankzij de efficiente gemeentelijke registratie van 
geboorte, huwelijk en overlijden. 
Op grond van het voorgaande lijkt het beter de Crowe therapie niet meer toe te 
passen. 
Vanwege het kleine risico dat bestraalde personen !open op het krijgen van een 
stralenge1nduceerde tumor concluderen wij dat het niet noodzakelijk is om speciale 
aandacht te besteden aan patienten die vrij van symptomen zijn of om bestraalde 
patienten op te roepen voor screeningsonderzoek. 
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APPENDIX 1 
QUESTIONNAIRE: THE APPLICATION OF THE 
CROWE THERAPY IN THE NETHERLANDS 
A.l.l INTRODUCTION 
In order to form an impression of the way and degree to which the Crowe Therapy 
was applied in the Netherlands, a questionnaire was sent to a number of ENT 
specialists in the middle of 1982. An additional aim of the survey was to gain an 
insight into the results and side effects of the therapy. The data obtained in this way 
were used to track down clinics with records suitable for the epidemiological study, 
to be carried out later, on the relationship between the Crowe Therapy and tumour 
induction. 
A.1.2 METHODS 
A questionnaire, with an accompanying letter and stamped addressed envelope, was 
sent to all 110 members of the Dutch Society of Ear, Nose and Throat Specialists 
who had joined the society in or after 1960 and whose name appeared in the 
society's annual report of 1980. Moreover, four surveys were conducted on the 
telephone with non-members of the society who, on the basis of the written ques-
tionnaires or via other means, were known to have applied the Crowe therapy. 
A.1.3 RESULTS 
Answers were received from 66 of the JlO ENT specialists approached (60"7o). One 
colleague appeared to have died shortly before and two answers did not supply any 
information. This left 63 reactions for processing (57%). A summary of the answers 
will be presented per question. 
Question I. Have you applied the Crowe therapy yourself or had it applied in your 
own or someone else's practice? 
This question was answered in the affirmative by 35 respondents (56%). Eight did 
not give any further information: seven had only applied the therapy during their 
training and one had referred patients, who were considered to be candidates for 
the Crowe Therapy, to a colleague. 
Twenty-eight respondents said no to this question. They were only questioned 
further with regard to possible observations of tumour induction due to radium 
irradiation (question 11). The positive answers of 27 respondents to questions 2 to 
10 are shown in Table ALl, together with the answers from the four surveys 
conducted per telephone. 
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Table ALl Results of the survey on the application of the Crowe therapy in the Netherlands 
No. City/town Years Pat/yr Mg Dose Indication* Results Complications 
Assen 53-55 1-2 25 SOM good 
2 Unknown 55-65 10' SOM v. satisfactory 
3 Lei den 48-73 200-250 12.5 30' SOM v. good 
4 Sluiskil 55-64 20-30 SOM good 
5 Tiel 54-67 50 50 3.12 1 SOM+RO favourable 
6 Alkm.aar 52-58 15 SOM v. good 
7 Utrecht 50-58 40-60 50 2.8 1 SOM good palat necrosis 
8 Utrecht 50-58 dozens 50 5q5 1 SOM no def. concl. radium ulcer, atlas 
necrosis, 
epipharyngitis 
sicca 
9 Den Bosch 51-68 50-100 25 4.101 SOM+M v. favourable 
10 The Hague 64-76 20 50 3.101 SOM favourable 
11 Amsterdam 46-60 100-150 50 3.(1-3)' SOM often succes. 
12 Amsterdam 58-68 0-20 50 3.3 SOM good 
13 Zaandam 53-63 50 SOM good 
14 Sneek 51-65 50 2.(4,5-8)' SOM favourable 
15 Haarlem** 53-69 many 25 3.(8,5-12)' SOM good 
16 Zutphen 50-51 25 25 SOM 
17 The Hague 57-60 sporadic SOM result of 
anaes. 
18 Groningen 48-65 20 25 SOM not spec-
tacular 
19 Groningen 50- 25 SOM 
20 Utrecht 53 50 SOM good cylinder broken 
from needle 
21 The Hague 1950s 10-20 25 SOM 
22 Enschede 50-55 4 SOM v. satisfactory 
23 Amsterdam 48-70 !50 50 SOM+PN good-excellent 
24 Den Helder 55-64 5-10 SOM 
25 The Hague** to 70 SOM 
26 Den Bosch 50-62 5-8 15 SOM good 
27 Bussum 56-70 25 25 3.10 1 SOM good fairly 
often 
28 Sittard 54-81 120 25 4.(7-15)' SOM v. good 
29 Haarlem 46-69 50 10 (I-3).60 SOM good 
30 Assen 46-70 50 50 3.20 1 SOM good 
31 Amsterdam 55-62 50 SOM not very 
effective 
* SOM = otitis serosa; RO = persistent otitis; M = mastoiditis; PN = polyposis nasi 
** in cooperation with radiologist/radiotherapist 
Question 2. In which hospital/practice did this therapy take place? 
The names of 27 hospitals/practices were mentioned, 24 in the written questionnaire 
and three on the telephone. This figure is smaller than the number of specialists who 
applied the therapy. This is the result of succession and of cooperation within one 
practice (see Figure ALl). 
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Figure Al.l Application of nasopharyngeal radium treatment in the Netherlands. Clinics in which 
treatment was given: Alkmaar, Amsterdam (4x), Assen, Bussum, Enschede, 's-Gravenhage (4x), Gro-
ningen, Haarlem (2x), Den Helder, 's-Henogenbosch (2x), Leiden (2x), Sittard, Sluiskil, Sneek, Tiel, 
Utrecht, Zaandam, Zutphen . 
.:l Information obtained by written enquiry. 
* Information obtained by verbal communication. 
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Question 3. In what period was the therapy conducted? 
The period of application of the therapy varied from a few years to twenty or so 
years. It was introduced in the Netherlands by Van Dishoeck in 1945 and was at its 
peak in the 1950s and at the beginning of the 1960s. The therapy was applied until 
the 1970s at five clinics. It has more or less been abandoned nowadays (see Figure 
Al.2). 
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Figure Al.2 Application of nasopharyngeal radium treatment in the Netherlands. 
Number of clinics, per date. 
1980 
date 
Question 4. Approximately how many patients were treated per year using 
radium? 
Exact answers were given to this question, varying from 1.5 to 225. The average was 
about 50 patients per year. Witb the aid of the answers to question 5, an estimation 
was made of the number of people who had been treated in this way: approximately 
24,500. We were careful not to count the answers of specialists who had been 
working at the same clinic during the same period more than once. 
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Question 5. How much radium sulphate did the needle contain? 
In eight cases 25 mg was mentioned and in ten, 50 mg. Other quantities were only 
mentioned once: 12.5 mg, 15 mg and 25 mg (radon). 
Question 6. What was the dose applied per age of the patients? 
This question produced a great diversity of answers, varying from 1 to 4 sessions 
of I to 30 minutes duration. 
Question 7. What were the treatment indications? 
By far the most respondents gave otitis serosa or a synonym as the indication for 
treatment. Recurrent otitis, polyposis nasi and inflammation following radical 
mastoidectomy were also mentioned. 
Question 8. What were the general results of the therapy for the various indica-
tions? 
A therapeutic effect was mentioned by 19 respondents. They chose one of the 
following classifications to describe the effect: 'good', 'very good', 'favourable', 
'very satisfactory', 'often successful', 'good to excellent' and 'good, fairly often'. 
Two respondents considered the results to be 'very mediocre'. Other responses 
which were encountered once each were: 'no definitive conclusion', 'no spectacular 
results', 'not very effective' and 'the effect was possibly the result of the anaesthetic 
used (procaine)'. 
Question 9. Has an accident with a radium source ever taken place at your prac-
tice? 
This question only produced the report of an accident which was already known: the 
breakage of a needle and ingestion of the radium-containing cylinder, SAZU, 1958. 
Question 10. Did you ever observe harmful side-effects in the short-term? 
Several respondents mentioned the consequences of too long applications, such as 
epipharyngitis sicca, radium ulcer and necrosis of the palate. Also, necrosis of the 
atlas was thought to have been observed. 
Question !I. Have you ever found a benign or malignant tumour in the head and 
neck region of a patient who had been exposed to radium irradiation? 
This question was presented to everybody, either in the questionnaire or on the 
telephone. It was answered twice in the affirmative. One of the respondents reported 
to have seen such a tumour during his training in Leiden (1949-1952). The other 
thought he had seen one or two such tumours in his own practice since 1960. Both 
respondents had given a negative answer to Question I, therefore, they had not 
conducted the treatment themselves. 
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A.l.4 DISCUSSION 
Only a few general conclusions can be drawn from the data acquired via the ques-
tionnaire. The response rate of 60o/o is not high enough to be able to make a more 
precise estimation of the application of the therapy in the Netherlands. For many 
respondents, the Crowe therapy was a treatment from the past. Many had already 
stopped practising by the time the survey was held and the majority who had applied 
the Crowe therapy had abandoned the method twenty or so years earlier. Moreover, 
the f"JgUres and treatment results estimated by the therapists themselves are not 
always completely reliable. lt is possible that personal feelings and/ or the general 
regard of the therapy led to under or over estimations. The fact that not all the 
clinics where the Crowe therapy was applied are known, is a distorting factor in the 
estimation of the number of people who were irradiated. 
Reviewing the results of the questionnaire, it appears that there were supporters and 
opponents of the Crowe therapy. The supporters treated many patients, observed 
good results and no side-effects. Those who saw side-effects had not carried out the 
treatment themselves. The most important result of the questionnaire was finding 
a number of clinics with records suitable for the epidemiological study to be 
conducted in continuation at a later date. 
A.l.S CONCLUSIONS 
It can be concluded that, for many years, the Crowe therapy was a generally 
accepted form of treatment by ENT specialists throughout the Netherlands and was 
-sometimes- applied in cooperation with radiologists or radiotherapists. An estima-
tion of the number of Dutch people who had been treated using the Crowe therapy 
since the Second World War, based on the information gained from specialists who 
had applied the therapy, gave rise to a figure of at least 24,500 people. When asked 
about the effects of the therapy, the majority of the respondents gave a positive 
answer. No judgements can be made on the side-effects of the treatment on the 
strength of this questionnaire. 
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APPENDIX 2 
THE LOST RADIUM NEEDLE, PUTTEN 1958 
A2.1 INTRODUCTION 
In the past, when radium application was a popular way of treating tumours, it was 
not unusual for radium needles or seeds to become mislayed. Such needles or seeds 
could, for instance, find their way into dust bins, sewers, a crevice in the floor, 
rubbish dumps or could be stolen. 
In tbe head and neck region, radium seeds from an inplant sometimes migrated via 
the soft tissues or via the arterial or venous blood-vessels to other parts of the body. 
This migration within the body was probably caused by the effect of the irradiation 
itself: as the tumour started to shrink the seeds took up different positions, or, if 
the wall of a large blood-vessel became necrotic the seeds could enter the circulation 
(quoted 1). 
Due to a particularly unfortunate coincidence, the radio-active contents of a 
radium needle became deposited in the environment. The following account of the 
accident is mainly based on a Report from tbe Director-General of Public Health 
to the Minister for Social Services and Public Health which appeared on 23 June 
1958 (2). 
A2.2 THE FACTS OF THE ACCIDENT 
On 15 January, a six-year-old girl attended the ENT policlinic at tbe University 
Hospital in Utrecht, accompanied by her father. She had already undergone 
adenotonsillectomy on account of tubal deafness at an earlier stage, but the opera-
tion had not produced the required results. 
After an examination of the patient, it was decided to treat her using 
nasopharyngeal radium applicaton, via a series of eight-minute sessions. A transla-
tion of the Dutch Report is as follows: 
'The doctor at the policlinic who had examined tbe girl proceeded to the treattnent 
area with tbe child and her father at approximately 11.30 a.m. While passing 
through an adjoining room, he invited a younger colleague who was working there 
and had never seen the treatment, to come and watch. 
In the treattnent room, he took the needle from a lead box, placed it in the patient's 
right nostril and set the alarm clock to go off in eight minutes. The young assistant 
entered tbe room after the radium needle had been inserted. Both assistants tben left 
the treattnent room. When the alarm went off eight minutes later, the older assistant 
went back to the patient, removed the radium needle, placed it in the left nostril and 
reset the alarm clock for eight minutes. After this he proceeded to his own office 
somewhere else in the building. When the alarm went off for the second time, the 
young assistant entered the treatment room, removed the radium needle and put it 
back into the lead box. 
As the girl and her father were leaving the treatment room at approximately 11.50 
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a.m., they met the older assistant who asked them to come back for a check-up two 
weeks later. 
After leaving the hospital, the girl and her father walked around the city for some 
time before proceeding to the station. At the station the girl was said to have sneezed 
and shown signs of nausea without actually vomiting. She vomited later that evening 
at home, after she had gone to bed. The vomit was collected in a newspaper by her 
father and incinerated in the living room fire'. As far as this with the translation 
of the Report. 
Th~ next morning during_ ap. inspection of the needie, the senior consultant 
discovered that the cylinder containing the radium, at the end of the needle, was 
missing. After a thorough search of the policlinic without any result, the conclusion 
was drawn that the cylinder had probably become lodged in the girl's nostril. After 
informing the police In Putten, the girl and her parents were asked to return to the 
hospital as quickly as possible for further investigation at the policlinic. 
Monitoring the child using Geiger counters and via X-ray examinations, showed 
that the cylinder was not in the girl's body. A further thorough search, the next day, 
of the policlinic, the surrounding area and the rubbish tip did not produce any 
results. 
In the afternoon of 17 January, a search was started in Putten, the child's place of 
residence. Radioactivity was discovered there, close to the living-room fire and in 
the garden where the fire ashes had been deposited. 
The provincial and national governments were informed and a series of activities 
followed to prevent any further radio-active contamination from taking place and 
to clear up the existing contamination. That same evening the inhabitants evacuated 
the house. The patient and her family were taken to the SAZU the next day and 
remained there until 26 February 1958. By that time the house had been decon-
taminated and restored and the family could move back in. 
A2.3 THE CLEANING-UP PROCEDURE 
It was thought that the missing cylinder containing radium had broken as a result 
of the high temperature in the fire and in this way had become partly deposited in 
the fire and partly in the ashes in the garden. lt was, therefore, no longer a matter 
of a closed source but of an open one. The ash was thought to have spread outside 
the garden via the wind. It was almost certain that the living room had been 
contaminated by the radioactive ashes. Not only was the house evacuated but also 
a nearby nursery school and the contaminated area was cordoned off. 
When the definitive dearing-up procedure was started on 21 January 1958, many 
organizations were called in to assist, such as the N. V. KEMA, the Public Health 
Department, the Medical-Biological Laboratory of the State Defence Department 
TNO (the Dutch Organization for Applied Scientific Research) and the Royal Dutch 
Navy. 
The activities consisted of decontaminating the area, the house and the chimney -
which was demolished later - and removing the fire and the contaminated material. 
Also for psychological reasons, the clearing-up of the contaminated material was 
carried out as thoroughly as possible. 
On 10 February, 28 crates and drums of contaminated material, which had been 
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filled up and sealed with concrete, were transported to Den Helder on two lorries. 
From there, on II February, they were loaded onboard the cruiser HMS 'De Zeven 
Provincien' and dumped into the Atlantic Ocean at a depth of about 500 metres. 
On 14 February the house was declared fit for inhabitance by the Chief Inspector 
of Pharmaceuticals and on 26 February the family returned to their fully restored 
and largely refurnished home. 
A2.4 THE AFTERMATH 
This accident, with all the consequences, was a news topic in the Netherlands and 
abroad for some while. The events were covered very thoroughly in the newspapers. 
In editorial articles the question of blame was raised and the sense of the family's 
stay at the SAZU was a subject of discussion. 
Within a few weeks of the accident a 'medical committee', which had been 
appointed by the medical faculty of the University of Utrecht, came to the conclu-
sion that no mistakes had been made during the treatment. For this reason no 
disciplinary measures were taken against the doctors involved. Besides this, an 
investigation was also set up by the judicial authorities. It was the opinion of the 
senior officer at that time that there was no law under which the activities or possible 
acts of negligence could be brought (3). 
Undoubtedly, this incident and the negative publicity which the radium irradiation 
treattnent gained in this country, formed part of the reason for abandoning the 
Crowe therapy. 
And what happened to the little girl - the 'victim' of the accident? All went well. 
She got married and has two healthy children. 
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NAME 
sirname 
ADDRESS 
street 
APPENDIX 3 
THE DATA FORM 
THE DATA FORM 
10 number: _______ _ 
CLINIC 
christian name(s) 
no. place 
DATE OF BIRTH: _____ _ 
day month year 
REGISTER OF POPULATION 
MUNICIPALITY SENT RECEIVED NEW ADDRESS PATIENT 
1. _ 1_1_ _1_1 _ 
2. _ 1_1_ _1_1 _ 
3. _ 1_1_ _1_1 _ 
·-
I I _1_1_ 
---
GENERAL PRACTITIONER SENT RECEIVED NEW ADDRESS PATIENT 
1. 
_ 1_1_ _1_1 _ 
name 
address 
2 .• ______ _ 
_ 1_1_ _1_1 _ 
name 
address 
QUESTIONNAIRE SENT RECEIVED 
1. I I _1_1_ 
---
TELEPHONE 2. _1_1 _ _ 1_1_ 
MEDICAL DATA SENT 1 TELEPHONE/ RECEIVED 
SENT 2 
I I _1_1 _ _ 1_1_ 
---'-------
2. _____ _ 
_ l_j_ _1_1 _ _ 1_1 _ 
3. _____ _ 
_ 1_1_ _ 1_1 _ _1_1 _ 
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;e; 
10 
SEX 
I. male 
2. female 
9. unknown 
DATE OF BIRTH 
§] 
AGE 
INSURANCE 
1. national health 
2. private 
9. unknown 
CLINIC 
DATE 1st CONSULT 
DIAGNDSI S/ !NO !CATIONS 
1. glue ears 
2. recurrent otitis 
3. other tubal dysfunction 
4. A + T 
5. sinusitis (i.d.) 
6. perceptive hearing loss 
8. other {please specify) 
9. unknown 
PUNCH CARDS Ill PUNCH CARDS Ill 
day month year 
age in year 
day month year 
RADIUM TREATNEtH 
1. yes 
2. no 
9. unknown 
1st TREATMENT DATE 
day month year· 
minutes 
2nd TREATNENT DATE 
day month year 
minutes 
3rd TREATNEUT DATE 
day month year 
minutes 
4th TREATMENT DATE 
day month year 
minutes 
5th TREATMENT DATE 
day month year 
minutes 
OTHER RADIW~ TREATNEfHS WHICH DO NOT FIT Hl 
THIS DIAGRAM: 
--------
APPENDIX 4 
WORK METHOD FOR THE COMPILATION OF A 
CONTROL GROUP, CLINIC 2 
It is the object to choose the control group in such a way that it matches the 
irradiated group as far as possible. Both groups should have the following 
characteristics in common: I) size, 2) man:woman ratio, 3) age distribution, 4) time 
of f"rrst consultation. 
It is permitted, on statistical grounds, to bundle the latter two characteristics in five-
year groups. 
The accompanying table of the irradiated group contains 47 figures. Each figure 
represents the size of a subgroup that must be selected from the records and placed 
into the corresponding envelope. 
Here is a step by step account of the procedure: 
I) The same records must be used as for the selection of the irradiated persons, i.e. 
52 index boxes A to Z mixed Sick Fund/Private patients. 
2) All the index boxes must be given a number I to 52, starting with A. 
3) The index boxes must be worked through according to the accompanying list of 
random numbers, i.e. first index box ll, followed by 48, 40, etc,. 
If all 52 boxes have been gone through and the control group still is not full, start 
again at box I L 
4) In order to obtain 326 control persons, 6 cards must be taken from 38 boxes and 
7 from 14 boxes. 
5) A card must be taken from each box, about 5 em from the front. Check to see 
whether the sex, year of birth (5 years) and the date of f"rrst consultation fit one 
of the envelopes, if they do, put the card inside and write the score on t.l:te 
envelope. 
6) If the card does not fit into any of the envelopes because it does not match .or 
the envelope is full, take the card immediately next to it instead. 
7) If the card does fit into an envelope, the next control subject must be selected 
I em farther back. (This is to prevent selections with the same surname). 
8) In the beginning, finding suitable records will be quick and easy, but later on it 
will become more and more diff:cult. 
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List of random numbers, between 1 and 52 
ll 48 40 31 33 44 52 43 02 04 47 21 13 09 45 50 35 29 
36 37 05 14 06 46 17 16 20 39 51 19 23 30 07 01 12 24 
22 27 34 28 38 42 25 08 10 49 26 32 15 41 03 18 
Table A4.1 Number of exposed subjects according to year of first contact. age and sex. Clinic 2 
Birth year Year of first contact 
<1945 1945-49 1950-54 !955-59 1960-64 1965 
M F M F M F M F M F M F 
1910-29 7 6 2 
1930-34 5 2 2 3 
1935-39 10 3 3 3 
1940-44 22 25 5 7 3 2 4 
1945-49 12 8 34 23 9 4 I 2 
!950-54 3 7 17 19 13 8 I 
1955-59 2 5 21 10 3 
1960-64 2 
65 
Total 56 44 47 41 33 30 44 21 8 2 
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APPENDIXS 
SEARCH FORM, FOR THE REGISTRY OF BIRTHS 
DEATHS AND MAR.R.IAGES 
Chief Inspector 
Registry of Births, Deaths and Marriages 
(of a particular municipality) 
Dear Sir or Madam, 
I would like to draw your attention to the following. 
In the 1940s to 60s children with ear disorders were often treated using radium. This 
treatment consisted of the insertion of a radium needle into the nasopharynx. About 
25,000 children have been treated in this way and have thereby been exposed to 
irradiation. 
In cooperation with the Capacity Group Epidemiology of the State University in 
Maastricht (the Netherlands) and with a subsidy from the Queen Wilhelmina Fund 
(Dutch Organization for Cancer-Control), we are conducting an epidemiological 
study at our department, on the long-term effects of the treatment on the health of 
approximately 2,500 children who have been treated. 
In order to be able to carry out this study, it will be necessary for us to establish 
the present status of these persons (the study population), dead or alive, the present 
addresses and if any have died, the cause of death. For the latter we have obtained 
permission from the Chief Inspector of Public Health in Leidschendam. 
May we kindly request you to furnish us with the information mentioned above for 
the persons who lived in your municipality. Please would you tell us whether: 
a. the person is still alive in your municipality, 
b. the person has moved house, 
c. the person has died while living in your municipality. 
Would you also fill in the date when you complete the forms. We are enclosing 
forms on which you can record the details. 
If you have any questions concerning this study, please do not hesitate to contact 
me or my research assistant. We are reachable by telephone between 9.00 and 13.00 
on all week days. The number is: 04490-18666, ext. 2!84. 
Yours sincerely, 
P.G. Verduijn 
ENT Specialist 
Please send the completed forms to: 
P.G. Verduijn, ENT Specialist 
Ziekenbuis 'De Goddelijke Voorzienigheid' 
W alramstraat 23 
6!31 BK Sittard 
Enclosures 
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Search form for the registry of births, deaths and marriages 
SEARCH FORM FOR THE REGISTRY OF BIRTHS, DEATHS AND MARRIAGES 
Christian name(s), Sir name, 
date of birth and address at that time 
1. What has happened to this person? 
{Circle answer A, B or C and fill in the details) 
A. still alive in the municipality mentioned above 
present address (1f d1fferent from above): 
street no. 
B. moved to another municipality 
address 
street 
municipality:: ______________ _ 
country 
no. 
date of move: ______ date of completion of form: _____ _ 
-----------------~~r----~9~~~----r:~~-------------------------------~~Y----~~~:~ ____ y:~~---
A. still alive in the municipality mentioned above 
present address (1f d1fferent from above): 
street 
B. moved to another municipality 
address 
street 
municipality:: ______________ _ 
country 
no. 
no. 
~~~n: ______ d-ofc~lRiM~fu~=------
day month year day month year 
-------------------------------------------------------------------------------------------
C. deceased 
date of death: _____ _ 
day month year 
in municipality 
death certificate no.:: ____________ _ 
date of completion of form: _____ _ 
day month year 
146 
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February 1985 
Dear Sir or Madam, 
Via newspapers, magazines and television, you will most likely have 
become aware that some factors in our environment probably play 
a part in the development of various diseases. These factors can be 
present, for instance, in our living or working environment and 
cause sickness in the long-term. The notion exists that certain 
medical treatments, such as radiotherapy or the application of 
certain medicatons, can have this effect. 
As a doctor who has specialized in the field of ear, nose and throat 
diseases, I would like to study this phenomenon in people who have 
been treated in the past for diseases of these organs. 
I have enclosed a health-questionnaire form and stamped addressed 
envelope, as it appears that you were treated some years ago at the 
ENT clinic in one of the following hospitals: 
- 'De Goddelijke Voorzienigheid' Hospital in Sittard, 
- Wilhelmina Hospital in Assen 
- Carolus Hospital in 's-Hertogenbosch 
- Elisabeth's Hospice in Harlem 
- University Hospital in Groningen 
I would appreciate it very much if you could spare a half hour of 
your time to fill in the form as fully as possible and return it to us 
in the envelope. 
We arc not only interested in your general state of health, but also 
particularly in disorders which are concerned with fertility and the 
possible occurrence of tumours. We have also included a number 
of questions about the use of stimulants. In order for our study to 
be successful, it is very important that you answer all the questions. 
We can assure you that the information will be treated strictly 
confidentially and processed anonymously, 
If you have any questions regarding this letter or the form, please 
do not hesitate to phone me or my research assistant. Our telephone 
number is: 04490-18666, ext. 2184. 
Yours sincerely, 
P .G. Verduijn 
ENT Specialist 
Enclosures 
t~~ ZIEKENHUIS "DE GODDELIJKE VOORZIENIGHEIO'' Ald. Klini~che Epidemiologic Walramstraat 23, 6131 BK SITTARO. 
lebruari 1985 
leer geachte Heer, Mevrouw, 
Via de kranten, tijdschrilten en tele~isie .zal het u bekend .zijn, dat lactoren 
in on.ze omgeving een rol kunnen ~pelen bij de ontwikkeling van ~·er5chi!­
Jende ziekten, ~len denkt bijvoorbeeld aan lactoren in het woon- en 
werkmilieu, die l'aak over !angere termijn ziekten kunnen veroorzaken. 
Het ~·ermoeden bestaat, dat ook bepaalde medische bchandelingen zoals 
bestraling of toed1cning van bepaalde medidjnen dcze ellecten kunnen 
hebben. 
r\ls arts, gespecialiseerd op het gebied van keel, neus en oren wil ik 
dit onderzoeken bij mensen die jaren geleden behande!d werden voor 
ziekten var1 die organcn. 
lk stuur u bijgaand lormulier omdat u lange tijd geleden onder behandeling 
bent geweest op de KNO-aldeling van een 1·an de \Olgende vljf zieken-
huizen: Ziekenhuis "De Goddelijke Voorzienigheid'' te Sittard 
Wilhe!minazickenhuis te Assen 
- Caro!uSl.iekenh<Jis te 's-Hertogenbosch 
- Elisabeth's Gasthuis te Haarlem 
- Academisch Ziekenhuis te Groningen. 
lk zou graag een half uur van uw tijd wi!len vragen om het formulier 
zo na<Jwkeurig mog,eli)k in te 1u!Jen efl in bijge;·oegde em·etoppe aan 
ons te retourneren. 
Behahe naar de algemene gezondheid~toestand, gaat onze interesse 
vooral uit naar stoornissen betreflende l'ruchtbaarheid en mogelijk ontstaan 
van gezwellen. 00k zijn enkele Hagen gesteld over het gebruik van 
genotmiddden. Ongeacht uw huidige getondheidstoe~tand ]5 bet van 
groot be!ang I'O()f het slagen van dit ondcrtoek dat u de vragen beantwoordt. 
!k kan u verzekeren dat uw gegevem I'Crtrouwelijk zullen blij~en en 
anoniem zullen worden bewerkt. 
Als dit schrijl'en ol het lormulier nog vragen bij u oproepl kunt u mij 
of mijn research-assistent bellen onder tel. nr. 04490-18666 tst. 2184. 
Blj voorbaat dank ik u hartelijk \'OOr uw medewerking. 
~ 
P.G. Verduijn, KNO-arts. 
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HEALTil QUESTIOt/NAIRE 
1. First h'e would like some background information: 
Date of birth L__,_j u_j LLJ 
doy r;onth year 
Height L__,_j u_j 1-kight u_j 
m em kg 
2. Have you ever been admitted to hospital for more than one night 
(except with regard to childbirth)? Please mark the relevant box: 
b 
d 
e 
Yes or No with a X. 
If you have anwered yes, for what reason and when 
were you adml tted? 
Reason 
VES 
D 
Year 
NO 
D 
3. Have you ever had any of the following diseases or complaints? Please 
mark the relevant boxes with a X. 
diabetes ..•...•...•.. , ...•..•.•.•..........•. 
anaemia .............. , ..•... , • , . , ......• , , •.. 
thyroid disease •.•.....•..•.•......•..•.....• 
hearing disorder .... , , , ....•.......•.•..•..•. 
you wear a hearing aid ...................... . 
cataract .............•..••..•..............•. 
epilepsy .•...••...•...•....•.•....•..•.•..•.. 
pituitary disease 
hormonal disorder .•...•..•.•.......•.•..•.... 
depression ............•.•....•....•.•........ 
treatment by psychologist or psychiatrist ...• 
YES 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
NO 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
'
• ZIEKENHUIS 
lj.<--: ';1 "OE GODOEUJKE VOORZIENIGHEID'' 
04400·10066tst2t!M 
GEZONDHEIDSVRAGENUJST 
1. E~rst wlllen weenkele a~htergrond~e~evens ~an u ~ragan: 
Oebooneda.lum L..,_J 
"' 
Lengle Ll 
m 
'-"-' m~' 
'-"-' om 
'-"-' I= 
Oawlch1 '-"-' 
•• 
2. Bani u oolt Ianger dan Un nacht In een zlekenhuls Opgenomeo geweasl (l'i<lhalia voor een evenlue!e 
ba~alllngl? Zetdanau b.een~ruls]a r&)ln he lop u vanloepasslng zljnde hol<je: JAol NEE. 
JA NEE 
0 0 
Zo Ia. waarvooren wa.nneer? 
WU!VOO/": I Jw 
3. He aft ude volgende ZIEKTEN ol KLACHTEN gehad? Zat au.b. ean kruls(e C33 rn he I op u ~an toepasslng 
zljnde hokja. 
" 
NEE 
sull<erzlekte 0 0 
bloedarmoede 0 0 
$Chlldkl!erzlekle. 0 0 
gehoorsroomls 0 0 
drag~n ~an a en geh<Xlrapparaat 0 0 
oog!enslrO<lbellng (slaar) 0 0 
epllepsle (wil.llende liekle). 0 0 
zla~ra var. de h:rpof)'!a(twsenaanhangsar) 0 0 
hormonal<) sloornls 0 0 
depressleve stemming 0 0 
Nhandellng d<Xlr psycholoog ol ps~chlaler 0 0 
~ 
4, HilS a tumour (benign or malignant), swelling, cancer or growth ever 
been diagnosed in or on your: (please mark the relevent box(es) 
YES HO 
~''············································· 0 0 
thyr·:id gland . , , ................. , , , .... . . ... . . .. 0 0 
pituitary gland.................................. 0 0 
salivary glands.................................. 0 0 
breast(s) ........................................ 0 0 
leukaemia . .... . . . . .... . . . . . ... . . . ... . . .. . . . .... . . 0 0 
Jp1ph glands..................................... 0 0 
oesophagiJs . . . • . . . . . • . . . . . . . . . . . . . . • . . . . . . . . . . • . . . 0 0 
Jip(s) ........................................... 0 0 
in your r:outh .... .. ...... .. ..... .. ........... .... 0 0 
nose........................... . ........ rJ rJ 
·thro~t .......••......••.............•....•....... 0 0 
other vrgaus , , , , , , , , , , . , ... , , , , • , , , , , , , , ..... , , , , 0 0 
If so, ple_tse specify the organ(s) ...................................... . 
......................................................................... 
5, Have you Ever had t1 ssue re-Mved for d biopsy? 
If w, fr-Y'I which organ and when was that? 
YES 
0 •• 0 
r~=~···································F················· ' ' . . . . . . . . . . . . . . . . . . . ' ' ' . . . . . . . . . . . . . . ' . . . . . . . . . . . . . . . . . . . . . . . ' . . . . . . . 
'······································································ 
6. Have you ever used any of the following r1edtcat1ons? 
Y[S .NO 
tablets for diabetes .............................. 0 0 
tnsulinl! ,,,,,,,, ......•......••............•....•• 0 D 
tablets for high blood pressure ................... 0 0 
horr--ones ......... , ...... , .. , ..... , , .... , , ..... , .. • 0 0 
thyroid n~:dlcatlon,, ..... , , , ..... , , , ..... , , ... , ... 0 0 
diuretics , , , , .. , , , , , ......... , .... , , ............. 0 0 
4. ts blj u ooll een tumor (~oedaatdl~ of ~waadMtdi~). gezwol, ~an~er ot groet~el ~UI~Uield vao de: {ook 
weer een ki'Jis!e 0 zetlen tnl>et l>o~Je~an YW ke-vze) 
huld 
schlldHier 
hypolyse (herse~aanhangsel) 
spee~selklleren 
borsl(en) 
bloe<J~an~er(lev~emle) 
(tymle)klleren 
stokd3rm 
'" In de mond 
neus 
'*' andere organen 
I 
Zo ja, ... etke? 
$_ Is er btl u ooit weelsel weqqenomen 'oor onder:zoe~? (blopsle) 
Zo ja, van we•k orgaa.n ol pie~ en wanMer? 
org3anolplek 
6 Heel\ v ooil de •·olgendemeditljnen geblvtkl? 
tablet len '00' su•Hrzlekre 
tnsullne 
tablellen tegen hoge bloeddru~ 
hormone~ 
sehlld~lierpreparaten 
ptasprrren 
JA NEE 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
JA NEE 
0 0 
JA NEE 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
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10. t\re you !"Mried or have you been l"arried? 
How !"any live babies did you have HI total? 
YES 
0 
HO 
0 
(not including adopted children) nu":Jber __ 
Hlve you been troubled with involuntary 
Infertility? (you could not have children) 
\1, ONLY fOR WOMEH 
YES 
0 
NO 
0 
The following questions concern your nenstruation and (posslbl~) 
pregnancies. Please l"lMk the relevent bo;.:;. 
a. Have vn•J ('Vi'!l' fC,enstruated? YES 
0 
HO 
0 
If so, l1ow old were you •·hen It first stdrted? years old 
b. Waslls your ren~truatlon regular 
c. llwe you e~er had a n!sCMrlage? 
irregular 
IES 
0 
HO 
0 
If so, ho<~ often hove you had a niscarr!age? __ tir.es 
d. Ha~e ycu reached the '"eropauze? YES 0 
NO 0 
not appl icat:de 0 
If so, how old were )'O~ •.hen !t occurred? __ years old 
Please will you return till; ~<or:oleted questionnaire to us in the sto'1ped 
addressed envelope (enclosed;. 
We tha~k you very much f{lf your cooperation! 
10. B~nlii<J~hu~dof gehu~d g~neesl? 
Hog,eetre,end geb-oren ~lnde1en krce{l uln totaat? 
(geadopleerde kiMeren n1et meege1ekend) 
Is er blj 11 spra~e 1 an on.rij...-ill!g~ on• r~chtbaarheld? 
(9~en klnderen kunMn kri)\len) 
11. ALLEEN VOOR VROUWEN 
aanlal __ 
JA tWO 
0 0 
JA NEE 
0 0 
Hler ;·otgen en~ere wag en O;eruw menslruotie en e,~ntuele z...-angerschappen Zet 11 a 11 b. een kruisje 
~ bl)heljuisteanh•oord 
a HeeJtuooilgervenslrueerd? JA tiEE 
0 0 
Zo )a, llo~oudwas u toen u d~ eerste rrenstrualle ~ree9? )aar O•Jd 
b Hoe isl...-as11w menstruat-e? regelmati9 0 
n'ot regelrvatlg 0 
c. Heeft 11 ooit Hn ol mHr mis'ra'l1en gehad? 
" 
NEE 
0 0 
Zo )a. !'to~'"'~ had u een miS'raam? aM tat 
d Heel! u de fl'tr.opaJze at bere,f.t? JA 0 
/lEE C 
n.et•antoepass<ng l i 
Zo ja. hoe oud ... as 11 to~n? j:l..liO.Jd 
Woll u dgze >~agenl.rst teruqzer.den rn bljge<eegda anlhOOrden.etopp~? 
Oil ~a~ zonder poslleget 
W•J d!nken u hortehtk >001 uw medewer~lngl 

-v. 
w 
January 1986 
Dear Sir or tvtadam, 
AI the begining of last yem I sent you a heHith questionnaire. May 
I take this opportunity to thank you for returning the completed 
form to me. 
I would like to ask you for your coopemtion once again. This time 
just for a few minutes. In your answer to question 2 you mentioned 
that you had been admitted to hospital for a certain disorder. I have 
enclosed a copy of the question. The answer I am referring to has 
been underlined in red. This piece of information may be of great 
importance to my study. In order to establish the exact nature of 
the disorder, I would appreciate it very much if you could answer 
the following questions. 
I. To which hospital were you admitted for the di~ordcr? 
2. In which year did this admission take place? 
3. What was the name of the specialist who treated you? 
4. Would you have any objections to our approaching this 
specialist for the purpose of gaining further information 
concerning the diagnosis? 
As was also the case with the first form, your answers will be 
treated with the strictest of confidence and processed anonymously. 
Plense will you return the completed form to me. A sl<lmped 
addressed envelope has been enclosed. 
If you have any questions regarding this letter or the form, please 
do not hesitate to phone me or my research assistant. Our telephone 
number is: 04490-18666, ext. 2184. 
Yours sincerely, 
P.O. Verduijn 
ENT specialist 
Enclosures 
""' ~f~ 
ZIEKE.NHUl5 "DE GODDEUJKE VOOIUIENIGIIEID'' 
Ald. Klin1sche Epidemiolo;;ie 
Wa!ramstrHt 1), f,J)I IlK SITTARD. 
leer gNchte Heer, ~vrou..-, januarl 1986 
Begin vong jaar zond lk U een gezor.dt'.e~>Jsvr.J9enlijst. OIJ deze wll Jk u harte-
lljk danken dJt lk deze lijSt ln•;evuld van U rocht terugontvang~n. 
Graaq zou lk nog,qaJs 1}..- ~"edeoHklng wlllen vrag~n. OJtroJ.al slechts en~ele minu-
ten. Het gBt IY'I het volgen·Je. 
U heeft blj vraaq 2 opgegeven dat U 1n een zlekenhui s opgeno"en t"nt ge~eest 
Y•}Or een tePHlde zlekte of .H~·loening. fen cople van die vraag Js tiijge;·oegd. 
~t gnt 0"1 llet r~t rood onderstreepte ant><•}Ord. Ott gegeven kan van belong zljn 
\OOr nijn onderzoek. 1);1 de preoese aard van •Je aJ.nJo<nln·) te kunn~n achterha\en 
w!l I~ U grBg de \Olg~r.de vr->gen stellen. 
1. In ><elk ziekenh•jJS ~·erd U 1100r ~doelde Hrdoenin•J opgenO"'~n? 
........................... 
2. In ~o<elk j~M gebeurde dat? .. 
3. fl.;e heette de behandelend spe(!allst? 
~. Vlndt u het goed d~t lk deze spcoallst o-1 
nadere Jnllchtingen ove,r de diagn~s\'! vra,J•J' ..................... . 
OJ~ voor deztJ gegevens bllj(t gelden dat ze ;·ertrou·,.;elljk t>)]]en worden ~han­
deld en ononle"' worden be•er~t. 
Zoudt U, na beant..,oordlng van de vrJgen, ·llles In bijgevOe•)•1e anlliOOrdenveloppe 
aan nlj Willen terugsturen? 
Voor eventuele vragen kunt U nij t~llen onder telefoonnr. 0~490-16666 tst. 21fl4. 
8ij 1·oarbJH dan\ lk U hutelijk voor U• r-e·~~;,erUn9. 
Huo~a(htend, 
.,, ~~,:. 
, _..,vv~~- v 
I _.----
Ktii}-Jrts P.G. Verduljn, 
--I'd~ ~0 ~e 
'"'tri o[ff] 
el-l [ffJ 
r"""i> ~o"'d G":l~"'d 
'"'<tri ~MZ tri~t:l z ..... 
'-' ~ 
I'd'""-..~ tri~ ~::J 
.... o [ff]z [ffJ 
'"'o 0""1 z 
~ 
"' .. 
January 1986 
Dear Sir or Madam, 
At the begining of last year I sent you a health questionnaire. May 
I take this opportunity to thank you for returning the completed 
form to me. 
I would like to ask you for your cooperation once again. This time 
just for a few minutes. 
In your answer to question 4 you mentioned that a tumour had 
been found. I have enclosed a copy of the question. The answer I 
am referring to has been underlined in red. This piece of informa-
tion may be of great importance to my study. In order to establish 
the exact nature of the disorder, I would appreciate it very much 
if you could answer the following questions. 
I. To which hospital were you admitted for the disorder? 
2. In which year did this admission take place? 
3. What was the name of the specialist who treated you? 
4. Would you have any objections to our approaching this 
specialist for the purpose of gaining further information concer-
ning the diagnosis? 
As was also the case with the first form, your answers will be 
treated with the strictest of confidence and processed anonymously. 
Please will you return the completed form to me. A stamped 
addressed envelope has been enclosed. 
If you have any questions regarding this letter or the form, please 
do not hesitate to phone me or my research assistant. Our telephone 
number is: 04490-18666, ext. 2184. 
Yours sincerely, 
P .G. Verduijn 
ENT specialist 
Enclosures 
,. ZIEKENHUlS "DE GODDELIJKE VOORZJENIGHEIO~ A!d. Klinische Epidemiologie 
WalramHraac 2J, 6JJI BK SITTARO. 
Zeer geachte K<~er, f.'.e~rou11, Januart 1966 
Begin vorlg jaar zontl tk U een gezondlletdsvragenlljst. BIJ deze w\1 lk U harte-
IIJk dan~en dH \k deze lljst lngeould van U ~'<lcht terugontvangen. 
Graag zou lk nogmaals Uw ~e~de~erklng wlllen vragen. Oltm~al s\echts enkele nlnu-
ten. l'.et gaat OPl het volgende, 
u heeft blJ vraag 4 opgege••en dat blj U oolt een t~~.or of gen•el Is vastgesteld. 
fen cop\e van dle vraag Is bljgeo·oegd. H<:!t gBt o" het ~et rood onderstreepte 
antwoord. Dlt gegeven kan va'n belang z!jn voor m!jn onderzoek. 01 de prec!'eze 
aard van de tuC",Qr te ~unnen achterhalen wll lk U graag de 'IOlgende vragen stet-
len. 
!, In wei~ zle~enh,JIS 11erd de twror vastgesteld? .............................. . 
2. In li€lk jaar gebeur·de dat~ ................................................ .. 
·3. floe heette de b<.>handelend spec13llst? ..................................... .. 
4. ~!ndt u het goed dat \k deze specialist om 
nadere tntlchtlngen o>er de diagnose ¥raag? ................................ . 
Oo~ ~toor deze gegevens blijft ge\den dat ze "ertrou·.ei\Jk zullen norden behan-
deld en anonie'll liOrden te"'erkt. 
Zcudt u deze brief na teant\ioord!ng ~an de vragen In b!jge~oegde envi!loppe aan 
'lllj willen retourneren. 
'/oor eo·entuele vragen kunt U miJ teilen on\!er telefoonnr. 04490-!8666 tst. 218~. 
Blj ,.·oorbHt d'lnk !k U hartelljk voor u·~ rede·.erklng. 
Hcogachtend, 
P.G. Verdu!jn v•" :QruvJ~i 
------
~ 
v. 
v. 
January 1986 
Dear Sir or Madam, 
At the begining of last year I sent you a health questionnaire. May 
I take this opportunity to thank you for returning the completed 
form to me. 
I would like to ask you for your cooperation once again. This time 
just for a few minutes. 
In your answer to question 5 you mentioned that some tissue had 
been removed for examination. I have enclosed a copy of the ques-
tion. The answer I am referring to has been underlined in red. This 
piece of information may be of great importance to my study. In 
order to establish the exact nature of the tissue, I would appreciate 
it very much if you could answer the following questions. 
l. To which hospital were you admitted for the disorder? 
2. In which year did this admission take place? 
3. What was the name of the specialist who treated you? 
4. Would you have any objections to our approaching this 
specialist for the purpose of gaining further information concer-
ning the diagnosis? 
As was also the case with the first form, your answers will be 
treated with the strictest of confidence and processed anonymously. 
Please will you return the completed form to me. A stamped 
addressed envelope has been enclosed. 
If you have any questions regarding this letter or the form, please 
do not hesitate to phone me or my research assistant. Our telephone 
number is: 04490-18666, ext. 2184. 
Yours sincerely, 
P.O. Verduijn 
ENT specialist 
Enclosures 
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ZlEKENiiUlS "DE GOOOEUJKE VOORZlEN/GH€10'' 
AJ<J, Klinische Epidemiologie 
Walr~mHra~t 2), 6Jll 8K SlTTARO. 
leer <;eJcht<i! Heer, P€Hou·~, j~nuarl 1986 
Segln ·•orlg jaar wno.1 ik U een gelondh(lds~ragenlijst, BIJ deze wil lk u Mrte-
llJk dan<;en dat lk deze JljSt lng~vuld 1'~11 U 010cht terugontvangen. 
Graag zou .tk M'J'l'Bls 1.1'>1 ~de>~erklng II[!Jen vragen. Citraal slechts en~ele mlnu-
ten. Het 9Ht (>:1 het ~·otgende. 
U heeft biJ vrao9 5 opgegeven dat blj u ooit ~<eefSeJ Is .... eggenOI"ien ~"oor onder· 
zoe~. ten cople ~an die vraag B bijgevoegd. Het gaH om het l"·et rood onder-
streepte antwoord. Oit gegeven kan V·lfl t>elang zljn voor m!Jn onderzoe~. 01 de 
preciese aard van r.et w~efsel te ~·Jnno·n achterhalen wil lk U graag de volgen~e 
Hagen stellen. 
I. In w~lk zlekenhut; ~·erd Mt w~afsel lleggeno,..en? 
2. In ~·elk jaM gebeurde dat? 
3. Hce ~eette <!e beMMelend speCldlist'/ 
4. Vlndt u het goe<:l dH Jk deze specialist on 
nadere lnllchttnsen o~er de diagnose vrdag 
............................ 
Oo~ voor de~e gegevens bliJft geldeo dat ze ~·eruouwelljk ZIJI!en worden Jxohan-
deld en anonieot worden be~erkt. 
loudt u. na t-e;ntwoQfdlng van de vragen, alles In bljge1·oegde antwoorden~eloppe 
dan nlj lo'lllen terugsturen? 
Voor eventuele Hagen kunt U njj Jxollen onder telefoonnr. 04490-18666 tst. 2184. 
Bij voorbHt dank Jk u ~artelljk voor U·~ medewerklng. 
Koogachtend, (- \ 1_ I ~ 
.V'£'-~':'-'1.~ 
<c.- • '\ .-- { 
P.G. Vuduljn, KNO-arts 

-v. 
._, 
Dear Colleague, 
For the last few years I have been conducting a study on the rela-
tionship between irradiation and the origination of tumours. 
The treatment I am interested in concerns the irradiation of the 
nasopharynx of people with otitis serosa, using radium. This 
therapy was applied very frequently by ENT specialists and 
radiologists in the 1950s and 60s. 
Recently, tumour induction has been suggested by several authors 
but never demonstrated convincingly, 
The study involves approximately 2,500 persons who have been 
treated in the past and a control group of comparable size. It is 
being conducted in cooperation with the Institute of Social Health 
of the Erasmus University in Rotterdam (Prof.Dr. P.J. van der 
Maas and Dr.Ir. J.D.F. Habbema). In a survey held at the begin-
ning of last year among the 5000 study persons, it appeared that 
many of the respondents had either suffered from a tumour or had 
been subjected to an operation indicative of such a disorder. 
Would it be possible for you to spare some time to help with the 
collection of study data, by verifying the diagnoses given by the 
respondents. In the accompanying letter, which also contains the 
subjects' permission, a space has been reserved for your 
pathological diagnosis. A stamped addressed envelope has been 
enclosed. It is possible that the married women have been filed 
under their maiden names. 
Unfortunately, it is not possible for me to offer you any payment 
for your time, but your cooperation would be greatly appreciated. 
When the study has been completed, 1 will be pleased to send you 
a summary of the results. 
Yours sincerely, 
P.G. Verduijn 
ENT specialist 
Enclosures 
f~ ZIEKENBUI.S ~oE GODDELIJKE VOORZIENIGHEID" Ald. Kl!nl$Che Epldemiologie Walramstraat 23, 6131 BK SITTARD. 
leer geachte col\ega, 
lk OOn reeds enlge jaren bezlg met een onderzoek naar de re\atle tussen 
t:>asttallng met radium en het ontstaan van tumoren, 
Het gaat om l>estrallng met radium In de neus-keelholte ter behandellng 
van otitis serosa. [)aze theraple WtJrd in de jaren vljftlg en zestlg a\-
gemeen toegepast door KOO-arts en radloloog, 
Twnorinductie werd recent door verschlllende auteurs gesuggei'!!erd fi'Hr 
noolt overtulgend aangetoond, 
Slj het onderz""k lijn plm. 2500 destljds behandelde personen en een 
even groot aantat controles ~etrokken. Hat onderzoek. geschle<lt onder 
meer In sa;r.-em;erklng met het lnstltuut H.aatsch6ppelljke Gezondheldszorg 
van de Eras.mos Untverslteit te Rotterdam (Prof.Dr. P.J. van der K!as en 
or, Jr. J,O,f, Habl>erna). , 
SIJ een begin vorlg jaar gehouden enquete onder de genoemde 5000 perso-
nen werd door vele respondenten opgegeven oolt aan een gezwelzlekte te 
hebl>en ge\eden of een operatle te hebben ondergaan die op een def'?ellj-
ke zlekte kan wljzen. 
Hlerbij wit \k Uw medewerklng vragen bij het verlfliiren van de opgege-
ven diagnose. Op bljgaande brief, waarop ook de toesterming van de pa-
ttent Is vermeld, Is een ged~lte gereserveerd voor uw PA·dlagnose. 
H<!la~s Is llet nlet mogel\jk U voor deze lnspannlng te honoreren. U zult 
het moeten doen f'let m\jn dank, Wel zal lk U te ztjner tljd het re· 
sultaat van mljn onderzoek toesturen. 
l"et col\~glale hoogachtlng.l-. 
' 
PS: b\jgaand een gefr4nkeerde retourenvelop. 
PPS: de gegevens vJn gehuwde vrouwen z\jn mogel\jk onder hun melsjes-
naam In IN archief te vinden. 
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APPENDIX 9 
DOSIMETRY* 
A9.1 THE RADRJM APPLICATOR 
The radium applicator constructed by Crowe and Burnam, which was to become the 
most popular design with other users, consisted of a cylinder of 21.5 mm length and 
an external diameter of 2.3 mm. The thickness of the wall, made of nickel alloy (Ni 
63"7o, Cu 28-34"7o, Fe 2.5"7o max., Mn 2"7o max. and Si 0.5"7o max.), was 0.3 mm. 
The cylinder was f'llled with radium sulphate. (Figure A9.1). 
Figure A9.1 Radium applicator which was used at Clinic 2. On the right: the cylinder filled with radium 
sulphate. On the left: the handle. 
Radium226 has a half live of 1600 years. In the disintegration to the stable end 
product, Pb206, a spectrum of alpha, beta and gamma radiation is emitted. 
The nickel alloy cylinder absorbs all the alpha particles and allows all the gamma 
radiation to escape without absorbtion. The low energy beta particles (up to 0.74 
Mev) are also absorbed by the nickel alloy, but the higher energy particles (0. 74-3.17 
Mev emitted by RaC) pass through. The maximum depth of penetration in water and 
soft tissue is 13 mm. At a distance of more than !3 mm from the needle, at which 
distance the parotis, thyroid and pituitary gland are situated, it is only necessary to 
take the gamma radiation dose into consideration. Moreover, the fact that only 
gamma radiation plays a part, means that the influence ofinhomogenity will be small, 
thus, bone and air cavities will not lead to serious changes in the dose distribution. 
Platinum absorbs considerably more beta radiation and also reduces the gamma 
radiation to some extent. Therefore, a correction factor had to be employed in the 
calculation. In Table A9.1 the applicators used and data concerning the duration 
of radiation treatment and interval are shown per clinic. 
*This part of the study was executed under the supervision of A. G. Visser. PhD, radiophysicist of the 
Rotterdam Radiotherapeutic Institute. 
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Figure A9.2 Antero-posterior skull X-ray with calibrated placebo 
applicator in situ (f, 4.75 yr). 
Figure A9.3 Lateral skull X-ray with calibrated placebo applicator in 
situ (m, 5.1 yr). 
Table A9.l Radium applicators and radiotherapy data, per clinic 
Clinic Applicator Radiotherapy data 
radium (mg) wall (mm) duration (min)* N sessions interval 
25 nickel alloy 0.3 28-60 4 1 week 
2 50 nickel alloy 0.3 36-72 3 2-4 wks 
3 25 nickel alloy 0.3 40-80 4 1 week 
4 10 Pt 0.1 60-240 !-4 to 1 yr 
5 25 nickel alloy 0.1 26-52 3 1-2 wks 
"' Total exposure time dependent on age 
A9.2 DOSE CALCULATION PROCEDURE 
Antero-posterior and lateral skull X-ray mms were taken of 25 children, 12 girls and 
13 boys, with a calibrated placebo applicator in situ (see Figures A9.2 and A9.3). 
The magnification factor was calculated on seven lateral mms. In Figure A9.4 this 
is set out against the age of the child. It appeared that the same magnification factor 
could be applied to the lateral films for the whole age range. A magnification factor 
of Ll was chosen. The actual magnification factors lay within 2"7o of this figure, 
which was negligible as far as the dose calculatons were concerned. 
The dose distribution was calculated for the applicator used at clinic I. Keeping in 
mind the magnification factor for the lateral films, a dose distribution was obtained 
which was valid in the medial sagittal plane (see Figure A9.5). The dose distribution 
calculated for the applicators at clinic l, was also valid for the applicators used at 
clinics 2,3 and 5, on the understanding that the doses found for clinic 2 were 
multiplied by two. For clinic 4 the dose should be divided by a factor 2.7 (10 mg 
Ra; Pt cylinder). 
The dose rate for the pituitary and thyroid gland were calculated using this dose 
distribution. This was not directly possible for the parotis because it is not situated 
on the medial line. The total distance between the centre of the needle and the 
parotis was determined with the aid of Pyrhagorus' Theorem, from the distance 
between the medial line (on the film) and the distance of the parotis from the medial 
sagittal plane (3.8 em). 
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Figure A9.4 Magnification factor of lateral X-ray films, per age. 
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Figure A9.5 Dose distribution 24.77 mg radium sulphate in 0.3 mm Monel applicator. Isodose curves 
are given in cGy/h. A transparent of this dose distribution on a scale of 1.1 : 1 was used to calculate 
organ doses. 
The sella turcica, which was easily visible on all the lateral films, was used as the 
measurement point for the pituitary gland. The position of the thyroid gland was 
established via a point in the middle of the tracheal shadow, at the level of the fifth 
cervical vertebra. It was determined that the parotis gland lay on the dorsal side of 
the ramus mandibulae, close to the angulus mandibulae. 
A9.3 RESULTS 
In Figure A9.6 the dose rates in cGy/h at the pituitary gland, parotis and thyroid 
gland are set out for the 25 mg radium applicator for the various age groups. The 
curve drawn through the points on the graph, shows the dose rate as a function of 
age. By applying the duration of radiation, which varied per clinic and per age 
category, the dose received by the organs in the head -and neck region could be 
calculated. 
The dose received by the tissues in direct contact with the applicator could also be 
calculated using these data, given the dose rate on the surface of the applicator (for 
25 mg 160 cGy/min (1)) (see Table A9.2). 
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Figure A9.6 Dose rate (cGy/h) for some head and neck organs, per age, for 24.77 mg radium sulphate 
in 0.3 mm Monel applicator. 
* thyroid. ~ parotid gland, 0 pituitary gland. 
Table A9.2 Dose received (cGy) depending on age, per 
organ and per clinic 
Clinic Thyroid Parotid Pituitary Tissue 
gland gland gland contact 
2-3 6- 8 12-14 4480- 96{)0 
2 5-7 14-19 29-36 11520-23040 
3 3-4 8-11 16-20 6400-12800 
4 2-3 4-13 ll.-18 3555-14222 
5 2-3 5- 7 10-13 4160- 8320 
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TilE OATA- JHPUT FORH 
ANSWERS TO llEALTH QUESTIONNAIRE 
Coding 
Uflless il different coding is specified, the following codes Me Villid: 
y = yes 
n = no 
Oo not fill ilnything in If it appears fro'1J the context that il -question did 
not need to be ilnswered because it was not applicable, or was not filled in. 
l~mstlonnaire li:>. 
Piltient ID 
1. BACKGROUND INFORMATION (QJestlon 1) 
1.1 Date of birth (day/month/year) 
1.2 Height inc<~ 
1.3 Weight in kg 
2 DISEASES AND/OR COOPLAINTS (QJestlon 3) 
Beginning of record 
D1UJ_U_Uo6 
o7U_U_l1o 
11U_i_U_UHi 
17(_1_l_)19 
2DU_U22 
2.01 Diabetes 23(_) 
2.02 Maemia 24(_) 
2.03 Thyroid disease 25(_) 
2.04 Hearing disorder 26( ) 
2.04.1 If so, does the person wear a hearing ilid? 27(_) 
2.05 Catilract 28(_) 
2.06 Epilepsy 29(_) 
2.07 Pituitary disease 30(_) 
2.08 Hornonal disorder 31 (_) 
2.09 Depression 32(_) 
2.10 Treatnent by psychologist or psychiatrist 33(_) 
3. TUMOURS (QJesttons 2,4 and 5) 
3.1 Do the answers to questions 2, 4 and 5 
Indicate the existence of one or more 
benign or malignant tumours? 
If so, specify a maximum of 3 tumours: 
3.1.1. What Is the code with regard to the 
organ or location of the tu11our? 
(See the coding list) 
3.1.2. Was the tumour 
benign I malignant? 
1 = deflnl tely benign 
2 = probably benign 
3 = possibly benign, possibly malignant 
4 = probably malignant 
5 "definitely nalignant 
6 =unknown, no judgement possible 
3.2.1. What Is the code with regard to the 
organ or location of the tu'llour? 
3.2.2. Was tile tu:wur 
benign I malignant? 
3.3.1. hhat is the code with regard to the 
organ or location of the tumour? 
3.3.2. Was the tumour 
benign I malignant? 
4. USE OF MEDICATION (Q.lestion 6) 
4.1 Ti!blets for diabetes 
4.2 lnsuline 
4.3 Tablets for high blood pressure 
4.4 fk.mnones 
4.5 Thyroid medication 
4.6 Diuretics 
341_1 
35{_1_)36 
371_1 
3B( j )39 
401_1 
41(_U42 
431_1 
441_1 
451_1 
461_1 
471_1 
401_1 
491_1 
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5 EXPOSURE TO IRRADIATION (Question 7) 
5. 1 No. of X-rays for 
5.1.1 Btoken bone(s) 
5. 1.2 Fitting shoes 
5.1.3 Breast screening 
5.1.4 Dental examination 
5.1.5 Screening for TB 
5.2 Exposure to other irradiation? 
n =no I =yes, with cobalt 
2 =yes, with rOntgen 3 =yes, with radium 
4 =yes, with various 5 =yes, unknown 
6. OCCUPATION RISK (Question 8) 
From the occupations listed, the one involving 
the greatest t'isk should be coded, see the 
coding list. 
6.1 Exposure to irradiation 
I = none/negllgable 
2 =a little 
3 = a great deal 
6.2 Contact with carcinogenic substances 
1 = none/neg! !gable 
2 =a little 
3 = a great deal 
7. USE OF STIMULANTS (Question 9) 
7.1 D:Jes the respondent drink alcohol? 
If so, how many glasses -on average- per week 
of 
7.1.1 Beer 
7.1.2 Wine, sherry, port etc. 
7.1.3 Gin, cognac, liqueur etc. 
50(_) 
51(_) 
52(_) 
53(_) 
54(_) 
55(_) 
56(_) 
57(_) 
58(_) 
59(_1_)00 
61(_1_)62 
63(_1_)64 
7.2 Has the respondent ever smoked? 
7.2.1 If so, at what age did he/she start? 
7.2.2 !Xles the respondent still smoke? 
7.2.2.1 If not, at what age did he/she stop? 
7.2.3 How many did/does the respondent smoke? 
65(_) 
66(_1_)67 
68(_) 
69(_1_)70 
7.2.3.1 Number of cigarettes per day (rolling tobacco) 71{_1_)72 
7.2.3.2 Number of pipes per day 
7 .2.3.3 Number of cigars per day 
8. MARRIAGE AND/OR CIIILDREN (Question 10) 
8.1 Is the respondent married or has he/she 
been married? 
73(_1_)74 
75(_1_)76 
77(_) 
8.2 How many live babies did the respondent have? 
(Not including adopted children,> 9 children = 9) 78(_) 
8.3 Has the respondent been troubled with Involuntary 
infertility (could not have any children)? 79( ) 
9 ONLY FOR WOMEN (Vraag 11) 
9.1 Has the respondent ever menstruated? 
9.1.1 If so, how old was she when it started? 
9.1.2 Is/was the menstruation regular? 
9.2 Has the respondent had one or more miscarriages 
and If so, how many? 
n = no, f lgure = yes, and the number 
(figure 9 = 9 or more) 
9.3 Has the respondent reached the menopause? 
9.3.1 If so, at Hhat age? 
80(_) 
81(_1_)82 
83(_) 
84(_) 
85(_). 
86(_1_)87 
End of record 
APPENDIX 11 
EXAMPLES OF CODING ACCORDING TO 
LOCATION AND NATURE FOR ANSWERS TO 
QUESTIONS 2, 4, AND 5 OF THE HEALTH SURVEY 
Answers Code 
Respondent's description Question No. Location Nature 
Lump on hand, benign 4 32 2 
Uterus 4 26 6 
Birth mark, since birth 4 17 2 
Lymph nodes, according to stomatologist benign 4 14 2 
Breasts 4 21 6 
Fallopian tube and ovary 4 27 6 
Skin 4 17 6 
Thyroid gland 4 02 6 
Nose 4 09 6 
Salivary glands 4 05 6 
Lymph nodes 4 15 6 
Popliteal space 4 32 6 
Piece of muscle removed 4 32 6 
Liver puncture 5 30 3 
Lungs 4 28 6 
Fluid from nipple 4 21 6 
Lip 4 07 6 
In the mouth 4 08 6 
Birth marks on head 4 17 3 
Knee bursa 4 32 1 
Stomach 4 30 6 
Leg 5 32 3 
Skin on back, 15 yrs ago 5 17 2 
Tumour ear lobe. 1983 4 16 2 
Atheromatous cyst 4 17 2 
Hodgkin's disease (neck) 4 14 5 
Lipoma on back 4 17 2 
Abdomen, 1968 5 17 2 
Lump on vocal cords 4 12 2 
Uterus, examined, no abnormalities found 5 26 3 
Growth on finger 4 32 3 
Intestines 5 30 3 
Uterus, fibroid 4 26 3 
Lipoma on head 4 31 2 
Ganglion 4 32 
Osgood Schlatter 4 32 
Wan on bottom, 1984 4 17 2 
Uterus 5 26 3 
Wart 4 17 2 
Cyst in pancreas 4 30 2 
Fibroid in uterine wall 4 26 3 
Throat 4 10 6 
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Sternum puncture 5 32 6 
Rectoscopy rectum, 1975 5 30 3 
Bone marrow puncture 5 not coded 
Uterus, fertility probl. 5 26 2 
Intestines, inflam. 5 30 2 
Cervical polyp 2 26 6 
Kidneys, 1977 5 30 3 
Large intestine, 1978 5 30 3 
Cyst throat 4 10 2 
Bartholin's cyst 4 26 2 
Cyst/polyp vagina 4 25 3 
Appendix and r. ovary 4 30 2 
Sinuses 5 09 3 
Throat cyst removed 4 31 3 
Kidney cyst, 1972 4 30 2 
Wart on penis 4 22 3 
2/3 of stomach removed 2 30 3 
Leukoplakia in mouth 4 08 3 
Prostate, benign 2 23 3 
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APPENDIX 12 
OCCUPATIONS WITH AN INCREASED RISK FOR 
CANCER 
Occupations with an increased risk for cancer 
Localization 
Bladder 
Prostate 
Kidney 
Scrotum 
Skin 
(squamous 
cell ca.) 
Skin 
(malig. 
melanoma) 
Lip 
Bone 
Pancreas 
Brain 
Stomach 
Liver (incl. 
angiosarc) 
Leukemia, malig. 
lymphoma. 
M. Hodgkin 
Nose and sinuses 
(adenocarcinoma) 
Suspicious materials and factors 
Coal products, aromatic amines, 
(benzidine, auramine, 
2-naphtylamine, 4-aminobiphenyl) 
cadmium* 
cadmium* 
polycyclic hydrocarbons, soot 
arsenic, polycyclic 
hydrocarbons (also: UV light, 
e.g. sunlight, ionizing radiat.) 
PCBs 
(polychlorebiphenyls)* 
? tar products 
radium. thorium, plutonium 
vinylchloride* 
nickel, asbestos 
aflatoxine, vinylchloride 
industry 
benzine, ionizing radiation, 
vinylchloride, various chemicals, 
(also infection)* 
wood, leather, nickel, 
isopropyloil* 
Occupations 
producers of arom. amines. colouring 
industry, pigment and paint manuf., 
rubber and cable manuf., textile dye 
and print, gas indust., tar and petrol 
worker, leather worker, fireman, hair-
dresser, tailor, printer, engineer, coal 
miner, cable layer, cook. 
battery manuf., etc. 
battery manuf.. etc. 
chimneysweep, metal worker, weaver 
welder, road worker, farmer, 
fisherman, radiologist 
PCB production 
fisherman 
watch maker using radioactive paint 
chemist, printer 
chemical and rubber industry 
nickel worker, coal miner, rubber 
industry, asbestos worker 
ground-nut worker, chemical 
chemical and nuclear industry, rubber 
industry, radiologist, cobbler, 
painter, glue worker, carpenter, chemist, 
teacher, radiologist, pathologist. 
carpenter etc., leather industry, 
cobbler, nickel industry, petro-
chemical industry, isopropyl alcohol 
manuf. according to cone. acid process 
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Lung 
Pleura, 
peritoneum, 
(mesothelioma) 
Tumours in 
children 
arsenic, chrome, nickel, 
ionizing radiation, asbestos. 
polycyclic hydrocarbons, mustard 
gas, isopropyloil +, bis(chlor 
methyl)-ether. chlormethylmethyl 
ether, epichlorhydrin, acrylon 
asbestos 
hydrocarbons•, anaesthetic gasses 
metal industry, moulding, steel indust. 
radiologist, nuclear worker, 
paper/petrol/transport industry, 
printer, uranium miner, professional 
chaufeur, isopropylalcohol manuf. 
according to cone. acid process. 
isolator, shipbuilder, asbestos rnanuf., 
asbestos cement, wearer of asbestos 
protective clothing (firemen), others 
with indirect asbestos contact: relatives 
of workers, laundry worker. 
children of painters, mechanics, petrol 
pump assistants, hosp. theatre personnel 
• Based on casuistic data or once-off systematic research without convincing results. 
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